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Abstract 
The ectopeptidase dipeptidyl-peptidase IV (DPPIV; CD26) specifically truncates dipeptides 
from substrates with an alanine or proline at the second N-terminal position of the amino acid 
sequence. Due to this specificity, the neurotransmitter neuropeptide Y (NPY) represents one 
of the best substrates for DPPIV but implications of the “DPPIV-NPY” interactions on 
behavioral responses in vivo have not been investigated.  
The aims of the present studies were (1) to characterize the phenotype of two mutant F344 rat 
substrains [F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-)], which exhibit an extreme 
reduction of their endogenous DDPIV activity, and of a wildtype-like F344 substrain 
[F344/Crl(Por)], and (2) to test the hypothesis whether this lack of enzymatic activity is 
associated with differential in vivo effects of centrally applied NPY. In a first experimental 
step, we mapped the Dpp4 gene, performed breeding experiments, and determined the glucose 
tolerance and the natural killer (NK) cell function in the three different substrains. In a second 
step, the influence of DPPIV deficiency on behavioral domains such as feeding behavior, 
anxiety, nociception, memory, and the sedative effect of ethanol was analyzed. In a third step, 
we investigated the effects of intracerebroventricularly (i.c.v.) applied NPY in various 
behavioral tasks for feeding behavior, anxiety, and nociception. 
Results demonstrated the position of the Dpp4 gene on rat chromosome 3 (RNO3) and a 
semi-dominant mode of inheritance. DPPIV deficiency improved the glucose tolerance and 
blunted the NK cell function. Furthermore, it was found to be associated with a reduced body 
weight and water intake, a hyperalgesic response under stress, and an anxiolytic-like 
phenotype. In addition, we observed a decreased susceptibility for the sedative effect of 
ethanol. After i.c.v. administration of NPY most behavioral effects of this peptide were more 
potent in the mutant substrains strongly suggesting that the anxiolytic- and hyperalgesic-like 
phenotype of the DPPIV-deficient F344 substrains is caused by a differential degradation of 
NPY. 
In conclusion, a differential cleavage of NPY in our different substrains can be considered as 
at least one of the main reasons for the differences in the behavioral and physiological 
phenotype. Overall, these animals provide a useful model to study various behavioral and 
physiological effects associated with DPPIV-enzymatic activity and to study the “DPPIV-
NPY-axis”. Furthermore, these animals could serve as a physiological and molecular model 
for behavioral modulations. 
 
 
 
Keywords: Dipeptidyl-peptidase IV – neuropeptide Y – behavioral effects 
 
 
 
Kurzzusammenfassung 
Die Ektopeptidase Dipeptidyl-Peptidase IV (DPPIV; CD26) spaltet spezifisch Dipeptide von 
Substraten ab, die ein Alanin oder Prolin an der zweiten N-terminalen Position der 
Aminosäuresequenz aufweisen. Aufgrund dieser spezifischen Eigenschaft ist der 
Neurotransmitter Neuropeptid Y (NPY) eins der besten Substrate für die DPPIV. Die 
Auswirkungen von „DPPIV-NPY“ Interaktionen auf Verhaltensantworten in vivo wurden 
allerdings bisher nicht untersucht. 
Ziele der vorliegenden Studie lagen (1) in der Charakterisierung des Phänotyps zweier 
mutanter F344 Rattensubstämme [F344/DuCrj(DPPIV-) und F344/Crl(Ger/DPPIV-)], die eine 
extreme Reduzierung der endogenen DPPIV-Aktivität aufweisen, und eines wildtyp-
ähnlichen F344 Substammes [F344/Crl(Por)], sowie (2) in der Überprüfung der Hypothese, 
ob das Fehlen der enzymatischen Aktivität mit unterschiedlichen in vivo Effekten von zentral 
appliziertem NPY verbunden ist. 
In einem ersten experimentellen Schritt kartierten wir das Dpp4 Gen, führten 
Vererbungsexperimente durch, bestimmten die Glucosetoleranz und die natürliche 
Killerzellfunktion in den drei verschiedenen Substämmen. In einem zweiten Schritt wurde der 
Einfluss der DPPIV-Defizienz auf Verhaltensdomänen wie Fressverhalten, Ängstlichkeit, 
Schmerzwahrnehmung, Erinnerungsleistung und sedative Effekte von Ethanol analysiert. In 
einem dritten Schritt wurden die Effekte von intrazerebroventrikulär (i.c.v.) injiziertem NPY 
in verschiedenen Verhaltenstests zum Fressverhalten, zur Ängstlichkeit und zur 
Schmerzwahrnehmung untersucht. 
Die Ergebnisse bestätigten die Lokalisierung des Dpp4 Gens auf Chromosom 3 (RNO3) der 
Ratte und eine semi-dominante Vererbung. DPPIV-Defizienz verbessert die Glucosetoleranz 
und schwächt die Killerzellfunktion. Ausserdem ist sie mit reduziertem Körpergewicht und 
reduzierter Wasseraufnahme, einer hyperalgetischen Reaktion unter Stress und einem 
angstlösenden Phänotyp assoziiert. Zusätzlich wurde eine verringerte Empfänglichkeit für 
sedativen Effekte von Ethanol beobachtet. Nach i.c.v.-Gabe von NPY waren die meisten 
Verhaltenseffekte von NPY deutlicher in den mutierten Substämmen nachweisbar. Dies 
deutet darauf hin, dass angstlösende und der hyperalgetische Phänotyp der DPPIV-defizienten 
Tiere auf einer differentiellen Spaltung von NPY basiert. 
Zusammenfassend zeigt sich, dass die unterschiedliche Spaltung von NPY in den 
verschiedenen Substämmen zumindest einer der Hauptgründe für die Unterschiede im 
 
 
 
verhaltensbiologischen und physiologischen Phänotyp ist. Insgesamt lässt sich feststellen, 
dass unsere Tiere ein nützliches Tiermodell zur Untersuchung von verschiedenen 
verhaltensbiologischen und physiologischen Effekten, die mit der DPPIV-Aktivität assoziiert 
sind, und zur Untersuchung der „DPPIV-NPY-Achse“ darstellen. Des Weiteren könnten diese 
Tiere als physiologisches und molekulares Modell für Verhaltensmodulationen dienen.  
Schlagworte: Dipeptidyl-Peptidase IV - Neuropeptid Y - Verhalten 
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1. Introduction 
The aim of the present study was to characterize the behavioral and physiological phenotype 
of three F344 rat substrains, which differ in their endogenous dipeptidyl-peptidase IV activity 
(DPPIV; CD26). Two F344 rat substrains, which were commercially available from Japanese 
and German breeding colonies of Charles River Laboratories (F344/DuCrj, Atsugi, Japan and 
F344/Crl, Sulzfeld, Germany) in the year 1998, exhibit an extreme reduction in endogenous 
DPPIV activity, whereas F344 substrains from breeding colonies in the USA (Portage and 
Raleigh) exhibit a wildtype-like phenotype (same laboratory code as the German substrain: 
F344/Crl). In this study the impact of the substrains´ differential DPPIV activity on the 
behavior and physiology as a model for DPPIV deficiency was analyzed. We focused 
especially on behavioral and physiological effects, that are possibly mediated by a differential 
cleavage of the DPPIV substrate neuropeptide Y (NPY), which is one of the best substrates 
for DPPIV. Using a systematic and multi-tiered approach for the phenotyping of the three 
different substrains (Karl et al., 2003a), we first characterized the genetics and some general 
physiological effects of the mutation in the Dpp4 gene (Karl et al., 2003b), applied a broad 
screening to identify key behavioral differences (Karl et al., 2003c), and tested finally by 
intracerebroventricular (i.c.v.) application of NPY if some of the observed differences could 
be due to a differential cleavage of NPY in the different substrains (Karl et al., 2003d; Karl et 
al., 2003e). 
 
1.1 Discovery and distribution of DPPIV 
The enzyme and binding protein dipeptidyl-peptidase IV was discovered in rat liver 
homogenates in 1966 (Hopsu-Havu and Glenner, 1966). The ectopeptidase DPPIV is a type II 
integral membrane peptidase being anchored to the plasma membrane by its signal sequence 
and is identical to the leukocyte differentiation marker CD26 (De Meester et al., 2000; De 
Meester et al., 1999). The enzyme is highly conserved among different species (Ludwig et al., 
2003). 
DPPIV is expressed at different levels in tissues like kidney, lung, liver, adrenal gland, spleen, 
testis, and brain. Due to its abundant expression on endothelial cells, the enzyme is in close 
contact to hormones, chemokines, and cytokines circulating in the blood. Moreover, the 
peptidase is found as a soluble enzyme in plasma and cerebrospinal fluid (CSF), in the latter 
at low levels. Furthermore, DPPIV/CD26 is expressed on cells of the immune system and 
here especially on activated T-helper lymphocytes and subsets of macrophages. In the adult 
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central nervous system (CNS) DPPIV has contact with neuropeptides mainly in the CSF, 
brain vessels, and leptomeningeal cells. Based on protein detection by immunohistology, 
DPPIV is particularly high expressed in the circumventricular organs and on leptomeningeal 
cells, whereas in the embryonic brain it is abundantly present on neuronal cells (Mentlein, 
1999). In the peripheral nervous system DPPIV is located in the perineurium and on 
Schwann-cells. The peptidase is also present at sites of physiological barriers (i.e. blood-brain 
barrier). Its location allows DPPIV to act on bioactive peptides in body fluids or during 
communication processes between immune cells (Mentlein, 1999). 
 
1.2 Functional role of DPPIV 
The role of DPPIV in the inactivation of bioactive peptides was recognized 25 years ago 
(Heymann and Mentlein, 1978; Kato et al., 1978) due to its unique ability to cleave dipeptides 
from the N-terminus from polypeptides and proteins carrying a Xaa-proline or Xaa-alanine in 
the second (penultimate) position of the amino acid sequence (De Meester et al., 1999; 
Reinhold et al., 2002). Many neuropeptides, immunopeptides (i.e. cytokines), and peptide 
hormones have proline residues at specific positions in their amino acid sequence, which 
serve as a cleavage point for DPPIV (Table 1). Thus, due to this specificity, DPPIV is 
potentially involved in the regulation of nervous, endocrine, and immune functions at various 
functional levels (Hildebrandt et al., 2000).  
 
Table 1:  
Neuropeptides Endomorphine-2, kentsin, enterostatin, and neuropeptide Y 
Immunopeptides RANTES, TNF-α, TNF-γ, IL-1, IL-2, IL-6 , IL-11, and IP-10 
Peptide hormones Growth-hormone-releasing factor, glucagon-like peptide 1, glucose-
dependent insulinotropic peptide, peptide YY, and substance P 
Substrates of DPPIV (data are displayed according to Hildebrandt et al., 2000). 
 
1.3 Genetics of DPPIV and DPPIV deficiency 
Several studies focused on the location and expression of the Dpp4 gene in man and mice. In 
humans the DPP4 gene is located on the long arm of chromosome 2  (HSA2, 2q24.3) and 
spans approximately 70 kb. It contains 26 exons, ranging in size from 45 b to 1.4 kb. The 
active site Ser630 of human DPP4 is surrounded by Gly-Trp-Ser630-Tyr-Gly, which 
corresponds to the motif Gly-Xaa-Ser-Xaa-Gly proposed for serine-type peptidases (De 
Meester et al., 1999). The cDNA codes for a polypeptide of 766 residues. The mouse Dpp4 
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gene is located on chromosome 2 (MMU2; partially homologous to HSA2/HSA11), 
encompasses more than 90 kb, and is also composed of 26 exons. Their length varies from 
100 bp to more than 20 kb. The cDNA codes for a polypeptide of 760 residues (Bernard et al., 
1994). 
In rats the Dpp4 gene maps to a region of chromosome 3 (RNO3; genome.ucsc.edu/cgi-
bin/hgGateway?org=rat), which is homologous to the Dpp4 gene containing MMU2 region. 
The mode of inheritance of the Dpp4 gene still remains unclear. Tsuji and coworkers (1992) 
analyzed the genetics of DPPIV in wildtype-like F344/Clea rats (Nihon Clea, Osaka, Japan) 
and DPPIV-deficient F344/DuCrj rats from a breeding colony of Charles River Laboratories 
(Crl) in Atsugi, Japan. On the basis of the cDNA sequence for DPPIV the primary structure of 
the enzyme seems to consist of 767 amino acid residues. It is initially synthesized as a 103 
kDa form. Afterwards, DPPIV is processed to the mature form of 109 kDa during the 
intracellular transport. Like in the human DPP4 gene a serine-protease typical Gly629-Trp-Ser-
Tyr-Gly633 sequence surrounds the active-site Ser631 of DPPIV. Recently, the three-
dimensional structure of rat DPPIV was analyzed. The protein exists as a dimer with 
structural analogies to the serine peptidase POP (Ludwig et al., 2003). 
Cloning and sequencing of Dpp4 cDNA in the DPPIV-deficient F344/DuCrj rats revealed a G 
to A transition at nucleotide 1897 in the cDNA sequence, which results in a substitution of 
Gly633 to Arg in the active-site sequence (catalytic center). This substitution leads to a 
conformational change of the ectopeptidase, which appears to be responsible for the loss of 
DPPIV activity and the absence of DPPIV in the plasma membrane of F344/DuCrj (Tsuji et 
al., 1992). Based on this point mutation, DPPIV activity is reduced or deficient in kidney, 
lung, liver, submaxillary glands, brain, and urine of these animals (Watanabe et al., 1987), 
although Dpp4 mRNA levels are similar in mutant F344/DuCrj and wildtype-like F344/Clea 
rats (Erickson et al., 1992). In contrast to the wildtype-like enzyme, mutant DPPIV of the 
F344/DuCrj substrain, although also being synthesized as a 103 kDa form, is rapidly degraded 
without normal post-translational processing to the mature form. The single substitution of 
Gly633 to Arg is sufficient to cause this rapid intracellular degradation of DPPIV (Tsuji et al., 
1992). 
The mutation in the German F344/Crl substrain has not been characterized to that extend. But 
similar to the F344/DuCrj substrain, comparable mRNA levels are detected in mutant 
F344/Crl rats from German breeding colonies and in wildtype-like F344/Crl rats from 
breeding colonies in Portage, USA. Only wildtype-like DPPIV is expressed in an active form 
(Gossrau, 1990; Thompson et al., 1991). 
 4  
 
 
Because of the involvement of DPPIV in cleavage processes of several neuro- and 
immunopeptides (Table 1), differences in DPPIV expression and/or activity between different 
rat strains or substrains can be of considerable importance for research regarding the direct 
and indirect role of DPPIV in the regulation of nervous, endocrine, and immune functions. 
Thus, in a first step, we mapped Dpp4 using a gene linked SSLP marker, performed breeding 
experiments to identify the mode of inheritance of DPPIV-like activity (cooperation with 
W.T. Chwalisz and Dr. D. Wedekind: Institute for Laboratory Animal Science and Central 
Animal Facility, Hannover Medical School, Germany), and screened several laboratory rat 
strains including F344 rat substrains from different breeding colonies obtained at different 
time points from Charles River Laboratories (Crl) for their endogenous DPPIV-like activity 
(cooperation with Dr. T. Hoffmann: Probiodrug AG, Halle, Germany). Furthermore, we 
determined the glucose tolerance and the natural killer cell function (the latter one in 
cooperation with Dr. R. Jacobs: Department of Clinical Immunology, Hannover Medical 
School, Germany) in mutant (F344/DuCrj, Atsugi, Japan and F344/Crl, Sulzfeld, Germany) 
and wildtype-like (F344/Crl, Portage, USA) F344 rat substrains in order to exemplify the 
functional importance of spontaneous mutations in the Dpp4 gene (Karl et al., 2003b). 
For clarity, the different F344 substrains were coded as followed: DPPIV-deficient F344 rats 
derived from breeding colonies in Atsugi, Japan were designated as F344/DuCrj(DPPIV-), 
DPPIV-deficient animals from breeding colonies in Sulzfeld, Germany, as 
F344/Crl(Ger/DPPIV-), wildtype-like rats obtained from colonies in Portage, USA, as 
F344/Crl(Por), and wildtype-like rats from colonies in Raleigh, USA, as F344/Crl(Ral). 
Additionally, the time point, at which the animals were obtained from Charles River 
Laboratories (1998/2001) was indicated in our code (“98” for 1998 and “01” for 2001), 
whenever this appeared to be necessary. 
 
1.4 Substrates of DPPIV and their physiological impact 
Exogenously administered inhibitors of DPPIV prolong the biological half-life of DPPIV 
substrates, with several of them being highly important clinical and pharmaceutical targets for 
drug development. For example, DPPIV inhibition stabilizes and hence improves the 
intestinal absorption of enterostatin, which, having an anorectic effect (Erlanson-Albertsson 
and York, 1997), produces a dose-dependent reduction in fat intake and body weight (Bouras 
et al., 1995; Bouras et al., 1996; De Meester et al., 2000). Furthermore, the insulinotropic 
hormones glucagon-like peptide 1 (GLP-1) and the glucose-dependent insulinotropic peptide 
(GIP) are inactivated by DPPIV truncation (Kieffer et al., 1995). GLP-1 has multifaceted 
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actions including stimulation of insulin gene expression (Hildebrandt et al., 2000) and the 
inhibition of food intake (Turton et al., 1996).  Inhibition of DPPIV increases the amount of 
the intact incretins GLP-1 and GIP, improves their insulinotropic effect, and has been 
proposed as a valid therapeutic approach for lowering glucose levels in type 2 diabetes or 
other disorders involving glucose intolerance (Mentlein, 1999). Interestingly, elevated urinary 
concentrations of DPPIV have been shown in non-insulin-dependent diabetic patients (Nagata 
and al, 1988). 
DPPIV inhibition also elicits analgesia by potentiating the actions of the endogenous opioid 
peptide endomorphine-2 (and endomorphine-1), which has a high affinity at µ opioid 
receptors and produces potent analgesia (Shane et al., 1999). In addition, DPPIV enhances 
nociception by processing substance P to a more potent derivative, a process, which may 
involve additional circuits via other substrates for DPPIV like NPY and endomorphine-2 
(Hildebrandt et al., 2000). These modulators of pain perception and processing may result in 
multiple interactions (and may modulate - as a net effect - the expression of pain). In addition, 
several studies demonstrate the involvement of DPPIV in the metabolism of NPY, which is 
involved in various other physiological and behavioral processes (see below and De Meester 
et al., 2000; Mentlein, 1999; Wettstein et al., 1995). 
Furthermore, DPPIV seems to be involved in human diseases like rheumatoid arthritis 
(Kamori et al., 1991; Williams et al., 2003), AIDS (Vanham et al., 1993), major depression 
(Maes et al., 1991), schizophrenia (Maes et al., 1996), and anorexia nervosa (Hildebrandt et 
al., 1999). Patients with psychiatric disorders (anxiety-disorders or psychosis) show a 
decrease in serum DPPIV activity (Maes et al., 1996; Maes et al., 1991), whereas an increase 
in DPPIV serum activity was reported in patients with hyporectic eating disorders (van West 
et al., 2000). 
Inhibition of DPPIV/CD26 plays also an important role in the process of activation and 
proliferation of human lymphocytes and can provoke many cellular effects, including 
suppression of DNA synthesis and reduced production of various cytokines (Kahne et al., 
1999). Elevation of DPPIV/CD26 activity exerts an immunoprotective effect, mainly via 
expansion of T cell activation (Morimoto and Schlossman, 1998). 
Because of the ability of DPPIV/CD26 to cleave several substrates and its involvement in 
various human diseases and immune functions, it is of great interest to investigate an animal 
model with a differential endogenous DPPIV activity. The DPPIV-deficient F344 substrains 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-), which exert an extreme reduction in 
endogenous DPPIV activity but produce DPPIV mRNA (Erickson et al., 1992), could be a 
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useful tool for investigating the effects of “natural” DPPIV inhibition via “germline-
knockout”-comparable mechanisms on the behavioral and physiological phenotype but with 
the advantage of using the species Rattus norvegicus instead of Mus musculus laboratorius. 
Theoretically, differences in the behavioral phenotype between the mutant F344 substrains 
[F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-)] and wildtype-like animals from Portage, 
USA [(F344/Crl(Por)] could be attributed to differential degradation processes of various 
DPPIV substrates such as enterostatin, GLP-1, endogenous opioids, NPY, or substance P in 
the CNS. Therefore, in a second step of this study, the influence of DPPIV deficiency on 
behavioral and physiological topics was analyzed in the mutant and wildtype-like F344 
substrains. For this the different substrains were observed in several schedules (Table 2), 
which are potentially affected by above-mentioned DPPIV substrates (Table 1) (Karl et al., 
2003c) after a systematic behavioral phenotyping (Crawley, 1999; Crawley and Paylor, 1997; 
Karl et al., 2003a). A differential degradation of these substrates (caused by the differences in 
endogenous DPPIV activity) could have a high impact on the various behavioral and 
physiological domains. 
 
Table 2:  
Behavioral and physiological domains Related test paradigmes 
Feeding behavior Voluntary food and fluid consumption 
Glucose homeostasis Glucose tolerance test 
Nociception Tail flick and hot plate 
Anxiety Open field, elevated plus maze, and social 
interaction 
Memory and learning Radial maze, object exploration, and passive 
avoidance 
Ethanol Voluntary consumption of ethanol 
Sedative effect of ethanol 
Tests related to symptoms of human 
psychiatric disorders 
Schizophrenia: 
Startle response and prepulse inhibition 
Depression: 
Porsolt swim test 
Schedules for various behavioral and physiological domains. 
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Among the various substrates for DPPIV, NPY is the most abundant neuropeptide in the brain 
(Allen et al., 1983) and it is rapidly cleaved by DPPIV (Mentlein, 1999). Thus, we focused 
especially on the endogenous metabolism of the DPPIV substrate NPY and its involvement in 
behavioral and physiological processes in the three F344 substrains.  
 
1.5 Neuropeptide Y as a substrate of DPPIV-like enzymatic activity 
1.5.1 Discovery, distribution, and function of NPY 
NPY, discovered in 1982 (Tatemoto, 1982; Tatemoto et al., 1982), is a member of the 
pancreatic polypeptide (PP-fold) family of peptides (Gehlert, 1998). It is composed of 36 
amino acids and its sequence is one of the most conserved peptide sequences known 
(Larhammar et al., 2001). The neuropeptide has a C-terminal amide that is essential for its 
biological activity and contains a large number of tyrosine residues on both ends of the 
molecule (Colmers and Wahlestedt, 1993; Gehlert, 1998; Michel et al., 1998). Significant 
NPY levels are found in most brain regions including cerebral cortex, hippocampus, thalamus, 
hypothalamus, and brainstem. NPY-containing cell bodies have a broad distribution as well. 
NPY-containing fibres are found in the peripheral nervous system within a variety of organs 
including the pancreas, intestinal tract, heart, thyroid, lung, kidney, and gonads (Allen et al., 
1983). The localization of nerve terminals and cell bodies suggest a wide-ranging role for 
NPY on behavior and physiology. In the periphery, NPY functions as a potent vasoconstrictor 
and has effects on reproduction, on the gut, and on the gastrointestinal and renal epithelial 
secretion. In the CNS, NPY seems to be implicated in feeding (food intake) and obesity, 
anxiety, nociception, memory retention, seizure susceptibility, neuronal excitability, circadian 
rhythm, inhibition of insulin release, metabolism, and human psychiatric disorders such as 
schizophrenia and depression (Gehlert, 1998; Kalra et al., 1999; Kask et al., 2002; Wettstein 
et al., 1995). Furthermore, NPY regulates the secretion of various hypothalamic 
neuropeptides, stimulates the corticotropic axis and has potent inhibitory effects on the 
gonadotropic and somatotropic axis. Interestingly, studies with NPY knockout animals 
negotiate some of the assumed effects of endogenous NPY (Bannon et al., 2000; Erickson et 
al., 1997; Erickson et al., 1996). NPY is stored in synaptic vesicles often with classical 
neurotransmitters such as norepinephrine. The release of NPY is prejunctionally regulated by 
endogenous noradrenaline acting on α2-adrenoreceptors and is increased in response to stress 
(Colmers and Wahlestedt, 1993). 
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1.5.2 Receptors for NPY 
All cloned NPY receptor subtypes [Y1, Y2, Y4, Y5, and y6 - the latter is not present in rats and 
its function is obscure in mice and humans (pseudo-receptor)] belong to the large super-
family of G-protein-coupled heptahelical receptors. Y1 and Y2 receptors are the major 
receptor subtypes expressed in the rat brain (Blomqvist and Herzog, 1997; Parker and Herzog, 
1999). DPPIV rapidly cleaves the first two N-terminal amino acid residues (Tyr-Pro) with 
high turnover rates from native NPY. The resulting C-terminal fragment NPY3-36 has a 
markedly reduced affinity to the NPY Y1 receptor subtype, while being as potent as the native 
peptide on the NPY Y2 and Y5 receptor subtype (although the receptor affinity is dependent 
on the endogenous level of NPY3-36). In the present study it is hypothesized that the loss of 
DPPIV activity in the mutant F344 substrains leads to changes in the NPY catabolism. We 
expect that in the wildtype-like F344/Crl(Por) rats DPPIV converts NPY to NPY3-36 and 
therefore to an agonist of Y2 and Y5 receptors, but terminates NPY´s action at the Y1 receptor 
(De Meester et al., 2000; Mentlein, 1999). In the mutant DPPIV-deficient substrains 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) NPY should not be cleaved and, therefore, 
still exhibits its high affinity to the Y2, Y5, and especially the Y1 receptor and acts prolonged 
at the latter one (Fig. 1). But since these rats could be regarded as “germline-knockout” 
animals, developmental compensation of the enzyme deficiency on various levels (including 
up-regulation of related enzyme systems or down-regulation of NPY receptor expression) 
may have taken place. 
 
Fig. 1: hypothesized differential cleavage of NPY in the different F344 substrains. 
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The Y1 receptor is the best-characterized receptor for NPY and predominates in the cerebral 
cortex, the thalamus, the hypothalamus, and in certain nuclei of the amygdala (Dumont et al., 
1998). The Y2 receptor subtype is found in the hippocampal and hypothalamic formation, the 
septum, and nuclei of the brainstem (Bischoff and Michel, 1999). Y5 receptor mRNA has 
been reported in several brain structures, including the limbic system (paraventricular 
hypothalamic nucleus, lateral hypothalamus, and arcuate nucleus) and the brainstem. 
Interestingly, Y5 receptor mRNA expression always coincides with the presence of Y1 
receptor mRNA (although not vice versa), possibly due to the overlapping organization of 
both receptors (Bischoff and Michel, 1999). 
One of the earliest discovered central effects of NPY was a profound increase in food intake 
along with an involvement of the peptide in body weight regulation (Kalra et al., 1999). 
Recent studies suggest that this response is likely to be mediated by the Y1 receptor (Inui, 
1999; Kushi et al., 1998; Pedrazzini et al., 1998), although considerable numbers of 
investigations also reported the Y5 receptor as being an appetite receptor (Bischoff and 
Michel, 1999; Gerald et al., 1996; Inui, 1999; Marsh et al., 1998). The distribution of the Y5 
receptor in the CNS hints to its role in hypothalamic processes such as feeding. Very recently, 
also the Y2 receptor has been discussed in regard to its feeding (food intake) regulation (Inui, 
2000; Kaga et al., 2001; Naveilhan et al., 1999). Interestingly, patients with anorexia nervosa 
and bulimia show altered levels of NPY in the CSF (Gehlert, 1998; Kalra et al., 1999). In 
addition to its effects on feeding behavior, NPY seems to produce potent anxiolytic-like 
effects in animal models of anxiety (Broqua et al., 1995; Heilig et al., 1989; Kask et al., 
2002). This effect appears to be mediated via specific Y1 receptors localized primarily in the 
amygdala (Heilig, 1995; Heilig et al., 1993; Kask et al., 2001a; Sajdyk et al., 1999; 
Wahlestedt et al., 1993). Central administration of NPY also reduces locomotor activity and 
homecage activity in rodents interpreted as sedation, presumably mediated also through the 
Y1 receptor activation (Heilig and Murison, 1987; Heilig et al., 1988; von Horsten et al., 
1998a). The antinociceptive effect of NPY (mediated by Y1 and perhaps Y2 receptors) seems 
to be particularly dependent on either the intensity or the modality of the painful stimulus 
(Lecci, 2001; Naveilhan et al., 2001b; Wettstein et al., 1995). In addition, very early studies 
on NPY found that the neuropeptide probably improves memory retention via Y2 receptors 
(Clearly et al., 1994; Flood and Morley, 1989; Morley and Flood, 1990). The same receptor 
seems to be involved in the regulation of the circadian rhythm of rodents (Biello, 1995; Biello 
et al., 1994; Biello and Mrosovsky, 1995; Calza et al., 1990; Golombek et al., 1996). 
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Furthermore, NPY influences the neuronal excitability, which is proved by its protective 
effect against seizure activity. This could be mediated through Y2 and Y5 receptors (Baraban 
et al., 1997; Erickson et al., 1996; Vezzani et al., 1994; Woldbye et al., 1997). NPY and its Y1 
receptor are also involved in the neurobiological response to the sedative effect of ethanol and 
the ethanol preference (Kelley et al., 2001; Thiele and Badia-Elder, 2003; Thiele et al., 2002; 
Thiele et al., 1998; Thiele et al., 2000). 
In humans, levels of NPY in the temporal cortex (a region, whose dysfunction may be related 
to schizophrenia) of schizophrenic patients are reduced (Colmers and Wahlestedt, 1993). 
Furthermore, NPY levels in the CSF seem to be negatively correlated with anxiety scores in 
patients diagnosed with major depression (Colmers and Wahlestedt, 1993). Reduced 
concentrations of NPY have been measured in the brain and CSF of suicide patients and 
antidepressants have been reported to increase NPY levels in rodent brains (Redrobe et al., 
2002). 
To prove our hypothesis that differences in the behavioral and physiological phenotype 
between the wildtype-like and DPPIV-deficient F344 rats could be based especially on 
differences in the metabolism of NPY and in receptor specificities, in a third experimental 
step of this study, we analyzed the effect of i.c.v. administration of different doses of NPY 
(0.0/0.2/1.0 nmol) in the wildtype-like F344/Crl(Por) and in the DPPIV-deficient 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) rats on behavioral tasks like feeding (food 
intake), anxiety, and nociception (Karl et al., 2003d, Karl et al., 2003e). 
 
1.6 Aims of the present study 
Because of the influence of DPPIV activity on several substrates, especially NPY (and 
associated changes in NPY receptor specificity) and possible resulting effects on different 
behavioral and physiological processes, we hypothesize differences in the phenotype of 
wildtype-like and DPPIV-deficient F344 rats. Therefore, we first investigated the genetics and 
variations of DPPIV activity in different inbred rat strains, especially in F344 substrains. 
Furthermore, we validated the functional relevance of these differences in DPPIV-like activity 
in regard to the glucose homeostasis and the NK cell function (Karl et al., 2003b). In a second 
step, a systematic behavioral phenotyping was performed based on a multi-tiered strategy 
(Karl et al., 2003a), which was focused on behavioral and physiological domains, which are 
well-known to be influenced by DPPIV substrates such as GLP-1, enterostatin, endomorphin-
2, substance P, and especially NPY (Table 1). For this purpose, the different substrains were 
screened in various experiments (Table 2) to get a largely complete overview about their 
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behavioral and physiological phenotype (Karl et al., 2003c). To investigate the hypothesis if 
differences in the phenotype between mutant and wildtype-like rats could be associated with 
differences in the NPY metabolism and receptor specificity (Fig. 1), in a third step, animals 
were tested in selected paradigms after i.c.v. treatment with different doses of NPY (Karl et 
al., 2003d) and additionally after i.c.v. treatment with the DPPIV inhibitor isoleucyl-
thiazolidide Ile-Thia (Karl et al., 2003e). More potent effects of NPY in the DPPIV-deficient 
rat substrains would suggest that observed differences in behavior and physiology between 
mutant and wildtype-like F344 substrains would be at least particularly caused by a DPPIV-
dependent differential degradation of NPY (or other DPPIV substrates). 
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Abstract 
The evaluation of behavioral effects is an important component for the in vivo screening of 
drugs or potentially toxic compounds in mice. Ideally, such screening should be composed of 
monitoring general health, sensory functions, and motor abilities, right before specific 
behavioral domains are tested. A rational strategy in the design and procedure of testing as 
well as an effective composition of different well-established and reproducible behavioral 
tests can minimize the risk of false positive and false negative results in drug screening. In the 
present review we describe such basic considerations in planning experiments, selecting 
strains of mice, and propose groups of behavioral tasks suitable for a reliable detection of 
differences in specific behavioral domains in mice. Screening of general health and 
neurophysiologic functions (reflexes, sensory abilities) and motor function (pole test, 
wirehang test, beam walking, rotarod, accelerod, and footprint) as well as specific hypothesis-
guided testing in the behavioral domains of learning and memory (water maze, radial maze, 
conditioned fear, and avoidance tasks), emotionality (open field, hole board, elevated plus 
maze, and object exploration), nociception (tail flick and hot plate), psychiatric-like 
conditions (porsolt swim test, acoustic startle response, and prepulse inhibition), and 
aggression (isolation-induced aggression, spontaneous aggression, and territorial aggression) 
are described in further detail. This review is designed to describe a general approach, which 
increases reliability of behavioral screening. Furthermore, it provides an overview on a 
selection of specific procedures suitable for but not limited to behavioral screening in 
pharmacology and toxicology. 
 
 
Keywords: Mouse - Behavioral phenotyping – Neurological reflexes – Motor functions – 
Learning and memory – Emotionality - Anxiety – Nociception – Psychiatric-like conditions - 
Aggression 
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2.1 Introduction 
The detection of discrete behavioral difference in rodents is a time consuming, cost intensive 
and laborious task in current biomedical research. Furthermore, scientists are challenged by a 
large amount of different techniques and may experience problems in developing a 
meaningful and rational strategy in planning their experimental designs. Several experimental 
steps must actually precede before hypothesis-driven behavioral differences in a specific 
behavioral domain can reliably be evaluated. This presumption has re-gained considerable 
attention during the past ten years since many researchers were faced with an unknown 
phenotype in their transgenic or knockout mice (CRAWLEY and PAYLOR 1997). However, the 
development of a “multi-tiered” strategy in the field of behavioral phenotyping of transgenic 
and knockout mice (CRAWLEY 1999) has generated certain novel implications for the general 
approach of behavioral testing, which are also important in screening for epigenetic, 
pharmacological, and toxic effects of novel compounds on behavioral performances. 
Uncoordinated experimental approaches in applying behavioral tests for specific behavioral 
domains bear a high risk of false negative and/or false positive results, if not a basic 
phenotyping does precede such tests. For example, if a compound induces blindness during 
development of mice, these mice perform badly in spatial learning tasks such as the Morris 
water maze or the radial maze. Both of these tests code for the behavioral domain “learning 
and memory” and essentially rely on the ability of rodents to use and to store visual 
information. The interpretation of differences in a spatial learning task as “learning 
impairments”, thus, is only valid if the mouse can properly see its surroundings and thereby 
develop spatial memory. Another example from recent studies in Huntington transgenic mice 
(CARTER et al. 1999), is diabetes mellitus, which – if remains undetected - most likely 
interferes with motoric and cognitive functions of mice. The consequence of this 
consideration is that every firm conclusion based on certain difference in a specific behavioral 
performance must be substantiated by the proof that the experimental animals are equipped 
with the corresponding sensory and sensorimotoric abilities. Otherwise, the finding bears a 
high risk to be false positive or false negative. 
Therefore, every experimental design in drug screening and toxicological research should 
include a proper evaluation of general health, sensory functions, and motor abilities of mice, 
before specific behavioral domains are tested. If this is done, the resulting “multi-tiered” 
rational strategy minimizes the danger of misleading findings.  
In the present review we describe an approach based on these basic considerations in planning 
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experiments and furthermore propose groups of behavioral tasks suitable for a reliable 
detection of drug or toxicological effects on the behavior of mice (summarized in Table 1).  
Screening of general health and neurophysiologic functions (reflexes, sensory abilities) and 
motor function (pole test, wirehang test, beam walking, rotarod, accelerod, and footprint) as 
well as specific hypothesis testing in the behavioral domains of learning and memory (Morris 
water maze, radial maze, conditioned fear, and avoidance tasks), emotionality (open field, 
hole board, elevated plus maze, and object exploration), nociception (tail flick and hot plate), 
psychiatric-like conditions (porsolt swim test, acoustic startle response, and prepulse 
inhibition), and aggression (isolation-induced aggression, spontaneous aggression, and 
territorial aggression) are described in further detail.  
2.2 Behavioral tests for a comprehensive behavioral screening 
Animals 
The mouse strain can greatly affect the behavioral phenotype and this fact actually must be 
taken into account before the behavioral screening starts. For example, 129/J and 129/SvJ 
mice exhibit a complete or incomplete lack of the corpus callosum and some C57BL/6J mice 
produce amyloid plaques, both which make these strains poor learners (HSIAO et al. 1996; 
WEHNER and SILVA 1996).  
 
2.2.1 Systematic behavioral phenotyping 
First steps and preliminary observations 
The first step in a behavioral analysis is to obtain a sufficient number of animals for each 
treatment group. Breeding problems often limit the availability of sufficient numbers of 
individuals. It is also important that the test animals are in the same range of age (differences 
of up to 10 days in age can be tolerated). For most behavioral paradigms, animals have to be 
adult (at least 70 days of age) to obtain general and reproducible results, which are not 
influenced by endocrinological processes during ontogenetic development. In general, 10 to 
12 mice of each treatment group or genotype should be used to minimize derivations within 
one group because of individual differences possibly occurring between animals (CRAWLEY 
and PAYLOR 1997). Furthermore, it is extremely important that each animal is screened for 
general health, home cage behavior, sensory abilities, and motor performance (see below). 
Usually this latter point is disregarded, if the animals are obtained from commercial breeders. 
Normally, researcher can rely on a constant genotype of mice provided by commercial 
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breeders. However, very recently we observed a segregation in the genotype of F344 rats 
obtained from a commercial breeder (KARL et al. 2003). Thus, at least in the case that a large 
research program will be based on a particular strain, a screening of all animals provides 
important information on several baseline performances of the particular genotype and might 
allow also to confirm this phenotype at later stages. Furthermore, if the ultimate hypothesis-
driven specific behavioral domain is “emotionality”, also observations of the social status and 
aggression of each mouse may provide important additional information. 
Neurophysiology  and health 
It is extremely important to detect any gross abnormalities, sensory, or motor deficits in the 
animals that will interfere with further behavioral testing. Therefore a “physical exam” is 
required (CRAWLEY 1999). Illness (signs are, e.g., poor grooming, labored breathing, very low 
body weight or other easily observable symptoms) will compromise the performance of the 
animals in different tests. Indices of general health are obtained by measuring body weight 
and rectal temperature and recording observations of any abnormal physical features (like 
poorly groomed fur, bald patches in the coat or absence of whiskers, which can lead to 
unusual home cage behavior). Illness can lead to increased aggression, hypoactivity, or also 
hypersensitivity to handling (CRAWLEY 1999). Furthermore, a blind or deaf mouse will not 
perform tasks, which require visual or auditory cue perception and discrimination. Therefore 
it is important to control sensory abilities and neurological functions. The following battery of 
tests, which are useful for detecting severe neurological dysfunctions, can be used (CRAWLEY 
1999; PICCIOTTO and WICKMAN 1998): 
1. The animal is placed in an empty cage for 3 min to record abnormal spontaneous 
behavior (like wild-running, excessive grooming, freezing). 
2. The response to an approaching unknown object is observed (normally,  the mouse 
will sniff or approach the object, will then turn away and avoid this object – 
abnormally, the mouse will attack the object or ignore it). 
3. modificated “visual cliff”: the mouse is placed onto the center of a platform. The 
latency to reach the edge of the platform (normally less than 10 s) and the 
frequency of dipping the head over the edge (normally several times a minute) is 
measured. 
4. A simple olfactory test can be used (e.g. latency to locate an odiferous piece of 
food, buried under the litter in a clean test cage - or time spent sniffing a novel odor 
painted onto the test cage wall, i.e. vanilla or lemon extract) to measure the 
olfactory abilities of the animal. 
 17 Behavioral Phenotyping: Exp Toxicol Pathol 55 (1). 2003. 69-83. 
 
 
5. Measuring of several reflexes (CRAWLEY and PAYLOR 1997; MIYAKAWA et al. 
2001): 
a) Balance: The mouse is placed in an empty cage, which is rapidly moved 
from side to side and then up and down. The normal postural reflex is to 
extend all four legs in order to maintain an upright, balanced position. 
b) Righting reflex: The postural reflex is measured. The animal is turned on its 
back and the time to right itself to an upright position is measured. Mice 
normally will right themselves up within seconds. 
c) Eye blink reflex and ear twitch reflex: These paradigms are measured by 
simply touching the eye with a cotton-tip swab and by slightly pinching the 
tip of the ear with a tweezers. 
d) Whisker-orienting reflex: The whiskers of a freely moving animal are 
touched lightly. Normally, the continual moving of the whiskers will stop 
and in many cases, the mouse will turn its head to the side of the stimulus. 
e) Constriction and dilatation reflex: This test determines the visual response 
of the pupil to light. In a dimly lit room, a penlight or a small flashlight 
beam is directed at the eye and the constriction and following dilatation 
(when the light is removed) of the pupils are observed. 
6. It is also important to observe the behavior of the mouse in the home cage (without 
any influences): locomotion, grooming, nesting, sleeping, reproductive (lactation 
and reproductive success) and aggressive behavior as well as playing behavior of 
pups. 
On the basis of these considerations it can be concluded that each behavioral 
investigation should start with a basic behavioral phenotyping. The resulting information 
about the animal’s health, neurophysiology, and sensory abilities are extremely important for 
all further experiments. This characterization should not only be performed prior to studies 
regarding the behavioral phenotype of animals but also prior to physiological measurement, 
because of the influence of health and neurophysiologic functions on both, the behavior and 
the physiology of animals. A systematic behavioral phenotyping must be a first step in 
research and all the different tasks mentioned above should be screened comprehensively. 
 
2.2.2 Motor functions 
Locomotion is a complex behavior affected by many different brain systems, including the 
telencephalic dopaminergic system and the cerebellum, as well as by peripheral abnormalities 
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(i.e. muscle weakness). Because locomotor activity is required for many complex behavioral 
tasks, increases or decreases in locomotor activity nonspecifically affect performance in many 
behavioral tests and should be measured before any other behavioral characterization is 
performed. The following tests are not only a sensitive control for more complex behavioral 
tasks, but also a useful tool to study cerebellar or dopaminergic functions. Several aspects of 
locomotor activity can be measured in parallel with tests for the response to novelty, 
exploratory behavior, or the locomotor response to drug treatment. All measures of activity 
are also sensitive to the circadian clock. Therefore, the experiments should be performed and 
compared under consideration of the circadian rhythm of the animals. The following list 
provides a considerable number of tests, which – if performed in a group – provide a rather 
comprehensive picture on the various aspects of motor functions.  
Pole test 
The pole test was developed in 1985 (OGAWA et al. 1985) to measure bradykinesia (slowed 
down movement ability). The mouse is confronted with a situation, in which it has to turn 
round and to climb down a pole. For this a wooden stick (diameter: 1 cm; length: 50 cm) with 
a cork ball on its top (diameter: 1.5 cm) is installed vertical on a heavy platform (SEDELIS et 
al. 2000). The mouse is placed directly under the ball at the top - the head held upwards. The 
time to turn round and to reach the platform at the bottom is measured (cut-off time: 120 s). If 
the animal slides down the wooden stick without active climbing or turning round, both 
parameters are recorded as 120 s. The apparatus is cleaned after each trial with 70% ethanol. 
Healthy animals can climb down the pole in 10-20 s. After loss of dopamine in the striatum 
the behavior is slowed down or vanishes completely. 
Beam walking test 
Motor coordination and balance of mice are assessed by measuring the ability of the mice to 
traverse a graded series of narrow beams to reach an enclosed safety platform (PERRY et al. 
1995). The beams consists of long strips of wood (1 m) with 28 mm, 12 mm, or 5 mm square 
cross sections and/or 28 mm, 17 mm, or 11 mm round diameters (CARTER et al. 1999). The 
beams are placed horizontally, 60 cm above the floor, with one end mounted on a narrow 
support and the other end attached to an enclosed box (20 cm square) into which the mouse 
can escape. Two lights (60 W) are positioned above the beam and to the narrow support (start 
of the beam). During training, the mouse is placed at the start of the 12 mm square beam and 
trained over 3 days (4 trials per day) to traverse the beam to the enclosed box. Once the mouse 
is trained (i.e. crossing of the 12 mm square beam in less than 20 s) it receives two 
consecutive trials on each of the square and round beams, in each case progressing from the 
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widest to the narrowest beam (cut-off time: 60 s). The latency to traverse each beam and the 
number of times the hind feet slip off each beam are recorded for each trial. Analysis of each 
measure is based on the mean scores of the two trials for each beam. To avoid influences of 
possible differences in the learning abilities of the mice the task can also be realized without 
any training session. Experimenters may experience with the motivation of animals to traverse 
the beams. In this case it may help to use the home cage of each animal as the escape box. 
Wirehang test 
Neuromuscular strength is tested by the wirehang test (CRAWLEY 1999; MIYAKAWA et al. 
2001). The mouse is placed on a wire cage lid and the lid is gently waved in the air so that the 
mouse grips the wire. The lid is then turned upside down approximately 50 cm above the 
surface of soft bedding material. The latency to fall onto the bedding is recorded (cut-off time: 
60 s). 
Rotarod and accelerod 
The rotarod/accelerod is the widely used test of neuromotor performance – a balance task 
performed on a motor-driven, rotating rod. It was developed in 1968 (JONES and ROBERTS 
1968). Motor coordination, balance and ataxia can be tested with the rotarod test. The rotarod 
measures the ability of the mouse to maintain balance on a rotating rod (BARLOW et al. 1996). 
Thus, the fore- and hind limb motor coordination and balance can be analyzed. This task 
requires an intact cerebellar function and motor coordination (CARTER et al. 1999). Mice with 
severe motor coordination problems will have difficulties to remain on the rotating rod. The 
motivation to stay on the rod can be increased by raising the rod to greater heights above a 
soft landing surface. Two methods have been established: 
1) Rotarod: each mouse is placed on the rotating rod and the time to fall off is 
measured (cut-off time: 60 s). Different constant rotation speeds are used in this 
paradigm. 
2) Accelerod: an accelerating rotarod allows the rotation speed to be constantly 
increased from 4 to 40 revolutions per minute (rpm), over a 5 min period. In the 
accelerating rotarod test the latency and the rotation speed, at which the animal 
falls off the rod, are recorded. 
The accelerod is more sensitive than the rotarod in detecting motor function deficits, i.e. 
induced by acrylamide or ethanol.  
Training: In order to exclude difference in motivation and motor learning, it is very important 
to sufficiently train the animals before testing. During the training phase for 2-4 consecutive 
days each mouse is placed on the rotarod at a constant speed (12 rpm) for a maximum of 120 
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s and the latency and frequency to fall off the rotarod within this time period is recorded. 
During the 120 s of the training trials, the animals are instantly replaced on the rotarod. 
Testing: a) Rotarod: Animals are subjected to two consecutive test sessions (trials) on each 
level (ranging from 4-40 rpm in 4 rpm steps) with an intertrial interval of 1 h for four 
consecutive days (SEDELIS et al. 2000). The average of the latency to fall off the rotating rod 
of the two trials per day per rotation speed level is recorded. b) Accelerod (can follow directly 
after the training or after the rotarod test session): Duration of each trial is in the maximum 5 
min. During this time, the rotation speed is constantly increased, i.e. from 4 rpm to 40 rpm 
within four and a half minutes. The latency to fall off the rod and the actual rotating speed 
level are measured. The animals are tested in two trials per day for four consecutive days with 
an intertrial interval of 1 h. The average latency of falling off the rod and the average actual 
rotating speed per day are recorded. 
Footprint test 
The footprint test evaluates the walking pattern of mice and thereby allows gait abnormalities 
to be detected. Footprint patterns of mice are analyzed after the mouse was walking along a 
narrow corridor (BARLOW et al. 1996). To obtain footprints, the hind and fore paws are coated 
with blue and black non-toxic paints. The mouse is then placed at one end of a dark tunnel 
(10x10x50 cm). A light (60 W) is positioned above the starting point of the tunnel. All 
animals have (optional) three training runs before the test session, which is performed during 
the dark phase of the light cycle. The mouse has to walk along the narrow, dark corridor (the 
motivation of the animal to walk along this tunnel can be increased by stimulation with food 
rewards). The footprints are recorded on a sheet of white paper that is placed on the floor of 
the tunnel. The footprint patterns are analyzed for three step parameters (CARTER et al. 1999): 
1) The stride length is analyzed by measuring the distance between each step on the same 
side of the body (distance between one right front or hind footprint and the next right 
front or hind footprint). 
2) The hind-base and front-base widths are measured as the average distance between left 
and right hind footprints and left and right front footprints. 
3) The distance from front footprint/hind footprint overlap is used to assess uniformity of 
step alternation. When the center of the hind footprint falls on top of the center of the 
preceding front footprint, a value of zero is recorded (when the footprints do not 
overlap, the distance between the centers of the footprints is recorded). 
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For each parameter, three values are measured of each run, excluding footprints made at the 
beginning and the end of the run (because of initiating/finishing movements). The mean value 
of each set of three values is used in subsequent analyses. 
Open field  
(see section “Emotionality/Anxiety and exploration”) 
Thus, several tests are available for the characterization of motor functions in rodents. 
As part of a systematic behavioral phenotyping, the pole test, the wirehang test, and the 
accelerod test should be realized to control the basic motor functions in mice. These tasks can 
be performed easily and briefly and detect gross abnormalities in natural climbing abilities, 
neuromuscular strength, motor coordination, and balance abilities. If a study concentrates on 
investigations regarding possible motoric dysfunctions, additionally, the beam walking test, 
the rotarod task, and the footprint paradigm should be included in order to obtain a more 
comprehensive analysis of the mice´s motor abilities. The open field is an additional and 
important tool for analyzing the locomotion of rodents. However, open field behavior of mice 
and rats is affected by two behavioral dimension, activity and emotionality/anxiety (DEFRIES 
et al. 1966; VON HORSTEN et al. 1998; WHIMBLEY and DENENBERG 1967). The interpretation 
of results is confounded by these two underlying constructs. Therefore, this test usually 
should not be used as a single measure of activity or anxiety.  
 
2.2.3 Learning and memory 
Learning is a complex phenomenon subserved by the activity of many brain regions. Some 
aspects of learning that can be measured in rodents include attention, working memory (the 
short-term memory used while a task is being performed), memory consolidation, and 
reference memory (the long-term memory, which lasts from 24 h to the lifetime of the 
animal). Various tests have been developed that evaluate preferentially one or another of these 
aspects of learning (HODGES 1996).  
Morris water maze 
Hidden platform version of the Morris water maze (MORRIS 1981; OWEN et al. 1997): 
This is a task for measuring spatial memory. Each mouse learns to swim in a circular pool of 
water to locate a submerged hidden platform. On the first day the mouse is alternated between 
standing on this platform and swimming for 10 s in the pool to familiarize the animals with 
the test apparatus. The mouse is given three blocks consisting of four trials each for a total of 
three days. On each trial, the starting position is randomized between four possible positions. 
The platform’s location remains constant throughout training for each mouse but is rotated 
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over three possible positions between treatment groups or genotypes. Each trial lasts 60 s or 
until the animal locates the platform. Mice that do not find the platform are guided to the 
platform and given a latency score of 60 s. All animals receive a 10-15 s rest period on the 
escape platform between trials. The time to reach the platform (latency to escape) is recorded 
for each trial (LIONE et al. 1999). Between blocks, the animals are placed individual in a 
heated enclosure (metal holding cages that have a single paper towel at the bottom under a 
heat light). 
After training on the third day, animals are given a 60 s probe trial during which the platform 
is removed from the pool. The probe trial starts from a start position opposite to the quadrant 
that originally contained the platform. The number of times the mouse crosses each of the 
four possible platform positions (platform crossings) is calculated from a videotaped 
recording of the probe trial. Then the preference score is calculated. It is defined as the 
number of crossings over the trained position minus the mean number of platform crossings 
over the other three positions. Therefore, a higher preference score indicates better spatial 
selectivity for the trained platform location. 
Cued (visible platform) version of the Morris water maze (OWEN et al. 1997): 
A white plastic sail (5 cm2) is attached to the platform and sits approximately 12 cm above the 
water surface. The sail is outlined with black electrical tape to provide visual contrast. Other 
than the following two exceptions, the training procedure is identical to the spatial (hidden 
platform) version of the task: 1) training takes place on only two consecutive days and 2) both 
the visible platform’s position and the animal’s starting position are randomized between each 
trial. 
Radial maze 
Radial mazes are frequently used to study hippocampal function, and different procedures 
permit to dissociate spatial and non-spatial memory capabilities in rodents (CRUSIO et al. 
1987). In the radial arm maze paradigm, rodents are trained to visit a pattern of arms in an 8 
arm maze to receive a food reward (for this food deprivation of the mice is necessary). The 
animal must keep the egozentric or allocentric/spatial information, which arms of the maze it 
has already visited during the course of the task, to perform well. Recent developments of 
mazes often try to assess choice accuracy for information presented within the day’s test 
session, and learning that has accumulated across days of testing. These two different types of 
tests are often referred to as working memory (WM) and reference memory (RM) tasks 
respectively (OLTON and SAMUELSON 1976). Nowadays most tasks are particularly geared 
towards measuring working and reference memory. 
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The original radial arm maze consists of an octagonal central area from which 8 arms radiate 
outwards, like spokes around a hub (HOLSCHER and SCHMIDT 1994). Optional, all arms can be 
closed by doors so that the mouse can be forced to stay in an arm or the center platform for a 
defined time. The maze is elevated above the ground, and has no high walls at the sides so 
that the room view is unobstructed. The maze is normally placed in a well-lit room containing 
several other objects. During all experiments the maze is kept in a constant position in the 
room (BUBSER and SCHMIDT 1990). At the outer end of each arm a food cup is located, which 
can be baited before each test. The cups are not rebaited during the test session. A food-
deprived mouse is placed into the maze, and quite rapidly learns to avoid choosing arms it 
already visited during the test session. It seems that mice can learn to visit each spatial 
location once, and remember the locations they visited (SUZUKI et al. 1980). 
Up to 2 weeks before starting the maze experiment, the food-deprivation schedule should be 
introduced gradually. Body weight should be kept at 80-90% of the pre-test body weight 
(MIYAKAWA et al. 1996). The mice should also be accustomed to the reward. Furthermore, 
mice should be picked up and put down so that they are used to the handling procedure 
(RAWLINS and DEACON 1993). 
There are some factors, which influence the spatial memory in the radial maze: a) motivation, 
b) stress and anxiety, c) age and gender (TROPP and MARKUS 2001; WINTER 1997). The 
operator must clean the apparatus after each trial, because mice use also olfactory cues to 
orientate in the maze (HODGES 1996).  
Working memory: 
In the training phase, food pellets are scattered along the arms. The mouse is placed in the 
center of the maze and can explore the apparatus for 10 min. On the consecutive days food is 
increasingly restricted to the further ends of the arms until on day 4 it is only available in the 
food cups. 
In the following test phase (day 5-18), the mouse is placed into the central area of the maze. 
All arms are baited. The tests ends either if the mouse has collected all pellets or after a 
maximum of 5 min. The chosen arms are recorded (if it is a previously visited arm – WM 
error) and numbers of right choices in the first eight tries, number of errors, the latency for the 
first arm entry, the total time for collecting all pellets, entry angles, and ratio of time and 
errors are analyzed. 
Reference and working memory: 
Animals are trained and tested like in the working memory schedule. But in this schedule only 
four arms are baited at the beginning of the test session – the other four arms are never baited. 
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Learning to avoid selecting these never baited arms constitutes a RM task. A reentry in an 
already visited arm is recorded as a WM error. To avoid errors in the results because of 
possible simple learning patterns (LANKE et al. 1993), each treatment group or genotype 
should be split in two groups so that baited arms for the one group constitute unbaited arms 
for the other group and baited and unbaited arms should be chosen randomly and not 
alternating. 
Conditioned-fear paradigm 
Cued and contextual conditioning is a fear-conditioning task that measures memory of an 
aversive experience and the stimuli present during this aversive experience. A standard foot 
shock shuttle box is used to control foot shock delivery and to measure the duration of 
freezing behavior (OWEN et al. 1997). Freezing, a standard response to a sudden aversive 
stimulus, is defined as a complete behavioral immobility except for natural respiratory 
motions (STIEDL et al. 2000; STIEDL et al. 1999; STIEDL and SPIESS 1997).  
Day 1: The first day of training consists of pre-exposure. The mouse is placed in the chamber 
and left there for 10 min to explore the environment. 
Day 2: 24 h later the animal is returned to the same test chamber. The mouse is allowed to 
explore the context for 2 min. During this time, baseline-freezing behavior is observed at 10 s 
intervals. After 2 min, an 80 dB auditory clicker stimulus sounds for 30 s immediately 
followed by a 0.35 mA foot shock (2 s duration). This pairing is repeated after a 2 min 
intertrial interval. Baseline-freezing is only measured before the first shock is administered. 
The mouse is returned to its home cage 30 s after the second foot shock. 
Day 3: 24 h later, the mouse is returned to the testing chamber. During the 5 min contextual 
phase, the animal’s contextual-freezing behavior is examined every 10 s. No auditory 
stimulus is presented at this time. Approximately 1 h later the mouse is returned once more to 
the now altered testing chamber (Plexiglas floor instead of grid floor) so that associations to 
the testing context are reduced. Furthermore, a divider is placed in the cover restricting the 
animal’s space to a small triangular area. Olfactory cues are changed by placing 
approximately four drops of liquid orange extract in the corner of the testing chamber, out of 
the animal’s reach. Once in the altered context, the animal is observed for 6 min. During the 
first 3 min, no auditory stimulus is presented (pre-CS). During the last 3 min, the auditory 
stimulus of Day 2 is presented (CS). The freezing behavior is examined at 10 s intervals for 
the entire 6 min testing period. A total percent freezing score is calculated for each animal at 
each of the four time periods tested: baseline, contextual, pre-CS, and CS (OWEN et al. 1997; 
VAN GAALEN and STECKLER 2000). 
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Active and passive avoidance 
Maze learning and avoidance tasks are among the oldest learning and memory tasks used in 
rodents. Passive and active avoidance tasks measure the memory of an aversive experience 
through the simple avoidance of a location, in which the aversive experience occurred. A 
commercially available automated apparatus consists of two connected chambers (for the 
passive avoidance task: one lighted, one dark). The animals will readily learn an avoidance 
response only if this response is closely related to the animals species-specific defensive 
behavior. 
Passive avoidance: 
Passive avoidance is a two-day task. This one-trial test of aversive memory pairs a mild foot 
shock with the entry into a dark chamber (BOVET et al. 1969). This task depends on fear of the 
foot shock and involves activation of the amygdala. Lesion studies and dopaminergic 
antagonists have also shown that both passive avoidance and active avoidance, in which the 
mouse is trained to avoid a shock, are dependent on an intact striatal function. Mice tend to 
prefer a dark, not brightly illuminated environment and will immediately enter the dark 
chamber when placed in the lighted chamber of the apparatus (CHAOULOFF et al. 1997; 
CRAWLEY and GOODWIN 1980). The animals should not be tested in the light phase because 
then they do not show an aversion to the lighted test box. The conclusion that a brightly lit, 
white environment is aversive to mice and inhibits their exploratory behavior is based on data, 
which are recorded in the dark phase of the animals (COSTALL et al. 1989).  
Day 1: In the training session, the mouse is placed in the lighted chamber for 10 s. The door 
to the dark chamber is then opened, and the latency to enter the dark chamber is measured as a 
control for visual ability and motor activity. Immediately after the mouse entered the dark 
chamber, a 0.3 mA, 1 s foot shock is delivered. The animal remains in the dark compartment 
for further 10 s to allow the formation of an association between the dark compartment and 
the received foot shock. The mouse is then returned to the home cage. 
Day 2: In the retention test session, the mouse is placed in the lighted compartment and the 
door is opened. The latency to enter the dark compartment is measured (cut-off time: 300 s). 
The mouse is then returned to its home cage. 
Active avoidance: 
Two-way active avoidance is a type of conditioning that results in associative learning. 
Essentially the animals learn to avoid a signaled noxious stimulus (electrical foot shock – 
signaled by light or sound) by initiating a specific locomotor response (moving to the other 
compartment of the apparatus). In the other compartment the signaled noxious stimulus 
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occurs again. This procedure is repeated several times. The task contains elements of conflict 
because the animal has to initiate a response towards a location where it previously 
experienced a noxious stimulus (WADENBERG and HICKS 1999). Hence speed of conflict 
resolution, anxiety, and fear are elements that influence avoidance probability. These seem to 
be especially important in the early phase of acquisition and have led to the use of this 
paradigm also as a model of anxiety. Anxiolytic drugs improve learning and performance in 
the avoidance task at low doses, probably due to the stress-reducing effect of anxiolytic 
agents. 
For active avoidance, using the same chambers as in the passive avoidance task, the mouse 
must move into the opposite chamber after the presentation of a light or sound stimulus to 
avoid receiving the foot shock. This procedure is repeated twice a day for several days. The 
latency to enter the non-shocked chamber is the measure of learning. 
Object exploration 
(see section “Emotionality/Anxiety and exploration”) 
In conclusion, different learning paradigms measure different types of cognitive 
processes. The Morris water maze and the radial maze appear to be very suitable and well-
validated tasks for spatial memory. However, the mouse is forced to swim in the Morris water 
maze test (which induces very high stress levels in mice) while - in contrast - the radial maze 
test uses food rewards to motivate cognitive processes. It is very likely that testing mice in the 
water maze represents a more potent stressor for the animals than radial maze testing. 
Furthermore, it should be kept in mind that stress represents an important determinate of 
cognitive performance, suggesting that a priori the selection of one of these tests should be 
based on the level of stress necessary for the experiment. In addition, stress levels must be 
considered when applying the conditioned-fear paradigm or the active/passive avoidance task. 
One advantage of the passive avoidance task, when evaluating drug effects, is the brief, two-
day-spanning design. In this design the aversive treatment is minimized to only one single 
event. Finally, it should be kept in mind that in all tests, which are based on painful stimuli 
such as electrical foot shocks, nociception of the animals has to be analyzed right before the 
learning paradigm, in order to avoid confounding effects of differences in pain perception on 
the learning process. 
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2.2.4 Emotionality/Anxiety and exploration 
Open field 
Locomotor activity and emotionality can be evaluated by placing the mouse in a square or 
circular (BADISHTOV et al. 1995) open field arena (OF) under standard room lighting 
(CRAWLEY 1985). The OF is divided in a peripheral and center area by a grid cross on the 
floor (SATINDER 1982). This paradigm mimics the natural conflict in mice between the 
tendency to explore a novel environment and the tendency to avoid a brightly lit open area 
(DEFRIES et al. 1966). The behavior is also influenced by thigmotaxis (TREIT and FUNDYTUS 
1988). Exploratory tendencies, emotional reactivity, or both can motivate a mouse exposed to 
a novel environment. Crawley (1985) mentioned that anxiolytic agents minimize the activity 
of the mice in the OF and so the exploratory behavior. The stimulating effect of emotionality 
on distance traveled in the OF was confirmed by another study (EIKELIS and VAN DEN BUUSE 
2000), although Denenberg (1969) discussed an inverse relation between the ambulation and 
the emotionality of mice. 
In the most schedules the mouse is tested only once in the arena for 10 min. In other studies 
the animals were tested four times and the summed activity and defecation scores were used 
as a measure of emotionality (WHIMBLEY and DENENBERG 1967). The level of illumination of 
the OF and also the background noise influences the locomotor activity and emotionality of 
the animals (WALSH and CUMMINS 1976). Environmental odors should be removed by 
cleaning the OF after each session to avoid influences of the behavior by odor trials. Other 
factors, which determine the behavior in the OF, are genetic, experiential and developmental 
background, biological rhythm, litter size and sex of the test animal – also pre- and post 
weaning treatment, and observation methods (WALSH and CUMMINS 1976). 
The animal’s horizontal activity and total distance (number of total square entries), vertical 
activity (number of rearings), and center distance are recorded. The ratio of center distance to 
total distance and the defecation rate can be taken as a measure of emotionality (DENENBERG 
1969). Furthermore, the latency and frequency of self-grooming should be recorded. Rearing 
combined with ambulation is proved to reflect a stable individual trait called “nonspecific 
excitability level”. Normally, it is taken as a measure for activity.  
Activity can also be scored by its absence. Two major parameters are the latency: 1) to leave 
the start area (to reach the periphery) or 2) to show freezing behavior (defined as the absence 
of movement). This is a widely used parameter usually taken as indicative of a high stress 
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rate. The recording of the OF behavior should be split in 2 min sessions so that also the 
development of the behaviors during 10 min can be analyzed. 
Hole board 
The hole board test provides independent measures of locomotor activity and directed 
exploration (VAN GAALEN and STECKLER 2000). The mouse is placed in a Plexiglas box with 
four up to sixteen holes equally spaced in the floor. Infra-red photocells directly beneath each 
hole provide automated measures of the number of head dipping and time spent head dipping 
in a 3 min test session (LISTER 1987). 
Head dipping or hole-poking is a spontaneous elicited behavior in the mouse. It is suggested 
that the frequency of head dipping represents inquisitive exploration, whereas the duration 
reflects inspective exploration. The hole board is validated pharmacologically: anxiolytic 
agents increase significantly the number of holes explored in a standard 3 min session 
(PELLOW et al. 1985). 
Elevated plus maze 
The elevated plus maze (EPM) is an ethologically-based approach-avoidance conflict test, 
which is sensitive to anxiolytic drug treatment (CRUZ et al. 1994; PELLOW and FILE 1986). 
Mice prefer a dark, enclosed, small place over a brightly lit, open, large space. However, mice 
are also highly exploratory. The EPM represents the natural conflict between the tendency of 
mice to explore a novel environment and the tendency to avoid a brightly lit open field like in 
the OF paradigm (MONTGOMERY 1958). The behavior is also influenced by thigmotaxis 
(TREIT and FUNDYTUS 1988) and the fear of heights. The elevated plus maze is in the shape of 
a “+”. The four arms extend from a central platform. Two alternate arms are dark and 
enclosed, while two alternate arms are open, lit and optional available with or without ledges. 
These ledges influence the behavior of mice (FERNANDES and FILE 1996). Additionally, the 
surface of all arms is raised 1 m above the floor (BALDWIN and FILE 1986). 
One of the first elevated plus maze tasks for mice was developed by Montgomery et al. 
(1955). The hypothesis that novel stimuli generate both an exploratory drive leading to 
approach behavior and a fear drive leading to avoidance behavior was employed to develop 
an elevated plus maze, in which the intensity of the fear drive (anxiety) could be measured by 
the ratio of open and enclosed arm entries (MONTGOMERY and MONKMAN 1955). The open 
and enclosed arms of the plus maze generate exploratory behavior and the avoidance of 
elevated open arms is an indication of the intensity of anxiety (HOGG 1996; LISTER 1987). 
This model was pharmacologically validated (HANDLEY and MITHANI 1984) – anxiolytic 
drugs were found to increase open arm entries (anxiogenic agents decrease number of 
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entries). These results were confirmed and extended (FILE 1987; PELLOW et al. 1985; 
RODGERS and COLE 1993). 
The mouse is placed onto the center field of the “+” (faced to an open arm) and is allowed to 
explore the maze for 5 min. Anxiety can be measured by the time spent on open arms as well 
as the percentage of open arm entries (HOGG 1996; PELLOW et al. 1985; PELLOW and FILE 
1986). These parameters are inversely related to anxiety. The number of total arm entries 
reflects also the general motor activity. Also the number of enclosed arm entries and rearing 
seem to reflect general motor activity (FILE 1986). Furthermore, head dipping over the edges 
of the open arms, risk-assessment, self-grooming and the defecation rate should be recorded. 
A mouse is taken to have entered an arm when all four legs are on the arm. After each session 
the apparatus has to be cleaned. Testing should be take place during the dark phase, starting 1 
h after the lights had been turned off. Dim illumination can be provided by a red light. 
Behavior should be video-recorded. 
Object exploration 
While many authors have emphasized the attractive properties of novelty, others have shown 
that an animal, if given the opportunity, will avoid novel stimuli (BARNETT 1975; VAN 
GAALEN and STECKLER 2000). In another study (MISSLIN and ROPARTZ 1981) the number of 
distinct contacts to a novel object in a familiar environment is significantly lower as if the 
animal is exposed to a novel object placed into a novel environment (COWAN 1976). Mice 
show in a familiar environment very few approach responses to a novel object and often push 
sawdust towards it (reason: contrast of familiar background and unfamiliar configuration). 
Thus, a novel object placed in a familiar environment releases avoidance responses in mice. 
But because of the attractive properties of novelty also rearing and stretch-attend postures 
play a role in the control of the responses towards the novel object (stretch-attend posture: 
directing the nose to the object within a distance of ≤ 2 cm and/or touching it with the nose – 
the body is stretched). In the object exploration task, the animal is confronted with two 
identical objects. After a habituation phase, one object is replaced by a novel object and the 
behavior of the mouse is recorded. Thus, this task investigates the emotionality (by placing a 
new object in a familiar environment) and the memory ability (by recognizing the novel 
object) of the animal. 
Day 1: In this paradigm the mouse is first habituated to a conventional open field area. 
Habituation lasts for 10 min. Subsequently, the animal is briefly returned to its home cage. 
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Day 2-3: 24 h after the habituation trial without a novel object, the mouse is exposed to two 
identical objects, placed in opposite corners (quadrants) of the open field area, for 10 min. 
This procedure is repeated on the following day. 
Day 4: The mouse is exposed again to two objects, one from the previous trial (familiar 
object) and a new object (novel object), which is different to the familiar object. The position 
of the two objects is counterbalanced and randomly permuted in the different treatment 
groups or genotypes. 
In the habituation trial (day 1), the place preference of the animal is controlled by recording 
the entries into and the time spent in the different quadrants. Similar parameters are measured 
during the two trials with the presentation of two similar objects (day 2-3) and the last trial on 
day 4 with the novel object. The latency and frequency of stretch-attend postures and 
rearings, the latency to approach the objects, the time spent in exploration, and the overall 
time spent in the object quadrants is measured in the test trials (day 2-4). 
Emotionality/anxiety of mice should be evaluated by at least two different tasks. The 
most common ones for mice are the open field test and the elevated plus maze test. Both 
paradigms depend on locomotion and therefore, the overall activity of the animals has to be 
measured in these schedules as well. If possible, additionally, the locomotion of the animals 
could be recorded in the hole board test. Importantly, mice should be tested standardized in 
the dark phase of the light cycle under dim red light to increase their activity and to avoid 
possible influences on the behavior by the mice’s endogenous circadian rhythm. Furthermore, 
animals should be completely undisturbed during the last 24 h before the experiment and pre-
experiences in other tests should be avoided. Finally, it must be kept in mind that most tests 
for emotionality/anxiety of rodents are based on the exposure to novelty. Therefore, repeated 
testing raises several unwanted problems with loss of reliability being probably most 
important. 
 
2.2.5 Nociception 
For the assessment of drug effects on nociception, mice could be screened using the tail flick 
and the hot plate task. It should be noted here that several other tests exist to measure pain 
perception (MILLAN MJ, 1999). 
Tail flick 
The tail flick test has been used widely as an experimental model to measure nociception, 
especially for the screening of analgesic drugs (DEWEY et al. 1969). The test is based on the 
withdrawal of the tail in response to a noxious cutaneous thermal stimulation (DOURISH et al. 
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1990; LEE and RODGERS 1990). This is a spinal reflex that requires both segmental 
connections and an ascending propriospinal connection from coccygeal and caudal sacral 
dorsal horn to motor neurons in the lumbar. The latency of the reflex is dependent upon 4 
variables: 
a) The time for activation of cutaneous nociceptors by the thermal stimulus. 
b) The time for afferent conduction of the impulse to the spinal cord dorsal horn neurons. 
c) The conduction within the central nervous system, or central delay. 
d) The time for conduction of the impulse from the ventral horn to, and activation of tail 
muscles. 
The tail flick reflex is modulated by supraspinal structures, which have excitatory or 
inhibitory effects on the activity of dorsal horn interneurons.  
This kind of nociception task measures a simple spinal reflex to a sudden, painful thermal 
stimulus. A photo beam is used to apply a heat stimulus to the tail. Latency to flick the tail out 
of the path of the light beam is measured (NAVEILHAN et al. 2001). The photo beam is turned 
off if the tail is not flicked away within 20 s (to avoid tissue damage). Three consecutive 
determinations with a 5 min intertrial interval are averaged to obtain the tail flick response 
latency (MAIER et al. 1982). In order to minimize possible tissue damage, a different patch of 
the tail skin is stimulated in each trial. 
Hot plate 
The hot plate assay is one of the most commonly used tests for determining the analgesic 
efficacy of experimental drugs in rodents (PICK et al. 1991). The mouse is placed on the 
surface of a hot plate, which is maintained at 52.5 °C (VAN GAALEN and STECKLER 2000). A 
plastic frame consisting of Plexiglas encloses the surface so that the mouse cannot jump out. 
The mouse´s latency to raise or lick hind paws, to flutter, or to jump up is recorded 
(RUBINSTEIN et al. 1996; WIESENFELD-HALLIN et al. 1990). If the mouse has not responded 
within 15 s it is removed from the hot plate to prevent tissue damage. 
There are several other paradigms besides the tail flick and the hot plate test for 
analyzing nociception, such as paw pressure experiments or acid-induced writhing tests. But 
these tests can induce severe injury in the animals and should be avoided – if possible - 
because of ethical considerations. Furthermore, the influence of the handling procedure on the 
mouse is stronger especially in paw pressure experiments and acid-induced writhing tests than 
in the hot plate task. Because of influences on the animal’s behavior due to restraining the 
animal in the tail flick test, the hot plate task should be preferred when selecting only one 
paradigm for screening of drug effects on nociception. 
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2.2.6 Tests related to symptoms of human psychiatric disorders 
Porsolt swim test 
The method is based on the observation that a mouse, when forced to swim in a situation, 
from which there is no escape, will, after an initial period of vigorous activity, eventually 
make only those movements, which are necessary to held its head above the water. This 
identifiable behavioral immobility indicates a “state of despair”, in which the mouse has 
learned that escape is impossible and resigns itself to the experimental conditions. The test is 
sensitive to antidepressants and is used as a model for aspects of human depression. The 
behavioral response to this paradigm might reflect “behavioral despair” and has been 
connected to a “learned helplessness” theory of depression (PORSOLT et al. 1978; SELIGMAN 
and MAIER 1967; SHERMAN et al. 1979). 
A naive mouse is plunged into a vertical Plexiglas cylinder (height: 40 cm; diameter: 18 cm) 
containing 15 cm of water (so that the mice cannot balance on its feet or tail) maintained at 25 
°C (PORSOLT et al. 1978; PORSOLT et al. 1977). The water surface is far enough away from 
the top of the cylinder, so that the animal cannot jump out. It is forced to swim inside the 
cylinder for 15 min. Each mouse, which does not swim or float, is immediately removed from 
the water. After 15 min in the water the mouse is removed and allowed to dry for 15 min in a 
heated enclosure (32 °C) before being returned to its home cage. This treatment produces long 
periods of immobility in the water (10-12 min total duration) and the mouse can be 
hypothermic and hypoactive for periods up to 30 min after the removal (therefore, this test is a 
great stressor for mice). The mouse is replaced in the cylinder 24 h later and the latency and 
total duration of immobility is measured during a 5 min test. The mouse is judged to be 
immobile whenever it remained floating passively in the water in a slightly hunched but 
upright position, its head just above the surface. It makes only those movements, which are 
necessary to keep the head above the water. 
The duration of immobility is decreased by treatment with antidepressant drugs and therefore 
this paradigm is used as a depression model (KORZENIEWSKA-RYBICKA and PLAZNIK 1998). 
But other studies proved (BORSINI and MELI 1988; BORSINI et al. 1986) that a reduction of 
immobility time can also be observed in animals, which live in an enriched environment. 
Furthermore, there seems to be no relationship between inescapability and immobility, since it 
was shown that rats in an inescapable test design did not show longer immobility durations 
than rats in an escapable test design (O'NEILL and VALENTINO 1982). The prior exposure to 
the water alone resulted in longer immobility. Thus, familiarity with the environment rather 
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than “despair” may induce behavioral immobility. Perhaps a “life threatening experience” 
plays a role in inducing behavioral immobility.  
Therefore, the Porsolt swim test does not provide a model resembling depressive illness in 
human beings (HAWKINS et al. 1978). Normally, antidepressive drugs have a chronic effect, 
but in the Porsolt swim test an acute effect of antidepressive treatment can be observed 
(decreased immobility duration). After all, this paradigm cannot be considered to be an 
adequate analog model for pathological depression. 
Acoustic startle response and prepulse inhibition 
The startle response is an unconditioned, reflexive response to a sudden environmental 
stimulus. Prepulse inhibition (a senorimotor gating reflex, similarly quantitated in rats, mice 
and humans) is a phenomenon, in which a weak prestimulus or prepulse suppresses the 
response to a startling stimulus. Deficits in prepulse inhibition (PI) are common in 
schizophrenic patients and may measure attentional dysfunctions that contribute to auditory 
hallucinations (BRAFF et al. 1978; BRAFF et al. 1999; CADENHEAD et al. 1993). The PI 
impairment observed in these neuropsychiatric patients is thought to reflect an underlying 
problem with inhibitory mechanism in neuronal systems used for senorimotor gating 
(SWERDLOW et al. 2000). This loss of auditory gating (as an aspect of schizophrenia) can be 
reproduced in an animal model (CAINE et al. 1992). Two tones are presented very close 
together. In most people it will not evoke a response to the second tone, but schizophrenic 
patients will respond to both tones (GRILLON et al. 1992). When a mild stimulus (prepulse) 
immediately preceded a startle stimulus, a healthy mouse will flinch less to the startle 
stimulus, although the prepulse does not startle the animal itself (PAYLOR and CRAWLEY 
1997). So the prepulse depresses the startle response in humans and rodents. The prepulse 
inhibition is one of the few paradigms, in which humans and rodents are tested in a similar 
fashion (GEYER and SWERDLOW 1998). Key neuroanatomical and neuropharmacological 
substrates mediating PI have been analyzed in rats. Direct pharmacological injections and 
lesion studies indicate that structures contributing to prepulse inhibition include the nucleus 
accumbens, hippocampus, amygdala, medial prefrontal cortex, pedunclopontine tegmental 
nucleus, ventral and caudodorsal striatum, median and dorsal raphe nucleus, and the superior 
colliculus (SWERDLOW and GEYER 1998). Neurotransmitters affecting prepulse inhibition 
include dopamine, acetylcholine, serotonin, glutamate, and norepinephrine (KOCH 1999). 
First, animals have to be habituated to the testing chambers for five consecutive days (5 min 
per day). Acoustic stimuli of 120/105 dB, a single prepulse interval (100 ms), and four 
different prepulse intensities (2/4/8/16 dB above background noise – i.e. white noise of 65 
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dB) are used. There are 5 min of acclimatization period (with background noise alone). Then 
the animal is presented with 72 startle trials, each trial consisting of one of three conditions: 
a) 30 ms 120 dB noise burst presented alone; 
b) 30 ms 120 dB noise burst preceded 100 ms by prepulses (30 ms noise bursts) that were 
2/4/8/16 dB above the background noise; 
c) No stimulus (background noise alone), which is used to measure baseline movement 
in the chamber; 
These six trial types are each repeated six times in a pseudorandom order (36 trials), such that 
each trial type is presented once within a block of six trials. This block of six trials is then 
repeated using an acoustic stimulus of 105 dB. Analysis is based on the mean of the six trials 
for each trial type (CARTER et al. 1999). 
In several studies, the Porsolt swim test is often discussed as an animal model for 
depression and the prepulse inhibition test as a model for schizophrenia. But obviously, each 
of these tests can only be used as one in a row of several additional experiments in order to 
finally draw a conclusion, which relates the finding to human psychiatric conditions. Some 
researchers even completely reject the possibility of developing an animal model for 
psychosis. In the same line, the effect of anti-depressant drugs in the Porsolt test should also 
be confirmed in other animal models for depression such as olfactory bulbectomy or even 
better postnatal maternal deprivation schedules and tests, which combine different stressful 
situations for animals (WILLNER 1990). It appears that the knowledge about the relationship 
between these animal models, the resulting behavior of rodents and their relevance for human 
psychiatric disorders has to be further developed before one or even a combination of such 
tasks can be considered as a valid model for this type of questions. 
 
2.2.7 Aggression 
 Isolation-induced aggression 
The adult male test animal is isolated for 14 days (i.e. kept single in a standard cage). After 
this period it is placed in a neutral cage together with a standard opponent mouse (BRAIN and 
POOLE 1974), which is an adult, male, weight-matched mouse of a defined genotype and a 
peaceful phenotype. The mice are placed simultaneously in opposite corners of the cage and 
fixed there for 5 s. Then the test starts, the mice can walk and interact freely in the cage. The 
latency and frequency of the agonistic behaviors biting, tail rattling, sideway threats, upright 
postures, and aggressive grooming and also of sociopositive behaviors like nosing, anogenital 
sniffing, crawling over/under, and allo grooming should be recorded during the next 10 min 
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(BRAIN and POOLE 1976; KOOLHAAS et al. 1980; LAGERSPETZ 1969). It is also possible to 
investigate the territorial behavior of the test animal by testing the mice in the home cage of 
the isolated mouse (BRAIN 1980).  
Spontaneous aggression 
If spontaneous aggression is to be measured, the adult male group-caged mouse is tested with 
a standard opponent in a neutral cage. Details of the procedure are similar to the methodology 
described above. 
Territorial Aggression 
Territorial aggression can be investigated by the Resident-Intruder paradigm. For this, the 
adult male, group-caged mouse is tested with a standard opponent in its home cage. The 
littermates of the test animal are removed from the home cage 10 min before the test. Then 
the standard opponent is taken to the test location. The resident mouse is fixed in one corner 
and the standard opponent intruder is placed in the opposite corner of the cage. After fixation 
for 2 s the test starts. The recorded parameters are similar compared to the isolation-induced 
aggression test (BLANCHARD et al. 1988).  
For the characterization of aggressive behavior in mice, all three different test 
paradigms, which analyze different kinds of aggression in rodents, should be used (for an 
overview about further aggression tests see: MICZEK et al. 2001). Because of influences of 
fight-experiences on the behavior in consecutive aggression schedules, animals should be 
tested only once (BRAIN and POOLE 1974). The use of a defined, peaceful standard opponent 
(i.e. A/J mice) is as important (LAGERSPETZ 1969) as a high level of standardization during 
breeding (i.e. litter size, gender-ratio of litter, presence or absence of father). Since most 
strains of mice are per se very aggressive, this behavioral domain has also an important 
impact on other behavioral domains such as emotionality/anxiety. Furthermore, several 
studies have demonstrated that the behavioral performance of mice depends on whether these 
animals are dominant or not within their cohort.  
2.3 Conclusion 
The accurate evaluation of a behavioral phenotype and screening for toxic effects in rodents is 
an important step for evaluating novel drugs and compounds. The detection of specific drug-
induced behavioral effects represents often a critical and far-reaching event in the 
development of novel drugs and compounds. In order to optimize current approaches and to 
obtain more reliable results, it is vital to exclude false positive and false negative results in 
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specific behavioral tests. These confounding factors result from previously undetected 
problems of the mouse in health and sensory performance. We therefore propose that an 
experimental design aimed at screening for unexpected drug effects should always be 
composed of monitoring general health, sensory functions, and motor abilities, right before 
specific behavioral domains are tested. 
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2.6 Table 
 
Table 1: Behavioral domains and the different corresponding experimental tasks – including 
relevant references. 
Behavioral 
domain 
Experimental  
task 
References 
 
Neurophysiology 
and health 
 
  
CRAWLEY 1999; CRAWLEY and PAYLOR 1997; 
LIONE et al. 1999; PICCIOTTO and WICKMAN 1998 
 
Pole test 
 
 
OGAWA et al. 1985; SEDELIS et al. 2000 
 
Beam walking test
 
 
CARTER et al. 1999; PERRY et al. 1995 
 
Wirehang test 
 
 
CRAWLEY 1999; MIYAKAWA et al. 2001 
 
Rotarod 
and 
accelerod 
 
 
BARLOW et al. 1996; CARTER et al. 1999; 
CRAWLEY 1999; JONES and ROBERTS 1968; 
PICCIOTTO and WICKMAN 1998; SEDELIS et al. 
2000 
 
 
Motor functions 
 
 
Footprint test 
 
 
BARLOW et al. 1996; CARTER et al. 1999 
 
Learning 
and memory 
 
Morris water maze
 
 
HODGES 1996; MORRIS 1981; OWEN et al. 1997 
 48 Behavioral Phenotyping: Exp Toxicol Pathol 55 (1). 2003. 69-83. 
 
 
 
Radial maze 
 
 
BUBSER and SCHMIDT 1990; CRUSIO et al. 1987; 
HODGES 1996; HOLSCHER and SCHMIDT 1994; 
LANKE et al. 1993; MIYAKAWA et al. 1996; 
MORRIS 1981; OLTON and SAMUELSON 1976; 
PICCIOTTO and WICKMAN 1998; RAWLINS and 
DEACON 1993; SUZUKI et al. 1980; TESKEY et al. 
1998; TROPP and MARKUS 2001; WINTER 1997 
 
 
Conditioned-fear 
paradigm 
 
 
CRAWLEY 1985; CRAWLEY 1999; OWEN et al. 
1997; VAN GAALEN and STECKLER 2000 
 
 
 
Active 
and passive 
avoidance 
 
 
BOVET et al. 1969; CHAOULOFF et al. 1997; 
COSTALL et al. 1989; CRAWLEY and GOODWIN 
1980; GROSSEN and KELLEY 1972; PICCIOTTO and 
WICKMAN 1998; STEWART et al. 1993 
 
 
Open field 
 
 
BADISHTOV et al. 1995; BRITTON and BRITTON 
1981; DEFRIES et al. 1966; DENENBERG 1969; 
PRUT and BELZUNG 2003; SATINDER 1982; TREIT 
and FUNDYTUS 1988; TRULLAS and SKOLNICK 
1993; VAN GAALEN and STECKLER 2000; VON 
HORSTEN et al. 1998; WALSH and CUMMINS 1976; 
WHIMBLEY and DENENBERG 1967 
 
 
Emotionality/ 
Anxiety 
and 
exploration 
 
 
Hole board 
 
 
LISTER 1987; PELLOW et al. 1985; VAN GAALEN 
and STECKLER 2000 
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Elevated 
plus maze 
 
 
BALDWIN and FILE 1986; CHAOULOFF et al. 1997; 
CRUZ et al. 1994; FERNANDES and FILE 1996; FILE 
1986; FILE 1987; FILE 1993; HANDLEY and 
MITHANI 1984; HOGG 1996; KORTE and DE BOER 
2003; LISTER 1987; MONTGOMERY 1958; 
MONTGOMERY and MONKMAN 1955; PELLOW et 
al. 1985; PELLOW and FILE 1986; RODGERS and 
COLE 1993; SHEILA and MITHANI 1984; TRULLAS 
and SKOLNICK 1993 
 
 
 
Object exploration
 
 
BARNETT 1975; COWAN 1976; MISSLIN and 
ROPARTZ 1981; TROPP and MARKUS 2001; VAN 
GAALEN and STECKLER 2000 
 
 
Nociception 
 
 
Tail flick 
and 
hot plate 
 
 
 
CRAWLEY 1999; DEWEY et al. 1969; DOURISH et 
al. 1990; LECCI 2001; LEE and RODGERS 1990; 
MILLAN 1999; MIYAKAWA et al. 1996; 
NAVEILHAN et al. 2001; RUBINSTEIN et al. 1996; 
WIESENFELD-HALLIN et al. 1990 
 
 
Tests related to 
symptoms of 
human psychiatric 
disorders 
 
 
Porsolt 
swim test 
 
BORSINI and MELI 1988; BORSINI et al. 1986; 
HAWKINS et al. 1978; HILAKIVI-CLARKE et al. 
1991; KORZENIEWSKA-RYBICKA and PLAZNIK 
1998; NIKULINA et al. 1991; NISHIMURA et al. 
1988; O'NEILL and VALENTINO 1982; PORSOLT et 
al. 1978; PORSOLT et al. 1977; SELIGMAN and 
MAIER 1967; SHEARMAN et al. 2000; WIELAND et 
al. 1986; WILLNER 1990 
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Acoustic 
startle response 
and 
prepulse inhibition
 
BRAFF et al. 1978; BRAFF et al. 1999; CADENHEAD 
et al. 1993; CADENHEAD et al. 2000; CAINE et al. 
1992; GEYER and SWERDLOW 1998; GRILLON et 
al. 1992; KOCH 1999; PAYLOR and CRAWLEY 
1997; SWERDLOW and GEYER 1998; SWERDLOW 
et al. 2000 
 
 
Aggression 
 
 
Isolation-induced 
aggression, 
spontaneous 
aggression, 
and 
territorial 
aggression 
 
 
BLANCHARD et al. 1988; BRAIN and POOLE 1974; 
BRAIN 1980; BRAIN et al. 1987; BRAIN and POOLE 
1976; KOOLHAAS et al. 1980; LAGERSPETZ 1969; 
MICZEK et al. 2001 
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Abstract 
Dipeptidyl-peptidase IV (DPPIV) is involved in endocrine and immune functions via cleavage 
of regulatory peptides with a N-terminal proline or alanine such as incretins, neuropeptide Y, 
or several chemokines. So far no systematic investigations on the localization and 
transmission of the Dpp4 gene or the natural variations of DPPIV-like enzymatic function in 
different rat strains have been conducted. Here, we map the Dpp4 gene to rat chromosome 3 
and describe a semi-dominant mode of inheritance for Dpp4 in a mutant F344/DuCrj(DPPIV-
) rat substrain lacking endogenous DPPIV-like activity. This mutant F344/DuCrj(DPPIV-) rat 
substrain constantly exhibits a nearly complete lack of DPPIV-like enzymatic activity, while 
segregation of DPPIV-like enzymatic activity was observed in another DPPIV-negative 
F344/Crl(Ger/DPPIV-) rat substrain. Screening of twelve different inbred laboratory rat 
strains revealed dramatic differences in DPPIV-like activity ranging from 11 mU/µl 
(LEW/Ztm rats) to 40 mU/µl (BN/Ztm and DA/Ztm rats). A lack of DPPIV-like activity in 
F344 rats was associated with an improved glucose tolerance and blunted natural killer cell 
function, which indicates the pleiotropic functional role of DPPIV in vivo. Overall, the 
variations in DPPIV-like enzymatic activity probably represent important confounding factors 
in studies using rat models for research on regulatory peptides.  
 
 
 
Keywords: F344 – Dipeptidyl-peptidase IV - CD26 – Gene mapping – Glucose tolerance – 
NK cell function 
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3.1 Introduction 
Dipeptidyl-peptidase IV (DPPIV/CD26) is an ectopeptidase with a triple functional role. 
DPPIV is involved in catalyzing the release of Xaa-Pro or Xaa-Ala dipeptides from the N-
terminus of circulating hormones and chemokines [1, 2]. Furthermore, the enzyme is involved 
in T cell dependent immune responses [3-5] and in cell adhesion processes [2, 6]. The 
biological activity of several hormones and chemokines can be abolished or modified by 
DPPIV in vitro and in vivo [2, 7]. Substrates of the DPPIV are neuropeptide Y (NPY), 
endomorphine, circulating peptide hormones like peptide YY, and chemokines like RANTES. 
However, it should be noted that cleavage of many of these substrates of DPPIV have been 
demonstrated only in in vitro studies, while the physiological relevance in vivo still remains 
unknown [2]. Additionally, cytokines and growth factors like IL-3, IL-10, and GM-CSF are 
characterized by a N-terminal structure with a proline in the second position. They are further 
potential substrates for this enzyme [2]. Thus, DPPIV is directly and indirectly involved in the 
regulation of endocrine, immune, and nervous functions [8]. 
In recent years a number of enzymes were identified expressing DPPIV-like activity [9, 10]. 
The fibroblast activating protein is a highly homologous protein to DPPIV, which possesses a 
gelatinase activity as well as a post-proline specific dipeptidyl-aminopeptidase activity. The 
protein was found on the surface of activated fibroblasts and on several cancer cells. It seems 
to play a role in cancer invasion and in angiogenesis [11-13]. DP8 and DP9 are also 
peptidases of the prolyl oligopeptidase family S9. For both a DPPIV-like activity could be 
proved [14, 15]. They are located intracellulary but physiological function remains unknown. 
Dipeptidyl-peptidase II (DP II, QPP) is a post-proline and post-alanine cleaving dipeptidyl-
peptidase with an acidic pH-optimum [16]. It is located in intracellular vesicles, including 
lysosomes. Attractin shares no sequence homology with the other dipeptidyl-peptidases but a 
DPPIV-like activity was found [17] and could be confirmed by another study [18]. Low 
molecular weight substrates could not distinguish between these DPPIV-like activities. Only 
DP II could be measured at pH 5 were at least DPPIV and attractin but probably also the other 
enzymes are inactive. Recently, there were the first inhibitors described, which show a clear 
preference for DP II over DPPIV [19]. 
DPPIV knockout mice confirm the importance of DPPIV-like enzymatic activity in regulating 
blood glucose levels [20]. This effect of DPPIV-like enzymatic activity on glucose 
homeostasis is likely to be mediated via a prolonged action of the incretins glucagon-like 
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which potentiate 
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the glucose-stimulated insulin secretion [21-23]. GLP-1 and GIP possessing an alanine at the 
penultimate position are rapidly degraded and inactivated by DPPIV. The intact N-terminus is 
absolutely required for the biological activity of these incretins [24]. Thus, the truncated 
forms GLP-19-36 and GIP3-42 are not insulinotropic any more [25, 26]. Despite these important 
and pleiotropic functions of DPPIV, so far, no systematic investigations on natural variations 
in DPPIV-like activity in different laboratory rat strains have been conducted. In contrast to 
humans and mice [27], also the genetics and the localization of the Dpp4 gene in rats 
remained unknown.  
Interestingly, and in addition to the above mentioned lack of knowledge on natural variation 
in DPPIV-like activity in rats, a sequence alteration (spontaneous mutation) of the Dpp4 gene 
has been described in independent studies of F344 rat substrains from breeding colonies of 
Charles River Laboratories in Sulzfeld, Germany (laboratory code: Crl) [28] and in Atsugi, 
Japan (laboratory code: DuCrj) [29, 30]. These mutations result in an almost complete lack of 
enzymatic activity. In contrast, F344 rats from Charles River Laboratories (Crl) in Raleigh or 
Portage, USA, exhibit a normal DPPIV-like activity, but unfortunately carry the same 
laboratory code (Crl) as the animals from Germany (Sulzfeld). For the purpose of clearness, 
we therefore extended the official laboratory codes of these F344 rat substrains by adding the 
country or town of origin (i.e. “Ger” for Germany, “Ral” for Raleigh/USA, “Por” for 
Portage/USA), a description of the phenotype (i.e. “DPPIV-“ for lack of DPPIV-like activity), 
and if necessary, the year of receipt of these substrains from the commercial breeders (i.e. 
“98” for 1998 and “01” for 2001). 
In F344/DuCrj(DPPIV-) rats a G to A transition at nucleotide 1897 in the Dpp4 cDNA 
sequence leads to a substitution of Gly633 to Arg in the catalytic center of the enzyme (Gly629-
Trp-Ser-Tyr-Gly633). The Ser631 is the active serine of rat DPPIV. As a result of this point 
mutation, DPPIV-like activity is deficient in plasma and other tissues of these F344 rats, 
although there is still evidence for mutant Dpp4 mRNA [31]. In the other DPPIV-deficient 
F344 substrain from Germany [F344/Crl(Ger/DPPIV-)] the gene sequence has not been 
characterized but there is also evidence for non-active Dpp4 mRNA [28]. Possibly, a mutation 
interrupts the translation of Dpp4 mRNA in the Japanese F344/DuCrj(DPPIV-) substrain [31] 
as well as in the German F344/Crl(Ger/DPPIV-) substrain. Both DPPIV-deficient F344 
substrains may provide an interesting model to further study the in vivo functional role of 
DPPIV for the cleavage of regulatory peptides and resulting various endocrine or 
immunological processes such as glucose tolerance or natural killer (NK) cell function. 
Likewise, differences in endogenous DPPIV-like activity in various rat strains may have an 
 55 DPPIV in different rat strains and F344 substrains: Regul Pept 115. 2003. 81-90. 
 
 
important impact for specific experiments focusing on in vivo effects of regulatory peptides, 
which are substrates for the DPPIV. 
Therefore, in the present study we mapped Dpp4 using a gene linked SSLP marker, 
performed breeding experiments to identify the mode of inheritance of DPPIV-like activity, 
and screened several laboratory rat strains including F344 rat substrains from different 
breeding colonies obtained at different time points from Crl for their endogenous DPPIV-like 
activity. Furthermore, we determined the glucose tolerance and NK cell function in DPPIV-
deficient and wildtype-like F344 rat substrains in order to exemplify the functional 
importance of spontaneous sequence variations in the Dpp4 gene.  
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 3.2 Materials and methods 
Animals 
All animals were housed at the Central Animal Facility of the Hannover Medical School 
(Ztm). Rats were maintained in a separated minimal barrier sustained facility and kept in 
Makrolon type III cages on standard bedding (Altromin GmbH, Lage, Germany). Food 
(Altromin Standard Diät 1320: Altromin GmbH) and water were available ad libitum. 
Environmental temperature was automatically regulated at 21 ± 2 °C, relative humidity at 55 
± 5% with an air change rate of 15 times per hour. The animal rooms were operated with a 
positive pressure of 0.6 Pa. Animals were maintained under 12:12 h light cycle, underwent 
routine animal care once a week and were microbiologically monitored according to FELASA 
recommendations [32]. All research and animal care procedures were approved by the district 
government, Hannover, Germany, and performed according to international guidelines for the 
use of laboratory animals. 
Origin of different F344 substrains from Charles River Laboratories 
The inbred F344 colony was originated by Curtis and Dunning at the Columbia University 
Institute for Cancer Research in 1920 [33]. In 1949 F344 animals were transfered to Heston 
(in F31) and in 1951 to the National Institute of Health (in F116). F344/Crl(Por) is derived 
from F344/Crl animals from the colony in Portage, which was established in 1998 with 
animals from the National Institute of Health subline. F344/Crl(Ral) were originated from 
F344/Crl animals from the colony in Raleigh (USA), which were derived from nucleus 
animals from Wilmington (New England) in 1985. The F344/DuCrj(DPPIV-) substrain was 
based on the colony of Curtis and Dunning in 1920. In 1960, the substrain was passed in 
generation F68 to Charles River Laboratories in Wilmington (Crl). After a rederivation via 
hysterectomy in the USA in 1965 (F81), the breeding was started in generation F110 at 
Charles River Laboratories in Japan in 1976 (Crj). F344/Crl(Ger/DPPIV-) rats were obtained 
as F344/Crl animals from Sulzfeld in Germany, which were derived from the nucleus-colony 
CDF from Wilmington in 1999. 
Unfortunately, several of these F344 substrains carry the same laboratory code (Crl). For 
clarity, animal groups were coded dependent on country or town of origin and the DPPIV-
related phenotype as followed: F344 rats derived from breeding colonies in Atsugi, Japan 
were designated as F344/DuCrj(DPPIV-), animals from breeding colonies in Sulzfeld, 
Germany, as F344/Crl(Ger/DPPIV-), wildtype-like rats obtained from colonies in Portage, 
USA, as F344/Crl(Por) and wildtype-like animals from Raleigh, USA, as F344/Crl(Ral). 
Additionally, the time point, at which the animals were obtained from Charles River 
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Laboratories (1998/2001) was indicated in our code (“98” for 1998 and “01” for 2001), 
whenever this appeared to be necessary. 
Dpp4 gene mapping 
Dpp4 maps to mouse chromosome 2 (MMU2) and the position of the homologous human 
gene (DPP4) is on human chromosome 2 (HSA2). Large parts of RNO3 are homologous to 
MMU2 and HSA2 (www.informatics.jax.org/menus/homology_menu.shtml). 
In this study genomic rat sequences available on the NCBI Rat Genome Blast page 
(www.ncbi.nlm.nih.gov/genome/seq/RnBlast.html) were used to identify polymorphic short 
tandem repeats in close proximity to Dpp4. To determine the position of Dpp4 in the rat 
genome, we analyzed 202 individual rats of a (LEW/Ztm-ci2 x BN/Ztm)F1 x LEW/Ztm-ci2 
backcross (N2) for inheritance of simple sequence length polymorphisms. For tissue 
collection, animals were sacrificed (anesthetized with carbon dioxide followed by cervical 
dislocation). For DNA preparation genomic DNA was prepared from ear or tail tissue with the 
Nucleo SpinTM Tissue kit (Macherey-Nagel GmbH, Düren, Germany). We used Taq-DNA-
polymerase (Peqlab Biotechnologie GmbH, Erlangen, Germany) and a PTC-200 thermal 
cycler (MJ Research Inc., Watertown, MA) for the polymerase chain reaction. Amplification 
was carried out in a 10 µl reaction with 1.5 mM MgCl2, 75 µm of each dNTP, 0.17 µm of 
each primer, 100 ng genomic DNA and 0.5 unit polymerase. After an initial step at 95 °C for 
4 min, 35 cyles of 15 s at 94 °C, 1 min at 55-56 °C and 2 min at 72 °C were performed, 
followed by 72 °C for 7 min. All PCR products were detected by gel electrophoresis using 3% 
NuSieveTM 3:1 agarose (Bio Wittaker Molecular Applications Inc., Rockland, Maine). 
All N2 rats were genotyped with the following SSLP markers to create a genetic linkage map 
of rat chromosome 3 (RNO3): D3Mgh8, D3Mit12, D3Mit4, D3Mgh1. Primer sequences for 
all markers used were obtained from the Rat Genome Database. All oligonucleotide primer 
pairs were synthesized by Carl Roth GmbH (Karlsruhe, Germany). Selection of gene linked 
short tandem repeats followed this step of the analysis. The rat genomic sequence used for 
this study was derived from the CHORI-230 Rat BAC library sequencing project. The library 
was constructed with the DNA of a 3-months old female BN(BN/SsNHsd/MCW) rat 
(www.chori.org/bacpac/). 
Rat genomic DNA sequence featuring identities to the rat cDNA sequence of Dpp4 [34] were 
identified with the NCBI Rat Genome Blast program. Tandem repeats within the rat genomic 
sequence were found using the Mount Sinai/The Department of Biomathematical Science 
Tandem Repeats Finder. Primer pairs for the short tandem repeats found in the rat genomic 
sequence were chosen using Oligo4.0TM (Molecular Biology Insights, Inc., Cascade, 
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Colorado) software and synthesized by Carl Roth GmbH. Short tandem repeats displaying 
variant alleles for LEW/Ztm-ci2 and BN/Ztm rat strains were used as gene linked SSLP 
markers. 
Mode of inheritance of DPPIV-like activity 
The mode of inheritance of DPPIV-like activity was determined using 
F344/DuCrj(98/DPPIV-), F344/Ztm, [F344/Ztm x F344/DuCrj(98/DPPIV-)]F1, and 
[F344/Ztm x F344/DuCrj(98/DPPIV-)]F2 rats. The enzyme activity of the parental strains, 
their F1, and their F2 generation was measured as described below.  
Determination of DPPIV-like enzymatic activity 
F344/DuCrj(98/DPPIV-), F344/DuCrj(01/DPPIV-), F344/Crl(Ger/98/DPPIV-), 
F344/Crl(Ger/01), F344/Crl(Por/98), F344/Crl(Por/01), and F344/Crl(Ral/01), as well as 
animals of various inbred rat strains maintained at Ztm (BDII, BDIX, BDE, BN, DA, E3, 
F344, LEW, LE, OM, WF, and WKY) were screened.  
EDTA-plasma samples were kept at –80 °C until use. DPPIV enzyme activity of the different 
rat strains was determined using glycyl-prolyl-4-nitroaniline (Gly-Pro-pNA) as substrate. A 
volume of 30  µl plasma was diluted with 120 µl 0.9% NaCl and 600 µl of 0.5 M substrate 
solution in HEPES buffer pH 7.6 were added. Release of 4-nitroaniline were monitored at 37 
°C and 390 nm up to 20 min using the UV1 spectrophotometer (ThermoSpectronics, Neuss, 
Germany). Activity (mU/ml) was calculated from the linear slope using a factor of 2193 
µmol/l calculated from the molar absorption coefficient and the plasma dilution. One unit is 
defined as the DPPIV activity, which cleaves 1 µmol Gly-Pro-pNA per minute. 
For determination of plasma activity of F344 rats during the inheritance study a more 
sensitive and faster microplate based fluorescence assay was used. The release of 4-Amino-7-
Methylcoumarin (AMC) from the substrate Gly-Pro-AMC was monitored at 360/480 nm 
(Ex/Em) and 30 °C using the Novostar fluorescence microplate reader (BMG, Offenburg, 
Germany). The assay consists of 20 µl plasma sample, 100 µl H2O, 100 µl HEPES buffer pH 
7.6, and 50 µl Gly-Pro-AMC. Activity was calculated from the linear slope using a factor of 
3.116*10-4 µmol/l calculated from an AMC standard curve and the sample dilution. One unit 
is defined as the enzyme activity, which cleaves 1 µmol Gly-Pro-AMC per minute. 
Both assays result in different activities due to differences in assay conditions and the 
different substrates used. Direct comparison of the same samples in both assays demonstrate 
that the activity determined by the assay using Gly-Pro-pNA as substrate is approximately 1.9 
times higher than the activity determined by the fluorescence assay (which was used for the 
mode of inheritance study). Both assays are selective for DPPIV-like activities. It has been 
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proven that the substrates are cleaved by DPPIV, by DP II and by attractin. Probably they are 
also substrates for DP8 and DP9. Importantly, the chromophores are not released by other 
proline-specific peptidases, such as prolidase, prolyl endopeptidase or aminopeptidase P. 
Glucose tolerance 
Animals of F344/Crl(Por/98), F344/DuCrj(98/DPPIV-), and F344/Crl(Ger/98/DPPIV-) 
substrains (n = 10) aging of 154 ± 5 days were used for this experiment. These animals were 
standardized in regard to their breeding conditions (littersize: n = 6, gender-ratio: 1:3 or 1:2), 
and number of animals per cage. Following an overnight fasting (12 h) 1 h after the onset of 
the light phase, animals (fasting) blood glucose levels were controlled. If the glucose 
concentration was < 7.8 mmol/l (< 140 mg/dl) the animals were orally administered with 
glucose (1.5 g glucose/kg) using a feeding tube [35, 36]. For this, rats were anesthetized 
shortly with Isofluran. Blood samples (10 µl) were collected from the tail vein of conscious 
unrestrained rats at 30, 60, 90, and 120 min following the oral glucose load and the glucose 
level was measured by a glucometer (Bayer AG, Leverkusen, Germany). Criteria for the 
definition of the glucose tolerance of the animals were blood glucose concentrations after 120 
min: < 7.8 mmol/l (< 140 mg/dl): normal glucose tolerance; 7.8-11.1 mmol/l (140-200 mg/dl): 
impaired glucose tolerance; > 11.1 mmol/l (> 200 mg/dl): Diabetes mellitus. 
Quantification of NK cell cytotoxicity in spleens of different F344 substrains 
A single cell suspension of splenocytes was prepared for each subject of F344/Crl(Por/98), 
F344/DuCrj(98/DPPIV-), and F344/Crl(Ger/98/DPPIV-) rats by gently pressing spleen tissue 
using the ends of stamps from sterile plastic syringes (n = 3 per each F344 substrains in three 
independent experiments). After erythrolysis and two washes in PBS, cells were re-suspended 
in exactly 10 ml RPMI 1640. Leukocyte numbers were determined using a Coulter cell 
counter and the splenocyte concentrations adjusted to 6 × 106 cells/ml with supplemented 
RPMI 1640 containing 10% fetal bovine serum. NK cytotoxicity was measured in classical 
51Cr-release assays using MADB106 target cells [37, 38], which were derived from standard 
cell culture conditions, as previously described [27]. Splenocytes, prepared through Ficoll-
Hypaque gradient [39], were used as effectors and effector-to-target (E:T) ratios of 12.5:1, 
25:1, 50:1, 100:1 were obtained. Co-incubation of effector and target cells was carried out 
either for 4 h with addition of 1000 U/ml IL-2 (EuroCetus, Amsterdam, The Netherlands) or 
for 18 h incubation, respectively [38]. Control wells containing only labelled targets were also 
plated to determine the spontaneous release. For determination of maximal possible release, 
the targets in one set of control wells were lyzed with Triton X-100. The spontaneous release 
was always less than 10% of the maximum release. Plates were centrifuged for 4 min prior to 
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incubation (37 ˚C, 5% CO2) and again prior to harvesting 75 µl of the supernatant for 
determining 51Cr release in a gamma counter. The specific cytotoxity was calculated by 
means of the following formula: [(experimental release) – (spontaneous release)] / [(maximal 
release) – (spontaneous release)] × 100.  
 
Statistical analysis 
The position of all RNO3 SSLP markers obtained from the Rat Genome Database as well as 
the position of our gene-linked marker were calculated using JoinMapTM2.0 (Centre for Plant 
Breeding and Reproduction Research; CPRO-DLO, Wageningen, The Netherlands) software. 
MapChartTM2.0 (CPRO-DLO) software was applied for drawing a linkage map of RNO3. The 
analysis of the blood plasma DPPIV-like activity was assessed by one-way ANOVA followed 
by the Fisher-PLSD-test for post hoc comparison, if appropriate. The analyses of the blood 
glucose level and NK cell mediated specific cytotoxicity were assessed by analysis of 
variance (ANOVA) for repeated measures followed by two-way and one-way ANOVA and 
the Fisher-PLSD-test as post hoc test, if appropriate. Differences were regarded as statistically 
significant if p < .05. In the figures and tables, all data are displayed as means ± standard error 
of the mean (SEM) and significant post hoc effects versus the wildtype-like control animals of 
the F344/Crl(Por/98) substrain are indicated by asterisks (*p < .05 - **p < .01 - ***p < .001).
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3.3 Results 
Dpp4 gene mapping 
Rat specific DNA sequences derived from BAC clones were useful for this investigation. We 
screened rat BAC sequence data for the presence of both a tandem repeat and identity to the 
cDNA of rat Dpp4. BAC clone CH230-34P1/AC1257121 contains the genomic sequence of 
Dpp4 as well as a (CT)36 tandem repeat. According to the sequence of this BAC clone the 
tandem repeat is located within an intron of rat Dpp4. This tandem repeat displayed variant 
alleles for LEW/Ztm-ci2 and BN/Ztm rats and was used as a gene linked SSLP marker 
(D3Ztm1). We used TGG GGG ATT ATA CTA ATT CAG TCC CCA (5´-3´) as upper 
primer and ACT TCC CTT GCA AGC ACA GAA AAC (5´-3´) as lower primer for 
amplification of D3Ztm1. The calculated product size (BN rats) of this gene linked SSLP 
marker is 299 base pairs. 
Linkage analysis revealed that the four D3 SSLP markers described by the Rat Genome 
Database map to RNO3. The maximum distance between D3Mgh8 and D3Mgh1 is 114.0 
centimorgan (cM) as calculated for the N2 population studied. Since D3Ztm1 showed 
significant linkage to these four RNO3 markers it was integrated into the scaffold previously 
created by those microsatellites. The position of Dpp4/D3Ztm1 was determined as 29.0 cM on 
our RNO3 genetic linkage map (Fig. 1).  
Mode of inheritance of DPPIV-like activity 
DPPIV-like activity in male F344/DuCrj(98/DPPIV-) rats was 3.0 ± 0.4 mU/ml, while female 
F344/Ztm rats exhibit an average DPPIV-like activity of 19.1 ± 0.7 mU/ml. In the [F344/Ztm 
x F344/DuCrj(98/DPPIV-)] F1 generation an average enzyme activity of 9.3 ± 0.4 mU/ml 
could be measured. The F2 progeny of the F344/Ztm x F344/DuCrj(98/DPPIV-) cross could 
be subdivided into three phenotypic groups. The first group had a low DPPIV-like activity of 
2.2 ± 0.1 mU/ml and was therefore considered homozygous for the mutant Dpp4 allele. A 
high endogenous DPPIV-like activity of 20.6 ± 1.4 mU/ml was found in the second group. 
These animals appear to be homozygous for the Dpp4 wildtype-like allele. The third group 
represents F344 rats with an intermediate DPPIV-like activity as this has been shown for the 
F1 generation. The mean value in this group was 10.8 ± 0.3 mU/ml, displaying an 
intermediate phenotype suggestive for a semi-dominant mode of inheritance. 
DPPIV-like enzymatic activity 
The different F344 substrains showed significant overall differences in the DPPIV-like 
activity (one-way ANOVA: p < .0001). The F344/Crl(Por/98) substrain (n = 27) exhibited a 
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normal DPPIV-like activity whereas the DPPIV-deficient substrains F344/DuCrj(98/DPPIV-) 
(n = 32) and F344/Crl(Ger/98/DPPIV-) (n = 31) showed a dramatic reduction in the DPPIV-
like activity (Fig. 2).  
The F344 animals ordered from the different breeding colonies of Charles River Laboratories 
in Germany, Japan, and the USA in 2001 showed a unique pattern of DPPIV-like activity and 
differed from the previously in 1998 obtained animals. Male and female animals of the colony 
in Raleigh, F344/Crl(Ral/01), and surprisingly also from Sulzfeld, F344/Crl(Ger/01) exhibited 
a considerable high DPPIV-like activity (Table 1). The latter was opposite to the extreme 
reduction of DPPIV-like activity in the F344/Crl(Ger/98/DPPIV-) rats subsequently bred in 
our laboratory. The animals of the Japanese substrain, F344/DuCrj(01/DPPIV-) did still lack 
DPPIV-like activity (one-way ANOVA: p = 0.02; Table 1). The results found in the F344 
substrain from the colony in Portage, F344/Crl(Por/01) were gender-dependent. Female rats 
exhibited a normal DPPIV-like activity, while males nearly completely lacked DPPIV-like 
activity (one-way ANOVA: p < .0001). This potent gender-dependent phenotype was 
different to the F344/Crl(Por/98) animals bred in our laboratory (Fig. 2).  
Furthermore, we also found a wide range of DPPIV-like activity in several other inbred rat 
strains maintained in the Ztm (Table 2). Among those strains LEW/Ztm exhibited the lowest 
(11.5 mU/ml) while DA/Ztm and BN/Ztm showed the highest DPPIV-like activity (DA/Ztm: 
39.8 mU/ml and BN/Ztm: 39.7 mU/ml). 
Glucose tolerance 
The fasting blood glucose levels of the three F344 substrains were not different (Fig. 3). The 
DPPIV-negative substrains F344/DuCrj(98/DPPIV-) and F344/Crl(Ger/98/DPPIV-) showed a 
significant lower blood glucose level during the oral glucose tolerance test in comparison to 
F344/Crl(Por/98), which were taken as a control group. This was shown by ANOVA for 
repeated measures (p < .0001) and one-way ANOVA for the blood glucose levels split by 
time at 30 min (p = 0.004), 60 min (p = 0.001), and 90 min (p = 0.01) after the oral 
administration of glucose. Although at the critical time point of 120 min after the 
administration the blood glucose tolerance of all three substrains was normal (< 7.8 mmol/l), 
the tolerance of the two DPPIV-deficient substrains during the schedule was improved 
compared to the wildtype-like animals. 
NK cell cytotoxicity in spleens of different F344 substrains 
NK specific lysis of MADB106 tumour cells using a classical ex vivo NK cell functional 
assay is shown in Fig. 4. In the DPPIV-deficient F344/Crl(Ger/98/DPPIV-) and 
F344/DuCrj(98/DPPIV-) substrains, NK cell mediated lysis against MADB106 tumor targets 
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is significantly decreased compared to wildtype-like F344/Crl(Por/98) rats. This effect was 
observed in both assays (4 h co-incubation in the presence of IL2; Fig. 4A; and 18 h 
incubation; Fig. 4B). Two-way ANOVA showed a significant effect of "substrain" (p < .001) 
and "E:T ratio" (p < .01) in the 4 h assay. Similarly, two-way ANOVA of the 18 h assay data 
revealed a significant effect of "substrain" (p < .001) and "E:T ratio" (p < .05). Furthermore, 
post hoc analysis of the 4 h assay data (Fig. 4A) revealed a significantly reduced NK 
cytotoxicity in the F344/Crl(Ger/98/DPPIV-) substrain when compared with the 
F344/DuCrj(98/DPPIV-) rats.  
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3.4 Discussion 
DPPIV-like enzymes specifically cleave several regulatory peptides including GLP-1, NPY, 
substance P, and chemokines, which are characterized by a N-terminal alanine or proline. 
Biological research on in vivo functions of these regulatory peptides is often carried out in rats 
or in rat derived biomaterial. The present study demonstrates that the Dpp4 gene is located on 
rat chromosome 3 and that it is inherited in a semi-dominant fashion. Furthermore, we show 
that laboratory inbred strains of rats exhibit obvious differences in DPPIV-like enzymatic 
activity, which probably affects degradation and half-life of regulatory peptides, which are 
substrates of the DPPIV. Even more important for researchers using F344 rats, we also 
observed that the commercially available F344/DuCrj(DPPIV-) rat substrain from a breeding 
colony in Japan (Atsugi) constantly exhibits a nearly complete lack of DPPIV-like enzymatic 
activity, while rats of the F344/Crl(Ger) substrain from breeding colonies in Germany 
(Sulzfeld) only occasionally showed a lack of DPPIV-like enzymatic activity. In regard to the 
physiological relevance of this enzymatic system, we furthermore demonstrated that a lack of 
DPPIV-like activity is associated with an improved glucose tolerance and a decreased NK cell 
mediated lysis of tumor cells. 
Using an SSLP marker located within the sequence of rat Dpp4 we were able to define the 
position of this gene on RNO3. This finding suggests that the gene content is conserved 
between this segment of RNO3 and the corresponding parts of MMU2 and HSA2, where the 
homologous orthologous genes of rat Dpp4 are located. Further on, we provide information 
about the distance of Dpp4 to anonymous microsatellite markers, which are generally used for 
linkage mapping of loci defined by phenotype alone. This should be a valuable prerequisite 
for further analysis of the influence of Dpp4 on the phenotypes of different rat strains. 
Since the present study demonstrates that F344/DuCrj(DPPIV-) rats, which are homozygous 
for the mutant Dpp4 allele, lack the endogenous DPPIV-like activity our data about the mode 
of inheritance provide strong evidence that the wildtype-like DPPIV remains active on an 
intermediate level in heterozygous F344 rats. Therefore, out- and intercrosses between 
F344/DuCrj(DPPIV-) and F344/Ztm might be a valuable tool to examine the impact of 
DPPIV-like activity also on other DPPIV-dependent physiological parameters.  
Furthermore, we screened different F344/Crl breeding colonies in Portage and Raleigh 
(USA), in Atsugi (Japan), and in Sulzfeld (Germany) in 1998 and 2001. The two independent 
sets of F344 rats from Japan F344/DuCrj(98/DPPIV-) and F344/DuCrj(01/DPPIV-) 
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constantly exhibit a nearly complete lack of DPPIV-like activity. In contrast, we found a 
variation between the F344/Crl(Ger/98/DPPIV-) colony, which we continued to breed in our 
laboratory, and another set of animals from the same colony from Crl, which we obtained 3 
years later [F344/Crl(Ger/01)]. While F344/Crl(Ger/98/DPPIV-) rats show a nearly complete 
loss of DPPIV-like activity, F344/Crl(Ger/01) are indistinguishable from the wildtype-like 
F344/Crl(Por/98) and F344/Ztm substrains. Surprisingly, rats recently obtained from the Crl  
colony in Portage, USA [F344/Crl(Por/01)], show a gender-dependent difference in the 
DPPIV-like enzymatic activity. Males have a dramatic reduction in the enzymatic activity, 
while females exhibit a wildtype-like phenotype. The differences in the DPPIV-like activity 
among the F344 rats from different breeding colonies of a world-wide operating vendor at 
different intervals clearly indicates a persisting segregation for the Dpp4 gene. Furthermore, 
the laboratory code of the substrains from the different breeding colonies in the USA and 
Germany is - unfortunately - identical. Overall, these findings on variation in DPPIV-like 
enzymatic activity indicate that scientists, who obtain F344 rats from this vendor or who work 
on DPPIV-dependent physiological processes in the rat should screen their animals in regard 
to their DPPIV-like activity. 
In addition, the present study shows that there is a considerable variance in the DPPIV-like 
activity in different inbred strains of rats. High levels are found especially in the DA/Ztm and 
BN/Ztm, while LEW/Ztm animals show a low activity. In spite of the microsatellite D3Ztm1 
being polymorphic between BN/Ztm and LEW/Ztm, it still remains unclear whether the 
various DPPIV-like activities can be attributed to differences among coding regions of the 
Dpp4 genes or to modifier genes of the respective genetic background. Regarding the F344 
substrains F344/DuCrj(98/DPPIV-) and F344/Crl(Ger/98/DPPIV-) we assume that the 
deficiency in DPPIV-like activity can be attributed to a previously described spontaneous 
mutation [31], which lead to a null allele. Modifier genes can be most likely excluded due to 
the fact that the genetical background of the different F344 substrains might be similar. 
Nevertheless, these findings might have important implications for research focusing on 
endocrine and immunological aspects directly or indirectly related to DPPIV/CD26 such as 
research on diabetes, T cell function, or cell migration in the rat.  
To our knowledge, only a few studies so far used DPPIV-deficient F344/DuCrj(DPPIV-) rats 
to investigate influences of DPPIV-like activity on glucose tolerance [35, 36, 40]. Because of 
partly contradictory findings regarding the glucose tolerance in these F344/DuCrj(DPPIV-) 
animals and since the DPPIV-deficient F344/Crl(Ger/DPPIV-) colony has not been tested, we 
investigated the glucose homeostasis in the three F344 substrains bred in our laboratory since 
 66 DPPIV in different rat strains and F344 substrains: Regul Pept 115. 2003. 81-90. 
 
 
1998. The results of the study provide strong evidence that DPPIV plays an essential role in 
the physiological control of blood glucose. This is reflected by an improved glucose tolerance 
in the DPPIV-deficient F344/DuCrj(98/DPPIV-) and F344/Crl(Ger/98/DPPIV-) rats. These 
findings are in agreement with studies in F344/DuCrj(DPPIV-) rats [35, 40] and in DPPIV 
knockout mice [20]. The lack of DPPIV-like activity in the two DPPIV-deficient substrains 
seems to be responsible for the improved glucose tolerance. 
GLP-1 is involved in glucose homeostasis by its multifaceted actions, which include 
stimulation of insulin gene expression, increase of glucose-stimulated insulin secretion [22, 
23], and inhibition of glucagon secretion, all of which contribute to normalize elevated blood 
glucose levels [41]. Administration of GLP-1 functions as an antidiabetic in patients with type 
2 diabetes [35] and GLP-1 receptor antagonists induce glucose intolerance in rats [42]. Thus, 
active GLP-1 has a powerful influence on glucose tolerance. Interestingly, inhibition of 
DPPIV-like activity is effective to suppress the degradation of exogenously administered or 
endogenously circulating incretins like GLP-1 [41, 43]. Besides DPPIV-inhibition by valine-
pyrrolidide or isoleucyl-thiazolidide (Ile-Thia) improve the glucose tolerance [23, 44] and Ile-
Thia also enhances the insulin secretion [45]. Obviously, inhibition of DPPIV results in 
increased levels of active GLP-1 and GIP [24] and an improved glucose tolerance. We 
conclude that a lack in DPPIV-like activity in the mutant F344 rats improves the glucose 
tolerance probably by an incretin-mediated mechanism [23]. Manipulation of plasma incretin 
concentrations by acute inhibition of DPPIV could be a therapeutic approach for improving 
glucose tolerance and could prevent transition to type 2 diabetes. Therefore, different F344 
substrains may represent a useful tool for research focusing on glucose homeostasis. 
The finding on a blunted NK cell mediated cytotoxicity against syngenic tumor cell targets 
suggests that DPPIV/CD26 is involved in mediating specific aspects of NK cell function. 
Previous work on the role of DPPIV/CD26 on NK cells has demonstrated that IL-2 
stimulation increases DPPIV/CD26 expression on a subpopulation of these cells [4, 46]. 
However, NK cell cytotoxicity of DPPIV/CD26-positive NK cells was not different compared 
to DPPIV/CD26-negative NK cells [46]. Since in addition DPPIV/CD26 inhibitors had no 
effect on NK cell function but instead suppressed DNA synthesis and cell cycle progression 
of NK cells, it was concluded that DPPIV/CD26 is involved in the regulation of NK cell 
proliferation, whereas natural cytotoxicity seems to be regulated independently [46]. The 
present finding that the mutant substrains exhibited a differential suppression of their NK cell 
function might suggest that either a lack of DPPIV/CD26 enzymatic activity or a differential 
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DPPIV/CD26 expression or both factors may mediate the decrease in NK cell mediated tumor 
lysis. 
However, important for the in vivo situation, it should be noted here that other partly 
completely different enzymes also mediate a DPPIV-like enzymatic activity [namely, 
fibroblast activation protein (FAP), DP8 and DP9, which like DPPIV belongs to the prolyl 
oligopeptidase protease family and the lysosomal enzyme DP II]. All of these peptidases 
possess a high homology around the active site. Furthermore, the structural unrelated protein 
attractin was found to express post-proline dipeptidyl-peptidase activity. At least for DP II 
and for attractin we could demonstrate that the Gly-Pro substrates are cleaved by these 
enzymes. Theoretically, a cleavage of substrates with a N-terminal penultimate proline is also 
possible by a subsequent action of aminopeptidase P and a prolyl aminopeptidase activity. 
This could be widely excluded for the measured plasma activities because control 
experiments demonstrates that the measured activity could be nearly completely inhibited be 
competitive DPPIV inhibitor Ile-Thia. But this small inhibitor may also be effective for 
inhibition of all other DPPIV-like enzymes, as it was proven for DP II and for attractin. 
In conclusion, we present a gene linked SSLP marker, which allowed us to map the semi-
dominant inherited Dpp4 to rat chromosome 3. Screening of DPPIV-like enzymatic activity in 
commercially available F344/DuCrj(DPPIV-) rats exhibited a nearly complete lack of 
DPPIV-like enzymatic activity, while F344/Crl(Ger) and F344/Crl(Por) rats obtained in 
different years (1998 and 2001) apparently segregate or show a gender-associated difference. 
In addition, different rat inbred strains revealed considerable differences in enzymatic activity. 
DPPIV deficiency of F344 substrains was found to be associated with an improved glucose 
tolerance and a decreased NK cell function. Overall, the variations in DPPIV-like enzymatic 
activity reported here could act as confounding factors in biomedical research using rats not 
screened (genetically monitored) for this factor beforehand and probably should be considered 
when selecting rat strains for studies on regulatory peptides, which are substrates for the 
DPPIV. 
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3.7 Tables and figures 
 
Table 1:  
 Male Female 
 n DPPIV-like activity n DPPIV-like activity 
F344/Crl (Por/01) 3                 6.6 ± 1.0 6 20.2 ± 0.4 
F344/Crl (Ral/01) 3               18.1 ± 1.2 6 16.8 ± 3.5 
F344/DuCrj(01/DPPIV-) 3                 3.5 ± 0.1 6 6.7 ± 0.7 
F344/Crl (Ger/01) 3               18.0 ± 0.2 6 17.8 ± 0.8 
Gender-dependent DPPIV-like activity [mU/ml] in the different F344 rat substrains obtained 
from Crl in 2001 [F344/Crl(Por/01), F344/Crl(Ral/01), F344/DuCrj(01/DPPIV-), and 
F344/Crl(Ger/01)]. Data represent means ± SEM. 
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Table 2:  
Rat strain 
(Ztm) 
DPPIV-like activity  
LEW 11.5 ± 1.1 
WF 14.0 ± 0.3 
OM 14.4 ± 1.5 
WKY 14.6 ± 1.3 
BDII 18.4 ± 1.7 
F344 19.1 ± 0.7 
BDE 20.9 ± 1.2 
LE 23.1 ± 1.0 
E3 24.7 ± 0.4 
BDIX 31.0 ± 0.8 
BN 39.7 ± 3.3 
DA 39.8 ± 0.9 
DPPIV-like activity [mU/ml] in different inbred rat strains obtained from the Ztm in 2001. 
Data represent means ± SEM (n ≥ 3 rats). 
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Fig. 1: Genetic linkage map of RNO3 including gene linked SSLP marker (D3Ztm1). 
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Fig. 2: DPPIV-like activity [mU/ml] in three different F344 rat substrains obtained from Crl 
in 1998 [F344/Crl(Por/98), F344/DuCrj(98/DPPIV-), and F344/Crl(Ger/98/DPPIV-)]; blood 
samples were taken from the tail vein. Data represent means + SEM. Significant post hoc 
effects versus the wildtype-like animals of the F344/Crl(Por/98) substrain are indicated by 
asterisks (***p < .001). 
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Fig. 3: Glucose tolerance [mmol/l] in three different F344 rat substrains obtained from Crl in 
1998 [F344/Crl(Por/98), F344/DuCrj(98/DPPIV-), and F344/Crl(Ger/98/DPPIV-)] following 
an overnight fast; administration of oral glucose (1.5 g glucose/kg) in animals, which were 
anesthetized shortly with Isofluran. Blood samples (10 µl) were collected at 30, 60, 90, and 
120 min following the oral glucose load. Data represent means + SEM. Significant post hoc 
effects versus the wildtype-like animals of the F344/Crl(Por/98) substrain are indicated by 
asterisks (*p < .05 - **p < .01 - ***p < .001). 
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Fig. 4: Splenic NK cytotoxicity against MADB106 cells in DPPIV-deficient F344 rat 
substrains [F344/Crl(Ger/98/DPPIV-) and F344/DuCrj(98/DPPIV-)] compared to wildtype-
like F344/Crl(Por/98) rats [%]; NK cytotoxicity was measured in an assay for 51Cr release 
from labelled target cells after (A) 4 h incubation with IL2 and (B) 18 h incubation using 
syngeneic MADB106 tumor cells as targets. Assays were repeated twice. Data represent 
means ± SEM. 
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Abstract 
The enzyme and binding protein dipeptidyl-peptidase IV (DPPIV; CD26) has a unique 
enzymatic specificity in cleaving dipeptides from neuropeptides, chemokines, and hormones. 
Thus, DPPIV is potentially involved in the regulation of functions of the nervous, endocrine, 
and immune systems. In the present study we compared DPPIV-deficient, mutant Japanese 
[F344/DuCrj(DPPIV-)] and German [F344/Crl(Ger/DPPIV-)] F344 rat substrains with a 
wildtype-like F344 substrain [F344/Crl(Por)] from the USA in a multi-tiered strategy using a 
great number of different behavioral tests. General health, neurological and motor functions, 
and sensory abilities of the different F344 substrains were not different. A reduced body 
weight and a reduced water consumption was observed in mutant animals. DPPIV-deficient 
rats exhibited increased pain sensitivity in a non-habituated hot plate test, indicative of a 
reduced stress-induced analgesia. In line with this finding, reduced stress-like responses in 
tasks like the open field, social interaction, and the passive avoidance test were found. 
Differences in DPPIV-like activity appear to be involved in neurophysiological processes 
because DPPIV-deficient animals were less susceptible to the sedative effects of ethanol. The 
varying phenotypes of the F344 substrains are likely to be mediated by differential 
degradation of DPPIV substrates such as substance P, glucagon-like peptide 1 (GLP-1), 
enterostatin, and especially neuropeptide Y. Potentially, DPPIV-deficient substrains represent 
an important tool for biomedical research, focusing on the involvement of DPPIV and its 
substrates in behavioral and physiological processes. 
 
 
 
Keywords: Dipeptidyl-peptidase IV - F344 rats – Substrain comparison - Basic behavioral 
phenotyping – Motor function - Nociception - Anxiety - Memory - Ethanol - Porsolt swim 
test - Prepulse inhibition – Feeding behavior 
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4.1 Introduction 
The enzyme and binding protein dipeptidyl-peptidase IV (DPPIV), which is identical to 
CD26, was discovered in 1966 (31) and is a member of the class of membrane-associated 
peptidases. Most vertebrate tissues contain this ectopeptidase, which is also in close contact 
with circulating hormones in the blood. In the adult nervous system, DPPIV cleaves 
neuropeptides mainly in the cerebrospinal fluid since it is found primarily in the 
circumventricular organs and on leptomeningeal cells in the central nervous system (CNS) 
(50). However, other DPPIV-like enzymes such as attractin may also contribute to these 
processes. DPPIV has a unique enzymatic specificity, cleaving dipeptides from peptides and 
proteins carrying Xaa-Pro or Xaa-Ala in their penultimate position (14). Many neuropeptides, 
chemokines and hormones have proline residues at specific positions in their amino acid 
sequence. Known substrates for DPPIV are growth-hormone-releasing-factor, glucagon-like 
peptide 1 (GLP-1), GLP-2, kentsin, enterostatin, substance P, peptide YY, and trypsinogen. 
Relevant substrates in immune reactions are chemokines as well as cytokines such as IL-2 
(28). In addition, it is known that DPPIV is involved in T-cell dependent immune responses 
(34) and in cell adhesion (50). The rapid degradation of Tyr-Pro dipeptides from the 
neurotransmitter neuropeptide Y (NPY) with high turnover rates by DPPIV (50) is of 
particular importance, because NPY is the most abundantly expressed neuropeptide within the 
CNS. NPY is involved in the central regulation of various neuroendocrine and behavioral 
functions like feeding, nociception, anxiety, and memory in rodents (35, 38, 85). Thus, 
DPPIV is both directly and indirectly involved in the regulation of nervous, endocrine, and 
immune functions. Despite these pleiotropic effects of DPPIV, no systematic investigations 
on the role of the DPPIV-like activity in the CNS have been conducted so far.  
Interestingly, a spontaneous mutation of the Dpp4 gene has been described in F344 rat 
substrains from breeding colonies of Charles River Laboratories (Crl) in Atsugi, Japan (77, 
84), and Sulzfeld, Germany (75). This mutation results in an almost complete loss of DPPIV 
activity in contrast to the wildtype-like F344 rats from Crl breeding colonies in Portage, USA 
(75, 79). Therefore, we considered the mutant Japanese and German F344 rat substrains to be 
similar to DPPIV “germline” knockout animals. Recently we were able to demonstrate an 
involvement of DPPIV in the substrains’ glucose homeostasis, which is most likely fine-tuned 
via DPPIV-dependent cleavage of the incretin GLP-1 in the periphery. These results validate 
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the relevance of the DPPIV-mutant F344 substrains for studying DPPIV-dependent processes 
(36). Obviously, these DPPIV-deficient F344 substrains may provide an interesting model to 
study the functional role of DPPIV in various other physiological processes, including various 
CNS-dependent behavioral processes. Specifically, the different enzymatic activity of DPPIV 
should result in a differential degradation of DPPIV substrates such as enterostatin or NPY, 
thereby having pronounced effects on the behavior of animals. 
Therefore, we compared DPPIV-deficient F344 substrains with the wildtype-like F344 
substrain. We applied a multi-tiered strategy for a behavioral and physiological 
characterization of an unknown phenotype in mice (11, 37) and modified this concept to the 
characterization of rats. General health, neurological and motor functions, and the sensory 
abilities of the rats were monitored. Furthermore, the effects of differential endogenous 
DPPIV-like activity on specific CNS-related behavioral domains such as feeding behavior, 
nociception, anxiety, learning and memory, and ethanol preference were investigated. 
Additionally, the neurophysiological role of DPPIV was evaluated in experiments screening 
for the sedative effect of ethanol and for symptoms related to human psychiatric disorders 
such as schizophrenia and depression. Since single tests for certain behavioral domains might 
not detect a specific defect, a large series of different tests for various behavioral domains 
were applied (Table 1). 
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4.2 Materials and methods 
Animals 
To ensure clarity of nomenclature, we coded animal groups as previously described (36): 
F344 rats derived from a breeding colony in Atsugi, Japan were coded as 
F344/DuCrj(DPPIV-), animals from a breeding colony in Sulzfeld, Germany, as 
F344/Crl(Ger/DPPIV-), and wildtype-like rats obtained from a colony in Portage, USA, as 
F344/Crl(Por). All animals were obtained from Charles River Laboratories in 1998. 
All F344 rats of the three different substrains were housed and bred at the Central Animal 
Facility of the Hannover Medical School (Ztm). Animals were maintained in a separated 
minimal barrier sustained facility and kept in Makrolon type III cages with standard bedding 
(Altromin GmbH, Lage, Germany). Food (Altromin Standard Diät 1320: Altromin GmbH) 
and water were available ad libitum. Environmental temperature was automatically regulated 
at 21 ± 2 °C and relative humidity was 55 ± 5% with an air change rate of 15 times per hour. 
The animal rooms were operated with a positive pressure of 0.6 Pa. Rats were maintained 
under a 12:12 h light regime (light onset at 4am) being further standardized in regard to their 
breeding conditions (littersize: 6, gender-ratio: 1:5 or 2:4), and number of animals per cage. 
Routine animal care was carried out once a week. Routine microbiologic monitoring 
according to FELASA recommendations (64) did not reveal any evidence of infection with 
common murine pathogens except for Pasteurella pneumotropica and Staphylococcus aureus. 
All research and animal care procedures were approved by the Review Board for the Care of 
Animal Subjects of the district government, Hannover, Germany, and performed according to 
international guidelines for the use of laboratory animals. 
 
Test sets of animals and phenotyping by determination of DPPIV-like 
activity 
To avoid major influences from the high number of different behavioral test paradigms 
applied to the animals, three independent sets of age-matched F344 rats of the three substrains 
were used for the present study (details see Fig. 1). One set of animals (experimental set II) 
was single-housed, whereas the two other sets of animals were group-caged (2 - 3 animals). 
Prior to the final experiments, these sets were single-housed for the ethanol-self-
administration task (experimental set I) and for the second feeding behavior task (feeding II – 
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experimental set III). All animals were characterized in regard to their DPPIV-like enzymatic 
activity as previously described (36) and were tested in the various behavioral paradigms in 
the animal room.  
 
Experimental design of the behavioral test paradigms 
General health and neurological examination 
Gross abnormalities that would interfere with further behavioral testing such as general 
health, sensory abilities, and neurological reflexes were controlled and compared between the 
different F344 substrains as described previously (11, 12, 37). Neuromuscular strength of the 
animals was tested in the wirehang test (69). Visual abilities were controlled by observing the 
response of the rat to an unknown object, a modified visual cliff task (59), and the so-called 
ring paradigm, in which the rat was dangled by the tail into the middle of a plastic ring 
(diameter: 20 cm) with three convexities. The occurrence of the rat´s reaching behavior with 
the forepaws in direction of one of the ring´s convexities was measured.  
Determination of motor functions 
This test of neuromotor performance is based on a motor-driven, rotating rod (33). An Ugo 
Basile accelerating rotarod (model 7750) for rats, supplied by Technical & Scientific 
Equipment GmbH (TSE GmbH), Bad Homburg, Germany, was used. During the four days of 
training session (onset 1 h after onset of the dark phase) animals were placed onto the 
apparatus at a constant speed of 20 rotations per minute (rpm) for 120 s. In the following four 
days of rotarod test session the animals were subjected for 1 min each to various increasing 
rotation speed levels (between 4 - 40 rpm) twice a day (intertrial interval: 1 h) for 1 min each. 
Afterwards, rats were tested for another four days (twice a day – intertrial interval: 1 h) in the 
accelerod test session, in which the rotation speed was constantly increased over a time period 
of 5 min. In both rotarod and accelerod test sessions, the latency to fall off the rod and the 
actual rotation speed were recorded (7). 
Feeding behavior 
The animals were housed either in groups (“Feeding I”) or singly in a cage (“Feeding II”). 
The observation period lasted 78 h each. The daily food and water consumption was 
measured. The consumption of the group-caged animals was recorded at the onset of the light 
and the dark cycle and 2 h after the onset of the dark cycle. The feeding behavior of the 
single-housed animals (“Feeding II”) was measured once a day at the onset of the light cycle. 
Multiple pairs of water tubes were monitored on empty cages to control for evaporation and 
accidental spillage (43). 
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Screening for differences in nociception 
Tail flick 
This test is based on the withdrawal of the tail in response to a noxious, cutaneous, thermal 
stimulation (17). A tail flick unit (TSE GmbH) was used. The rat was held on the apparatus 
top panel so that its tail received the infrared energy. Latency to flick the tail out of the path of 
the light beam was measured. In order to minimize possible tissue damage, different patches 
of tail skin were stimulated per trial (cut-off time: 15 s) (66). 
Hot plate 
The hot plate assay is one of the most commonly used tests for determining the analgesic 
efficacy of experimental drugs in rodents. A 30x30 cm hot plate analgesia meter (Columbus 
Instruments, Columbus, USA), maintained at 52.5 °C, was used for this experiment. Latency 
to lick or raise hindpaws was recorded. To prevent any tissue damage, the rat was removed 
from the hot plate if the animal did not respond within 20 s (56, 70). Animals were tested in a 
non-habituated task (“Hot plate I”) and after 5 days of habituation (placing the rat onto the 
inactivated apparatus daily for 3 min) in a habituated task (“Hot plate II”). 
Evaluation of anxiety 
In early studies various authors defined the open field and the elevated plus maze as tests for 
emotionality (1, 16, 83). The construct “emotionality” was defined by Denenberg with high 
defecation scores and low ambulation in the open field being indicators of high 
“emotionality” and vice versa. In more recent years, the same paradigms are discussed in 
regard to their potential to provide indicators of anxiety and the construct “emotionality” is 
less frequently used (24, 49, 63). This may mainly be due to the fact that the construct 
“emotionality” is likely to be confounded by effects, which primarily affect locomotor activity 
only. Therefore, we use the term “anxiety-like behavior” in regard to these tests. 
Open field (OF) 
Locomotor activity and anxiety of rats can be evaluated by placing the animal in an open field 
arena (16). This paradigm mimics the natural conflict between the tendency to explore a novel 
environment and the tendency to avoid a brightly lit, open area (15). The exploratory activity, 
the anxiety-like reactivity, or both different behavioral dimensions can influence the animal´s 
behavior (37). In this task an inverse relationship between exploration/defecation and the 
anxiety (emotionality) of rodents is described (16, 80). The apparatus used in this experiment 
has been described previously (80) and was dimly illuminated (10 lux). 1 h after onset of the 
dark phase animals were placed into the center of the open field arena (start area) and 
observed for 10 min in 2 min intervals. The latency to leave the start area, the latency and 
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frequency of self-grooming, rearing, and rearing at the wall, distance traveled (number of 
square entries), the ratio of distance traveled and time spent in the center and the periphery of 
the arena, and the defecation score were recorded (83). Exploration was measured by 
ambulation, latency and frequency of rearing and rearing at the wall, and latency to leave the 
start area. We used an increase in the ratio of traveled distance, in the time spent in the center 
of the arena and in ambulation and a decrease in the defecation score as indicators for 
anxiolytic-like behavioral responses (63), although the defecation score is discussed 
controversially in the literature (26, 68, 83). To avoid cohort removal effects, one animal per 
cage per day was tested (39).  
Elevated plus maze (EPM) 
The pharmacologically validated EPM deals with the preference of rodents for a dark, 
enclosed, small space over a brightly lit, large, open space (45, 54). The open and closed arms 
generate exploratory behavior and the avoidance of the elevated, open arms is an indication of 
the intensity of anxiety (29, 45). An elevated plus maze (TSE GmbH) was used as previously 
described (4). Illumination was dim (10 lux). 1 h after onset of the dark phase the animal was 
placed onto the center platform facing an open arm. In the following 5 min the time spent on 
open arms as well as the percentage of open arm entries were recorded. The number of closed 
and total arm entries were considered to provide indices of general motor activity (58) and an 
increase in the time spent on open arms and in the percentage of open arm entries is used as 
an indication of anxiolysis (22, 49, 58). In addition, rearing, self-grooming, and the 
defecation score were measured. To avoid cohort removal effects, one animal per cage per 
day was tested. 
Social interaction 
The rat social interaction test is used widely to measure anxiety-like behavior (21) and to 
detect anxiogenic and anxiolytic-like effects of drugs (39). Active social interaction (SI) time 
is inversely related to the anxiety of the animals (23), which is confirmed by the observation 
that the maximum active SI time is found when rats are tested in a familiar test arena with a 
low level of illumination (23). Furthermore, a decrease in SI time is correlated with an 
increase in other anxiety-like behaviors: defecation, freezing, and displacement activity (i.e. 
eating of non-edible objects by rats that are not food deprived). Therefore, the decrease in 
social behaviors is consistent with behavioral indications of increased arousal or anxiety and 
is not explained by any changes in other competing behaviors such as exploration (20, 21). 
The apparatus used for this study has been previously described (39). 1 h after onset of the 
dark phase two weight-matched rats of the similar substrain but from different cages were 
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exposed to the arena, which was brightly illuminated (180 lux). The total duration and the 
frequency of different behaviors like anal sniffing, following, allo grooming, walking over, 
crawling under, and nosing were recorded and summed during 10 min. Additionally, the 
motor activity of the rats was analyzed by recording distance traveled (counting the number of 
entries into squares). 
Learning and memory 
Radial maze 
The radial maze test, in which rodents are trained to visit a pattern of arms to receive a food 
reward (precision pellets for rodents: Campden Instruments LTD, Loughborough, England), is 
specific to measure spatial memory – which includes working and reference memory (71). 
We used an octagonal alley maze (automated radial arm maze: TSE GmbH), made of grey 
PVC. The apparatus was placed in a well-lit room (180 lux) containing 4 completely different 
structured walls (with different geometrical cues painted on each wall, which served as 
external cues). Food deprivation started one week before the experiment. The body weight 
was kept at 85-95% of the pre-test body weight by presenting food after the daily trials for 
only 2 h (13, 53). Animals were tested during the light phase as previously described (30, 81): 
Day 1-3: habituation of rats to the maze and baited food cups for 10 min;  
Day 4-11: the same four randomly chosen arms were baited in the naive sessions; animals 
were placed into alternate non-baited start arms and were tested twice a day for 5 min or until 
all pellets were collected; entries in already visited arms were recorded as working memory 
errors, whereas entries in never baited arms were counted as reference memory errors; 
Day 12-16: the previously unbaited arms were baited (and vice versa) in order to test the 
ability of the rats to relearn (reversal learning); 
Day 17: in the intratrial delay the rats were retained in the second visited arm after entering 
for 30 s to control the rats´ ability to bridge delays, which seems to rely on a functioning 
hippocampus and/or basal ganglia; 
 Day 23: in this intertrial delay session (after 5 days without testing the animals in the radial 
maze) similar arms were baited, as conducted six days prior; the animals´ ability to remember 
the prior baited arms is analyzed during this session. 
The number of working and reference memory errors, arm entries and right choices, the 
latency to leave the start area, the total duration for collecting all pellets, the sequence of arm 
entries, and the defecation score were analyzed. 
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Passive avoidance 
The passive avoidance task measures the response resulting from an associative learning 
process (8). The apparatus used was a Shuttle box system (TSE GmbH). In the training 
session (1 h after onset of the dark phase), the rat was placed for 10 s into a lightened 
chamber, after which the door to the dark compartment was opened. Instantly after entering 
the dark chamber, the door of the dark chamber was closed and a 0.8 mA footshock was 
delivered for 1 s. The animal remained in the dark compartment for further 10 s to allow the 
formation of an association between the location/surrounding and the footshock. In the 
retention test session 24 h later, the rat was placed into the light chamber again and the door to 
the dark chamber remained opened. The latency to enter the dark chamber (light-dark 
transversion time)  and the defecation score were measured (10) in the training and the 
retention test session (cut-off time: 300 s). Differences in the light-dark transversion time 
between the substrains in the retention session could be a hint for a different ability of the 
animals to remember the aversive stimulus received in the dark chamber 24 h earlier. In the 
training session the light-dark transversion time is discussed to be affected by anxiety, 
because rats exhibit an aversion of a brightly lit compartment (10) and diazepam decreased 
the latency to enter such a compartment (8). Therefore, we interpreted differences in the light-
dark transversion time in the training session as an indicator of anxiety in animals. 
Tests related to symptoms of human psychiatric disorders 
Prepulse Inhibition (PPI) 
Prepulse inhibition of a startle response is the phenomenon, in which a weak prepulse 
suppresses the response to a startling stimulus (57). Deficits in prepulse inhibition are 
common in schizophrenic patients (72). An automated startle system (TSE GmbH) was used. 
Animals were habituated to the startle chambers on five consecutive days for 5 min each. The 
test schedule was based on that used by Caine and coworkers (6), with minor modifications, 
and the animals were tested 1 h after the onset of the dark phase in two sessions (startle 
stimulus: 90/120 dB) with an intertrial interval of 48 h. The rat´s startle amplitude was 
recorded for each trial. 
Porsolt swim test 
Rats, when forced to swim, will eventually only make those movements, which are necessary 
to hold the head above the water (behavioral immobility). This behavioral immobility is taken 
as a state of “behavioral despair” and can be reduced by antidepressant treatment (3, 60). In 
this task the rat was plunged into a vertical plexiglass cylinder (height: 40 cm; diameter: 18 
cm) containing 15 cm of water maintained at 25 °C. The animal had to swim for 10 min. The 
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animal was then removed and allowed to dry for 15 min in a heated enclosure (32 °C). 24 h 
later the rat was tested again for 5 min. The latency and total duration of behavioral 
immobility was measured during both trials. 
Ethanol consumption and sensitivity 
Ethanol self-administration 
The two-bottle choice technique of assessing ethanol self-administration was established in 
1940 (65). Animals were housed individually. Two bottles were presented, one bottle 
containing tap water, while the other contained ethanol [96% (v/v)] of increasing 
concentrations [for three days each: 3%, 6%, 10%, and 20% (v/v)]. Daily fluid consumption 
was recorded 4 h after onset of the light phase. The bottles´ positions were alternated each 
day. Multiple pairs of water and ethanol tubes were monitored on empty cages to control 
evaporation and accidental spillage. Consumption of ethanol was expressed relative to total 
fluid consumption (ethanol preference ratio) and relative to body weight. 
Sedative effect of ethanol 
The time to regain the righting reflex after an ethanol injection was measured (73). Rats 
received an intraperitoneal (i.p.) injection of ethanol [2.37 g/kg body weight, 20% (v/v) mixed 
in isotonic saline]. At the onset of the ethanol-induced sedation (defined as loss of righting 
reflex: loss of the ability to stand on all four paws after being placed on the back; three times 
within 30 s) rats were placed on their back onto bedding material. The time that elapsed 
between the loss and the regain of the righting reflex was recorded. 
 
Statistical analysis 
Analysis of the various behavioral and physiological data was assessed either by applying 
repeated measures analysis of variance (ANOVA) on successive measurements or by one-way 
ANOVA. In repeated measures ANOVA the nominal independent variable “substrain” was 
used as the “between factors” (for the “between-subject effects”) and different continuous 
response variables within successive measurements were used as the “within-factors” (e.g. 
body weight over time; for the “within-subject effects”). In case of significant differences in 
regard to the “between factor”, this was followed by one-way ANOVAs (factor: “substrain”); 
split by the dimension of the continuous response variable. One-way ANOVAs were followed 
by the Fisher-PLSD-test for post hoc comparison to evaluate pairwise differences among 
levels of main effects. Differences were regarded as statistically significant if p < .05. The 
number of animals per substrain (n) was 10. Presenting the degrees of freedom indicates 
exceptions from this. Significant post hoc effects versus the control animals of the 
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F344/Crl(Por) substrain are indicated by asterisks (*p < .05; **p < .01; ***p < .001), whereas 
significant differences between the two DPPIV-deficient rat substrains F344/DuCrj(DPPIV-) 
and F344/Crl(Ger/DPPIV-) are shown by rhombs (#p < .05 - ##p < .01 - ###p < .001). All 
data are presented as means ± standard error of the mean (SEM).
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4.3 Results 
DPPIV-like activity 
One-way analysis of variance of the DPPIV-like activity of the test animals from the three 
different substrains revealed significant differences in the enzymatic activity [F(2, 55) = 
111.4; p < .001; Fig. 2]. A nearly 5-fold lower level of DPPIV-like activity was evident in the 
two mutant substrains F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) when compared to 
the enzymatic activity found in the wildtype-like rats from the F344/Crl(Por) substrain. 
 
Behavioral test paradigms 
General health and neurological examination 
Screening for general health, neurological reflexes, and sensory abilities established the good 
health, normal status of reflexes, good neuromuscular strength, and normal sensory abilities in 
all animals of all substrains (statistical analysis by one-way ANOVA). Interestingly, the body 
weight was significantly decreased in animals of the mutant substrains (Fig. 3) that were aged 
between 42 and 70 days [repeated measures ANOVA; “between factor”: F(2, 15) = 9.5; p = 
0.02], which was confirmed by separate one-way ANOVAs split by day [day 42: F(2, 15) = 
13.4; p = 0.0005; day 49: F(2, 15) = 8.2; p = 0.004; day 56: F(2, 15) = 6.3; p = 0.01; day 63: 
F(2, 15) = 10.8; p = 0.001; day 70: F(2, 15) = 9.1; p = 0.003]. Importantly, screening of body 
weight in older rats of all three substrains directly before each behavioral test did not reveal 
any significant differences in body weight anymore.  
Determination of motor functions 
No differences were found in neuromotor performance in the rotarod and accelerod paradigm 
(data not shown). 
Feeding behavior 
Monitoring the feeding behavior of group-caged rats (“Feeding I”) revealed no significant 
differences in food intake between the three different F344 substrains but a trend toward 
reduced fluid consumption in the DPPIV-deficient F344 substrains (data not shown). In 
single-housed rats (“Feeding II”) we again found no significant differences in food 
consumption (data not shown). However, significant differences in water intake were found 
[repeated measures ANOVA; “between factor”: F(2, 26) = 9.5; p = 0.0008 - followed by one-
way ANOVA: day 1: F(2, 26) = 4.5; p = 0.02; day 2: F(2, 26) = 7.8; p = 0.002; day 3: F(2, 
 93 DPPIV deficiency and behavior: Physiol Behav 80. 2003. 123-34. 
 
 
26) = 5.0; p = 0.02; Fig. 4) with a reduced fluid consumption in F344/DuCrj(DPPIV-) and 
F344/Crl(Ger/DPPIV-].  
Screening for differences in nociception 
No significant differences in tail flick latency were observed in this type of pain measurement 
(data not shown). However, in the hot plate, repeated measures ANOVA revealed a 
significant substrain effect [“between factor”: F(2, 27) = 15.2; p < .001] and additionally, a 
significant substrain × habituation interaction [F(2, 27) = 16.7; p < .001; Fig. 5]. This 
interaction was due to the fact that in the first non-habituated hot plate (“Hot plate I”) the 
latency to respond reflected a “hyperalgesic-like response” (i.e. reduced latency to respond by 
approximately 40%) in the two mutant substrains [one-way ANOVA: F(2, 27) = 20.2; p < 
.001]. However, these differences in pain sensitivity disappeared [one-way ANOVA: F(2, 27) 
= 2.0; p = 0.1] when the same animals were habituated to the apparatus for five consecutive 
days (“Hot plate II”). 
Evaluation of anxiety 
Open field 
The distance traveled (number of square entries), the ratio of center to total square entries, and 
the defecation score of the three different F344 substrains did not differ significantly. 
Interestingly, a significantly decreased latency to rear up [one-way ANOVA: F(2, 24) = 9.1; p 
= 0.001; Fig. 6A] and a significantly increased frequency of this “exploratory-like” behavior 
[one-way ANOVA: F(2, 24) = 7.5; p = 0.003; Fig. 6B] was found in the DPPIV-deficient rats 
of both substrains. 
Elevated plus maze 
The ratio of open to total arm entries was similar in the three different F344 substrains 
[F344/Crl(Por): 27.2 ± 16.9; F344/DuCrj(DPPIV-): 21.0 ± 13.8 and F344/Crl(Ger/DPPIV-): 
21.7 ± 11.7]. We also found no significant differences regarding the motor activity (number of 
closed and total arm entries) of the animals (data not shown). 
Social interaction 
One-way ANOVA proved that the overall time spent on behaviors like anal sniffing, 
following, allo grooming, walking over, crawling under, and nosing was significantly 
increased in the F344/Crl(Ger/DPPIV-) animals compared to the wildtype-like F344/Crl(Por) 
rats [F(2, 27) = 4.5; p = 0.02]. The summed social interaction time of the 
F344/DuCrj(DPPIV-) substrain was not significantly increased (Fig. 7) compared to the 
control animals. Furthermore, one-way ANOVA exhibited a significant increase in the 
frequency of nosing [F(2, 27) = 5.0; p = 0.02] in the F344/Crl(Ger/DPPIV-) animals (32.1 ± 
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3.5) compared to the F344/DuCrj(DPPIV-) (21.6 ± 3.9) substrain and the wildtype-like 
F344/Crl(Por) animals (18.4 ± 2.1). 
Learning and memory 
Radial maze 
In the complex radial maze task, the learning and memory of the F344 rat substrains were not 
significantly different in the naive, reversal, and intratrial sessions (data not shown). In the 
intertrial session on day 23, the two DPPIV-deficient substrains showed a decreased retention 
ability compared with the wildtype-like substrain regarding the number of reference memory 
errors [F344/Crl(Por): 2 ± 0.3; F344/DuCrj(DPPIV-): 3 ± 0.2 and F344/Crl(Ger/DPPIV-): 2 ± 
0.1], although this failed to be statistically significant using parametric analysis. 
Passive avoidance 
In the passive avoidance task no differences in associative learning of the different substrains 
were found. Interestingly, we found a significant substrain × light-dark transversion time 
interaction [two-way ANOVA: F(2, 23) = 3.4; p = 0.05], which was due to the increased 
latency in the mutant F344/DuCrj(DPPIV-) (113.5 ± 40.9 s) and F344/Crl(Ger/DPPIV-) (79.6 
± 33.6 s) substrain compared to the control substrain F344/Crl(Por) (24.7 ± 4.3 s) in the 
training session. The difference was significant between F344/DuCrj(DPPIV-) and control 
rats in the training session [one-way ANOVA: F(2, 23) = 4.4; p = 0.03; Fisher-PLSD-test: p = 
0.02]. Additionally, none of the wildtype-like rats entered the dark compartment in the 
retention session. Furthermore, only the wildtype-like animals defecated in the training 
session [F344/Crl(Por): 2.2 ± 1.4]. 
Tests related to symptoms of human psychiatric disorders 
All animals showed a clear startle response, indicating normal hearing abilities. However, no 
significant differences in prepulse inhibition were found (data not shown). Also, the Porsolt 
swim test revealed no differences in the duration of behavioral immobility between the 
different F344 substrains (data not shown). 
Ethanol consumption and sensitivity 
The different substrains did not differ in their ethanol preference in the voluntary ethanol 
consumption task of different ethanol concentrations (data not shown). Interestingly, all 
substrains showed a significantly higher preference for ethanol than for tap water when 
ethanol concentrations of 3% [repeated measures ANOVA: F(2, 26) = 15.4; p = 0.0002] and 
6% [repeated measures ANOVA: F(2, 26) = 11.5; p = 0.001] were presented (Table 2). The 
sedative effect of ethanol, quantified by the duration of the loss of righting reflex, was 
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significantly shortened in both mutant substrains [one-way ANOVA: F(2, 15) = 5.5; p = 0.02; 
Fig. 8]. 
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4.4 Discussion 
The systematic phenotyping of F344 substrains with or without endogenous DPPIV-like 
enzymatic activity demonstrated an important involvement of the ectopeptidase DPPIV in 
several behavioral and physiological processes. The two DPPIV-deficient F344 substrains 
[F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-)] exhibited a significantly reduced body 
weight and water intake, a significant hyperalgesia in the non-habituated hot plate task, and a 
significantly differential response to the habituation for this experiment. In the OF we 
observed significantly increased exploratory-like behavior in these rats, while anxiety was 
significantly reduced in the F344/Crl(Ger/DPPIV-) rats in the social interaction test and in 
F344/DuCrj(DPPIV-) rats in the passive avoidance task. Interestingly, a reduced susceptibility 
to the sedative effect of ethanol was evident in the mutant F344 substrains. 
The observed differences in body weight in the different F344 substrains could be based on 
elevated endogenous levels of the DPPIV substrate enterostatin in young DPPIV-deficient 
rats. Enterostatin, which is stabilized by DPPIV inhibition with val-pro-asp-pro-arg (VPDPR) 
(50), produces a dose-dependent reduction in fat intake and a chronic decrease in body weight 
and body fat levels (19), which could be responsible for the initial differences in the body 
weight between the mutant and wildtype-like rats. 
DPPIV is the principal metabolizing enzyme for GLP-1. Studies with DPPIV knockout mice 
(48) and F344/DuCrj(DPPIV-) rats (42, 55) described the inactivating effect of DPPIV on 
active GLP-1 levels in vivo. GLP-1 functions as a potent inhibitor of water intake in rodents 
after intracerebroventircular (i.c.v.) administration, and stimulates urinary excretion of water. 
Furthermore, both i.p. and i.c.v.-injection of GLP-1 inhibit both basal- and angiotensin II-
induced drinking behavior (18). Therefore, the decreased water intake of DPPIV-deficient 
animals could be mediated via elevated levels of non-cleaved GLP-1 in both mutant 
substrains compared to the control animals. 
The hyperalgesic phenotype of F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) rats in the 
hot plate test could be related to the involvement of DPPIV substrates such as substance P and 
NPY in pain sensitivity. Analgesia in the hot plate task is proven to be elicited by low doses 
of intraventricularly or intrathecal administered substance P (61). On the other hand, high 
doses of this substance produce hyperalgesia (46). Therefore, differences in the degradation of 
substance P between the mutant and wildtype-like substrains could be involved in the 
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decreased pain threshold of the DPPIV-deficient F344/DuCrj(DPPIV-) and 
F344/Crl(Ger/DPPIV-) rats. Interestingly, the DPPIV substrate NPY is also involved in the 
mediation of nociception (2, 32). The neurotransmitter is known to increase the pain threshold 
in rats in the hot plate paradigm (5, 51) and selective NPY receptor agonists [Y2 agonist: N-
acetyl(Leu28, Leu31)NPY24-36 and Y1 agonist: (Leu31, Pro34)NPY] decrease thermal 
hyperalgesia (78). A further hypothesis for the differential pain sensitivity in the non-
habituated hot plate test is due to the fact that the wildtype-like F344/Crl(Por) exhibited a 
higher stress-associated behavioral response in tests for anxiety compared to DPPIV-deficient 
rats (as indicated by an increased SI time in the social interaction test, a high ambulation in 
the open field, and an increased light-dark transversion time and decreased defecation score in 
the passive avoidance task). Since a powerful stress response increases NPY release in the 
CNS (9, 62), the endogenous NPY level of the wildtype-like animals could be higher than the 
NPY levels of the mutant animals and therefore lead to a decrease in pain sensitivity in the 
control animals. Additionally, the higher stress response could increase the pain threshold of 
the control animals by the so-called stress-induced hypoalgesia (41, 52). This is confirmed by 
the significant differential response to the hot plate habituation between the substrains. In 
contrast, we were unable to find differences in the tail flick test. This could be based on 
differences between the two nociception schedules: the measurement of nociception in the hot 
plate test is significantly influenced by processes in the CNS, whereas the tail flick test 
measures predominantly spinal reflexes (44). Furthermore, we speculate, that only in the tail 
flick task the animal´s behavior is strongly influenced by the necessary handling procedure 
(fixation of the animal). 
In the open field we recorded earlier and more often exploratory-like behavior (rearing) of the 
mutant substrains than in the wildtype-like animals. It is commonly assumed that low 
ambulation indicates high anxiety and vice versa (1).  In additional tests for anxiety the lower 
anxiety of the DPPIV-deficient substrains is confirmed by a significantly increased social 
interaction time of the F344/Crl(Ger/DPPIV-) animals in the social interaction test and an 
increased light-dark transversion time of the F344/DuCrj(DPPIV-) rats in the passive 
avoidance task. Furthermore, the wildtype-like animals did not enter the dark compartment 
during the retention session in the second task (and defecated more often than the mutant 
animals). The pattern of these findings hints to a reduced behavioral stress response in the 
mutant F344 substrains. These differences in the level of arousal and/or anxiety between the 
different F344 substrains could be based on a differential degradation of NPY, the best 
peptide substrate for DPPIV (14), in the mutant and control animals, which has been reported 
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to reduce stress responsiveness in transgenic NPY overexpressing rats (76). Cleavage of NPY 
to NPY3-36 by DPPIV leads to a loss of Y1 receptor specificity. NPY3-36 has a considerably 
reduced activity at the NPY Y1 receptor subtype but still a high activity at the Y2 and Y5 
receptor subtypes (25). Therefore, the non-degraded, native NPY in DPPIV-deficient rats is a 
more potent activator of the Y1 receptor subtype than the degraded NPY3-36 in the wildtype-
like animals. Importantly, NPY administration increases the preference for open arms in an 
elevated plus maze test (5) and decreases anxiety in the social interaction test (40, 67). 
Furthermore, rats, antisense-treated to reduce NPY Y1 receptor density, show anxiogenic-like 
behavior in the elevated plus maze test (27, 82), suggesting that the anxiolytic-like effect of 
NPY is primarily mediated via the Y1 receptor subtype. Since the NPY catabolism of our 
mutant substrains and the wildtype-like animals is probably linked to DPPIV, the reduced 
anxiety of the DPPIV-deficient F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) animals 
could be based on elevated levels of non-cleaved NPY. The reduced stress-response of our 
DPPIV-deficient animals is also found in NPY overexpressing transgenic rats (76), which 
could be a further hint for the involvement of NPY in the reduced anxiety of our mutant F344 
substrains. Interestingly, DPPIV-cleaved cytokines like IL-2 could also be involved in the 
increased exploration of the mutant animals (86). The differences within the two DPPIV-
deficient substrains F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) in both the social 
interaction test and passive avoidance task could be due to different compensatory 
mechanisms during ontogeny, but further studies on this phenomenon are required.  
NPY-deficient mice showed increased ethanol consumption and are less susceptible to the 
sedative effect of ethanol, whereas NPY overexpressing mice exhibited an opposite 
phenotype (74). DPPIV-deficient rats should, in comparison to control animals, behave like 
NPY overexpressing mice because of higher levels of non-cleaved endogenous NPY. In 
addition to a comparable ethanol consumption of mutant and control F344 rats, the DPPIV-
deficient substrains exhibited a reduced susceptibility to the sedative effect of ethanol. This 
may be explained by several processes, but in regard to a possible involvement of the NPY 
system in this phenomenon, further investigations have to be conducted. Finally, we did not 
find significant differences between the mutant and wildtype-like animals in prepulse 
inhibition and the Porsolt swim test, although an influence of DPPIV on psychiatric and 
psychosomatic diseases has recently been proposed (47).  
In conclusion, the DPPIV-deficient F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) rats 
exhibited a reduced behavioral stress response in tests like the hot plate, social interaction, 
and passive avoidance. These findings suggest an involvement of DPPIV-like activity in the 
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regulation of anxiety-like behaviors, and these effects are possibly mediated by differential 
degradation of as yet unspecified/alternative DPPIV substrates. Due to the pattern of 
behavioral differences between mutant and control animals, which are similar to transgenic 
NPY overexpressing rats, it seems as if a differential cleavage of NPY could especially 
explain several, but not all, of the described differences herein. We have demonstrated that 
significant variations in DPPIV-like activity among commercially available F344 rats from 
different breeding colonies of Crl appear to be associated with significant differences in the 
behavioral, anxiety-like, exploratory, and neurophysiological phenotype. The existence of 
substrains among the F344 genotype should be of considerable interest for many researchers. 
Our F344 substrains provide an interesting model to study the functional role of DPPIV in 
various physiological and behavioral processes. Overall, the present approach for detecting 
distinct differences in a rat´s phenotype is based on a systematic behavioral and physiological 
phenotyping. This includes a broad range of different behavioral tests, which are necessary for 
an extensive characterization and for detecting specific behavioral differences. This strategy 
for analysing mutant rodents is becoming an increasingly important and useful tool in 
biomedical research.  
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4.7 Tables and figures 
 
Table 1:  
Behavioral/Physiological domains Experimental tasks 
General health and neurological 
examination 
Response to an unknown approaching object 
Modified visual cliff 
Several reflexes (e.g. eye blink and ear twitch) 
Motor functions Rotarod and accelerod 
Feeding behavior Food and fluid consumption  
Nociception Tail flick 
Hot plate 
Anxiety Open field 
Elevated plus maze 
Social interaction 
(Passive avoidance) 
Learning and memory Radial maze 
Passive avoidance 
Tests related to symptoms of 
human psychiatric disorders 
Prepulse inhibition (schizophrenic-like) 
Porsolt swim test (depression-like) 
Ethanol consumption and 
sensitivity 
Ethanol self-administration 
Sedative effect of ethanol 
Behavioral/Physiological domains and the different corresponding experimental tasks
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Table 2: 
Ethanol 
concentration 
F344/Crl(Por) F344/DuCrj(DPPIV-) F344/Crl(Ger/DPPIV-) 
3%  64.9 ± 6.2 69.3 ± 6.5 67.2 ± 5.9 
6%  60.5 ± 8.4 60.0 ± 7.5 61.4 ± 8.4 
10%  43.1 ± 6.7 47.8 ± 6.8 45.9 ± 6.1 
20%  23.6 ± 5.6 22.5 ± 4.6 32.9 ± 6.5 
Ethanol self administration; ethanol preference ratio of single-housed rats was recorded for 
different ethanol concentrations (3%/6%/10%/20%) as total ethanol consumption relative to 
total fluid consumption (mean ± SEM) [%]. 
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Fig. 1: Test setting; test biography of the three different experimental sets of age-matched 
F344 rats (n = 10 per substrain); additionally, the animals´ age in the various behavioral tests 
is shown. 
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Fig. 2: DPPIV-like activity [mU/ml] of all test animals was screened; blood from the tail vein 
was sampled and analyzed. Data represent means + SEM and provide the p-values of the 
corresponding post hoc test (Fisher-PLSD-test). Significant effects versus the wildtype-like 
animals are indicated by asterisks (***p < .001). 
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Fig. 3: Body weight development [g] of the different substrains, aged between 42-70 days. 
Data represent means + SEM and provide the p-values of the corresponding post hoc test 
(Fisher-PLSD-test). Significant effects versus the wildtype-like animals are indicated by 
asterisks (*p < .05; **p < .01; ***p < .001). 
 
 113 DPPIV deficiency and behavior: Physiol Behav 80. 2003. 123-34. 
 
 
 
Fig. 4: Water intake; the water intake was measured in single-housed animals for 3 
consecutive days; the consumption [ml] was recorded at the onset of the light phase of the 
light cycle. Data represent means + SEM and provide the p-values of the corresponding post 
hoc test (Fisher-PLSD-test). Significant effects versus the wildtype-like animals are indicated 
by asterisks (*p < .05; **p < .01; ***p < .001). 
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Fig. 5: Nociception was analyzed in the hot plate task; the non-habituated or habituated rat 
was placed onto the surface of the apparatus, which was maintained at 52.5 °C, and the 
latency to respond (lick or raise hindpaws) was recorded [s]. Data represent means + SEM 
and provide the p-values of the corresponding post hoc test (Fisher-PLSD-test). Significant 
effects versus the wildtype-like animals are indicated by asterisks (**p < .01; ***p < .001). 
 
 
 115 DPPIV deficiency and behavior: Physiol Behav 80. 2003. 123-34. 
 
 
 
Fig. 6A: Exploratory behavior in the OF; the latency of rearing [s] was recorded during a 10 
min session; the task took place 1 h after onset of the dark phase; the group-caged animals 
were tested on two consecutive days to test only one animal per cage per day. Data represent 
means + SEM and provide the p-values of the corresponding post hoc test (Fisher-PLSD-test). 
Significant effects versus the wildtype-like animals are indicated by asterisks (**p < .01; ***p 
< .001). 
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Fig. 6B: Exploratory behavior in the OF; the frequency of rearing [n] was recorded during a 
10 min session; the task took place 1 h after onset of the dark phase; the group-caged animals 
were tested on two consecutive days to test only one animal per cage per day. Data represent 
means + SEM and provide the p-values of the corresponding post hoc test (Fisher-PLSD-test). 
Significant effects versus the wildtype-like animals are indicated by asterisks (*p < .05; ***p 
< .001). 
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Fig. 7: Anxiety; the time spent in active social interaction was recorded in the social 
interaction test [s]; two unfamiliar weight-matched rats of the same substrain were exposed to 
an open field 1 h after onset of dark phase for 10 min. Data represent means + SEM and 
provide the p-values of the corresponding post hoc test (Fisher-PLSD-test). Significant effects 
versus the wildtype-like animals are indicated by asterisks (**p < .01). 
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Fig. 8: Sedative effect of ethanol; the time to regain the righting reflex after an ethanol 
injection was measured [min]; rats received an intraperitoneal (i.p.) injection of ethanol [2.37 
g/kg body weight, 20%(w/v) mixed in isotonic saline]. Data represent means + SEM and 
provide the p-values of the corresponding post hoc test (Fisher-PLSD-test). Significant effects 
versus the wildtype-like animals are indicated by asterisks (*p < .05; **p < .01). 
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Abstract 
Dipeptidyl-peptidase IV (DPPIV; CD26) is involved in several physiological functions by 
cleavage of dipeptides with a Xaa-Pro or Xaa-Ala sequence of regulatory peptides such as 
neuropeptide Y (NPY). Cleavage of NPY by DPPIV results in NPY3-36, which lacks affinity 
for the Y1 but not for other NPY receptor subtypes. Among other effects, the NPY Y1 receptor 
mediates anxiolytic-like effects of NPY. In previous studies with F344 rat substrains lacking 
endogenous DPPIV-like activity we found a reduced behavioral stress response, which might 
be due to a differential degradation of NPY. Here we tested this hypothesis and administered 
intracerebroventricularly two different doses of NPY (0.0, 0.2, 1.0 nmol) in mutant and 
wildtype-like F344 substrains. NPY dose-dependently stimulated food intake and feeding 
motivation, decreased motor activity in the plus maze and social interaction test, and exerted 
anxiolytic-like effects. More important for the present hypothesis, NPY administration was 
found to be more potent in the DPPIV-negative substrains in exerting anxiolytic-like effects 
(increased social interaction time in the social interaction test) and sedative-like effects 
(decreased motor activity in the elevated plus maze). These data demonstrate for the first time 
a differential potency of NPY in DPPIV-deficient rats and suggest a changed receptor-
specificity of NPY, which may result from a differential degradation of NPY in this genetic 
model of DPPIV deficiency. Overall, these results provide direct evidence that NPY-mediated 
effects in the central nervous system are modulated by DPPIV-like enzymatic activity.  
 
 
 
Keywords: Dipeptidyl-peptidase IV – CD26 – Neuropeptide Y – F344 –– Social interaction 
test - Anxiety – Elevated plus maze - Sedation - Food intake - Feeding motivation  
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5.1 Introduction 
The enzyme and binding protein dipeptidyl-peptidase IV (DPPIV) belongs to a class of 
membrane-associated peptidases (De Meester et al., 1999). The ectopeptidase is identical to 
the leukocyte differentiation marker CD26 and is involved in T-cell dependent immune 
responses (Kahne et al., 1999) and in cell adhesion (Mentlein, 1999; Shingu et al., 2003). Due 
to its unique ability to liberate Xaa-Pro and Xaa-Ala dipeptides from the N-terminus of 
regulatory peptides, important substrates include neuropeptides such as neuropeptide Y 
(NPY), peptide YY (PYY), and endomorphin (Hildebrandt et al., 2000; Mentlein, 1999). 
Further substrates are glucagon-like peptide 1 (GLP-1), GLP-2, enterostatin, substance P, and 
various chemokines (De Meester et al., 2000). In the adult nervous system, DPPIV is found 
primarily in the circumventricular organ and on leptomeningeal cells. The enzyme has direct 
contact to neuropeptides such as NPY in the cerebrospinal fluid (Mentlein, 1999) and also to 
endothelial cells of blood vessels including those contributing to the blood brain barrier 
(Hildebrandt et al., 2000). In addition, a soluble form of DPPIV exists in the blood plasma 
(Mentlein, 1999). 
Because of these pleiotropic effects of DPPIV, we previously investigated the role of the 
DPPIV-like activity on behavioral and physiological processes in a mutant rat model of 
DPPIV deficiency. Spontaneous mutations in the Dpp4 gene of F344 substrains from 
breeding colonies of Charles River Laboratories (Crl) in Sulzfeld, Germany (Thompson et al., 
1991), and Atsugi, Japan (Tiruppathi et al., 1993; Watanabe et al., 1987) result in an almost 
complete lack of DPPIV-like activity in these animals. This DPPIV deficiency does not exist 
in wildtype-like F344 rats from Crl breeding colonies in Portage, USA (Karl et al., 2003a). In 
a systematical behavioral and physiological characterization of the different substrains, we 
observed differences in the mutant, DPPIV-deficient F344 rats showing increased water 
intake, improved glucose homeostasis, blunted natural killer cell function, reduced anxiety-
like behaviors, and increased sensitivity for the sedative effect of ethanol (Karl et al., 2003a; 
Karl et al., 2003b). We hypothesized that at least some of these differences may be due to a 
differential metabolism of NPY. 
The neurotransmitter NPY was discovered in 1982 (Tatemoto et al., 1982) and is a member of 
the pancreatic family of peptides. Significant NPY levels were found in most brain regions 
including the cerebral cortex, hippocampus, thalamus, hypothalamus, and brainstem (Allen et 
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al., 1983; Colmers and Wahlestedt, 1993). The neuropeptide is a 36 amino acid peptide with a 
large number of tyrosine residues. Based on this amino acid sequence, NPY is cleaved by 
DPPIV. It has a high affinity to the enzyme and is also metabolized in human serum by 
DPPIV (De Meester et al., 2000). Among several other physiological responses NPY 
especially affects feeding behavior and anxiety (Kalra et al., 1999; Kask et al., 2002; 
Wettstein et al., 1995). The neurotransmitter binds to several NPY receptor subtypes (Y1, Y2, 
Y4, and Y5) in rats, which belong to the large superfamily of G-protein-coupled receptors. 
They are widely distributed in the brain (Blomqvist and Herzog, 1997) and mediate regulatory 
effects of NPY (Parker and Herzog, 1999). The NPY Y1 receptor is one of the major receptor 
subtypes expressed in the rat brain (Dumont et al., 1998) and is particularly involved in the 
regulation of anxiety (Kask et al., 2002). Importantly, DPPIV removes the first two N-
terminal amino acid residues (Tyr-Pro) of NPY with high turnover rates and generates the C-
terminal fragment NPY3-36. NPY3-36 has a markedly reduced affinity to the NPY Y1 receptor 
subtype, while being as potent as the native peptide on the NPY Y2 and Y5 receptor subtypes. 
Possibly, the previously described behavioral and physiological differences of the two 
DPPIV-deficient F344 substrains from Japan, F344/DuCrj(DPPIV-), and Germany, 
F344/Crl(Ger/DPPIV-), on the one hand, and the wildtype-like substrain from USA, 
F344/Crl(Por), on the other hand (Karl et al., 2003b), could be due to a faster degradation of 
endogenous NPY to NPY3-36 in the control substrain. This would result in a relatively reduced 
endogenous NPY Y1 receptor-like tone. Such a mechanism could sufficiently explain the 
reduced anxiety-like behaviors in the mutant, DPPIV-deficient substrains. 
To test this hypothesis, it was investigated whether NPY applied intracerebroventricularly 
(i.c.v.) produces differential effects in the DPPIV-deficient substrains. Thus, we characterized 
the effect of i.c.v. administration of different doses of NPY in the F344/DuCrj(DPPIV-), 
F344/Crl(Ger/DPPIV-), and F344/Crl(Por) rats on various behavioral tasks aiming at a 
characterization of feeding behavior (food intake) and anxiety-like behaviors.  
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5.2 Materials and methods 
Animals 
For clarity, animal groups obtained in 1998 were coded as previously described (Karl et al., 
2003a): F344 rats derived from breeding colonies of Crl in Atsugi (Japan) were called 
F344/DuCrj(DPPIV-), animals from breeding colonies in Sulzfeld (Germany) 
F344/Crl(Ger/DPPIV-), and wildtype-like rats obtained from colonies in Portage (USA) 
F344/Crl(Por). 
All F344 rats of the three different substrains were housed and bred at the Central Animal 
Facility of the Hannover Medical School as previously described (Karl et al., 2003a). Animals 
were maintained in a separated minimal barrier sustained facility and kept in Macrolon type 
III cages with a standard bedding (Altromin GmbH, Lage, Germany). Food (Altromin 
Standard Diät 1320: Altromin GmbH) and water were available ad libitum. Environmental 
temperature was automatically regulated at 21 ± 2 °C and relative humidity was 55 ± 5% with 
an air change rate of 15 times per hour. The animal rooms were operated with a positive 
pressure of 0.6 Pa. Rats were maintained under a 12:12 h light regime (light onset at 4am). 
They underwent routine animal care once a week. Routine microbiologic monitoring 
according to FELASA recommendations (Rehbinder et al., 2000) did not reveal any evidence 
of infection with common murine pathogens except for Pasteurella pneumotropica and 
Staphylococcus aureus. All research and animal care procedures were approved by the 
Review Board for the Care of Animal Subjects of the district government, Hannover, 
Germany, and performed according to international guidelines for the use of laboratory 
animals. 
Determination of DPPIV-like enzymatic activity 
All test animals were characterized in regard to their DPPIV-like enzymatic activity as 
previously described (Karl et al., 2003a). For determination of plasma activity of F344 rats a 
microplate based fluorescence assay was used. EDTA-plasma samples were kept at –80 °C 
until use. DPPIV enzyme activity of the different rat substrains was determined by monitoring 
the release of 4-Amino-7-Methylcoumarin (AMC) from the substrate Gly-Pro-AMC at 
360/480 nm (Ex/Em) and 30 °C using the Novostar fluorescence microplate reader (BMG, 
Offenburg, Germany). The assay consists of 20 µl plasma sample, 100 µl H2O and 100 µl 
HEPES buffer pH 7.6 and 50 µl Gly-Pro-AMC. Activity was calculated from the linear slope 
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using a factor of 3.116*10-4 µmol/l calculated from an AMC standard curve and the sample 
dilution. One unit is defined as the enzyme activity, which cleaves 1 µmol Gly-Pro-AMC per 
minute. The assay is selective for DPPIV-like activities. It has been proven that the substrate 
is cleaved by DPPIV, by DP II, and by attractin. Probably, they are also substrates for DP8 
and DP9. Importantly, the chromophores are not released by other proline-specific peptidases, 
such as prolidase, prolyl endopeptidase, or aminopeptidase P. 
Surgery of i.c.v. cannulation 
For surgery, animals were anesthetized with intramuscular (i.m.) ketamine hydrochloride (0.1 
ml/100 g body weight; Albrecht, Aulendorf, Germany) and dormitor (0.01 ml/100 g body 
weight; Pfizer GmbH, Karlsruhe, Germany). The i.c.v. cannulation technique was identical to 
that outlined in a previous report (von Horsten et al., 1998a). After placement of the rat in a  
stereotactic apparatus (model 900: David Kopf Instruments, Tujunga, USA), the incisor bar 
was adjusted on position zero and the ear bars were adjusted to equal positions so that the 
rat´s head was fixed in the apparatus. The eyes were protected against drying with eye-
ointment (Bepanthen Augen- und Nasensalbe: Hoffmann-La Roche AG, Grenzach-Wyhlen, 
Germany). The skull was exposed by a midline incision, the periost was removed, the bone 
surface was dried, and the position of the bregma was identified. Three stainless steel anchor 
screws (Breitfeld & Schliekert, Karben, Germany) were secured to the skull and a stainless 
steel guide cannula (Plastics one, Roanoke, USA) was implanted in the right lateral ventricle 
and cemented in place with dental cement (Durelon Maxicap: Espe Dental AG, Seefeld, 
Germany). The coordinates for the lateral ventricle were 0.7 mm caudal and 1.6 mm lateral to 
the bregma, with the guide cannula (Plastics one) extending 3.4 mm ventral to the skull 
surface. Flow of small amounts of 0.9% saline (Braun Melsungen AG, Melsungen, Germany) 
through the protracted injection (internal) cannula (Plastics one) was used to verify that the 
guide cannula was positioned just above the ventricular system. The guide cannula was then 
fitted with a dummy cannula (Plastics one) of the same length to prevent leakage of 
cerebrospinal fluid. Animals were housed individually after surgery. The anatomical position 
of the cannula was verified by post mortem i.c.v. dye application (Berlin blue) and inspection 
of the stained third ventricle in randomly chosen rats. The animals of the three F344 
substrains F344/DuCrj(DPPIV-), F344/Crl(Ger/DPPIV-), and F344/Crl(Por) were operated at 
an age of 95 (±5) days. The observation of the animals’ behavior in different behavioral test 
paradigms (an overview is given in Fig. 1) commenced after a recovery phase of at least 10 
days. 
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Drugs, i.c.v. injections, and dosages 
A stock solution of human/rat NPY (2 mol; Polypeptide GmbH, Wolfenbüttel, Germany) was 
adjusted under sterile conditions to final concentrations (0.2 nmol/5 µl and 1.0 nmol/5 µl) 
using 0.9% saline. The final concentrations were made 24 h before the different experiments. 
For the i.c.v. administration animals were taken out of the home cage and the dummy cannula 
was replaced by the internal cannula. Peptide or 0.9% saline was injected i.c.v. in a volume of 
5 µl over 20 s through the internal cannula extending 4.4 mm ventral to the skull surface. The 
internal cannula was attached to a microsyringe (Hamilton Bonaduz AG, Bonaduz, 
Switzerland) with approximately 30 cm of polyethylene tubing (Plastics one), which allowed 
the animal to move freely during the i.c.v. injection. Then the internal cannula was replaced 
by the dummy cannula again and the rat was returned into the home cage. All experiments 
started 15 min after the administration procedure. For the procedure of i.c.v.-injection, 
animals were habituated to experimental handling daily within 7 days prior to the start of the 
first experiment. During this habituation phase the handling procedure was exactly the same 
except for the application of the compound.  
Two different doses of NPY were used for this study and a 3 (substrain) × 3 (treatment) 
experimental design was set up. Thus, F344 rats of each substrain were divided into three 
treatment groups each (n = 7), which were treated with 0.9% saline (vehicle: 0.0 nmol/5 µl), 
or two different doses of NPY (0.2 nmol/5 µl, or 1.0 nmol/5  µl).  
 
Experimental designs of the behavioral test paradigms 
Feeding behavior (food intake) 
The feeding response (latency to start eating and the overall food consumption) following an 
i.c.v administration of NPY were measured for 2 h. Two experiments were performed: in 
experiment I, the feeding response after i.c.v. treatment was recorded in the light phase; in 
experiment II, 60 h later, the same response was measured 1 h after onset of the dark phase 
(Kushi et al., 1998; Marsh et al., 1998). 
Anxiety 
In early studies various authors defined tasks like the open field and the elevated plus maze as 
tests for emotionality (Archer, 1973; Denenberg, 1969; Walsh and Cummins, 1976). In more 
recent years, the same paradigms have been discussed in regard to their potential to provide 
indicators of anxiety, and the construct “emotionality” has been less frequently used (File and 
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Seth, 2003; Mechiel Korte and De Boer, 2003; Prut and Belzung, 2003). Therefore, we use 
the term “anxiety-like behavior” in regard to these tests. 
Elevated plus maze 
The elevated plus maze (EPM) represents the natural conflict of rats between the tendency to 
explore a novel environment and the tendency to avoid a brightly lit, open area (Handley and 
Mithani, 1984; Montgomery, 1958). The behavior is also influenced by thigmotaxis and the 
fear of heights (Treit and Fundytus, 1988). The time spent on open arms of the EPM as well 
as the percentage of open arm entries (ratio of open to total arm entries) are inversely related 
to anxiety (Hogg, 1996; Pellow et al., 1985; Pellow and File, 1986). The number of enclosed 
and total arm entries reflects the general motor activity (File, 1986). An automated EPM (TSE 
GmbH, Bad Homburg, Germany) with ledges (Fernandes and File, 1996) for rats was used. 
The animal was placed onto the center platform facing an open arm. In the following 5 min 
the entries onto open/enclosed arms, the time spent on open/enclosed arms or on the center 
platform, behaviors like rearing and self-grooming, and the defecation score were recorded on 
video (Baldwin and File, 1986; Lister, 1987). Illumination was dim (10 lux) and the 
experiment started 1 h after onset of the dark phase. A rat was taken to have entered an arm 
when all four paws were on this arm. After each session the apparatus was cleaned with 70% 
ethanol. To avoid influences of the animals´ endogenous rhythm on behavioral activity, tests 
were performed on three consecutive days with the animals of all substrains being grouped by 
dose of i.c.v. NPY treatment. 
Social interaction 
Pairs of rats, placed in a novel environment, engage in active social interactions, which 
include a variety of social behaviors (File, 1988; File and Hyde, 1978). The rat social 
interaction test is used widely to measure anxiety-like behaviors (File, 1988) and to detect 
anxiogenic and anxiolytic-like effects of drugs (Kask et al., 2001a). The overall active social 
interaction (SI) time is inversely related to the anxiety of the animals (File, 1980; File and 
Hyde, 1978; Karl et al., 2003c), which is confirmed by the observation that the maximum 
active SI time is found when rats are tested in a familiar test arena with a low level of 
illumination (File and Hyde, 1978). Furthermore, a decrease in SI time is correlated with an 
increase in other behaviors indicating increased anxiety: defecation, freezing, and 
displacement activity (i.e. eating of non-edible objects by rats that are not food deprived or 
self-grooming). Therefore, the decrease in social behaviors is consistent with behavioral 
indications of increased arousal or anxiety and is not explained by any changes in other 
competing behaviors such as exploration (File, 1980; File, 1988). The apparatus used was a 
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squared steel open field (50x50x50 cm) that was placed inside a sound isolation box. The 
floor was divided into 25 squares by a cross grid (Kask et al., 2001a). Two unfamiliar rats of 
the  similar substrain and NPY treatment were exposed to the area. In the following 10 min 
the total duration and the frequency of the different behaviors anal sniffing, following, allo 
grooming, walking over, crawling under, and nosing of each rat were recorded. Additionally, 
the frequency of self-grooming and the motor activity (traveled distance - by recording the 
total number of square entries) were analyzed. The behavior was monitored online using a 
video camera placed above the open field inside the isolation box. The arena was brightly 
illuminated (180 lux) and experiments started 1 h after onset of the dark phase. After each 
session the apparatus was cleaned with 70% ethanol. As in the EPM test, rats were tested on 
three consecutive days to avoid influences of the rats´ endogenous rhythm. 
 
Statistical analysis 
The analysis of the various behavioral data was assessed using a two-way analysis of variance 
(ANOVA; factor: “substrain” × “treatment”) and by one-way ANOVA (factor: “substrain” or 
“treatment” - split by the corresponding factors) followed by the Fisher-PLSD-test for post 
hoc comparison, if appropriate. Differences were regarded as statistically significant if p < 
.05. In the results section present the degrees of freedom, F-values, and p-values of two- and 
one-way ANOVAs are given, while in the figures and tables the p-values of the corresponding 
post hoc tests (Fisher-PLSD-test) are provided. In most cases the number of animals per 
substrain and treatment group was n  = 7. Presenting the degrees of freedom indicates 
exceptions from this. Significant post hoc effects for the factor “substrain” versus the control 
animals of the F344/Crl(Por) substrain are indicated by asterisks (*p < .05; **p < .01; ***p < 
.001), whereas significant differences between the two DPPIV-deficient rat substrains 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) are shown by rhombs (#p < .05; ##p < .01; 
###p < .001). Significant post hoc effects for the factor “treatment” versus the vehicle-treated 
animals are indicated by crosses (+p < .05; ++p < .01; +++p < .001), whereas significant 
differences between the two different NPY doses 0.2 nmol and 1.0 nmol are shown by “x” (xp 
< .05; xxp < .01; xxxp < .001). All data are displayed as means ± standard error of the mean 
(SEM). 
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5.3 Results 
DPPIV-like activity 
One-way analysis of variance of the DPPIV-like activity of all animals exhibited significant 
differences between substrains (Fig. 2). An almost complete lack of enzymatic-like activity 
was found in the two mutant substrains [F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-)] 
and a wildtype-like pattern of DPPIV-like activity was found in the rats from the 
F344/Crl(Por) substrain [F (2; 61) = 400.4; p < .0001]. 
 
Behavioral test paradigms 
Feeding behavior (food intake) 
Two-way ANOVA revealed a significant treatment effect on food intake in the dark phase 
[factor “treatment”: F (2; 55) = 54.7; p < .0001] as well as in the light phase [factor 
“treatment”: F (2; 55) = 116.8; p < .0001]. Each of the different substrains exhibited a dose-
dependent increase of overall food consumption after i.c.v. administration of NPY (data not 
shown). Neither significant effects for the factor “substrain” nor any significant interactions 
were observed, although mutant, DPPIV-negative rats showed a trend for reduced food intake 
stimulation in the light phase. Similarly, two-way ANOVA revealed that i.c.v. treatment 
shortened significantly the latency to eat dose-dependently [factor “treatment”: in dark phase: 
F (2; 55) = 13.1; p < .0001; one-way ANOVA for F344/DuCrj(DPPIV-): F (2; 18) = 17.6; p < 
.0001 - in light phase: F (2; 55) = 26.9; p < .0001; one-way ANOVA for F344/Crl(Por): F (2; 
18) = 10.1; p = 0.001; one-way ANOVA for F344/DuCrj(DPPIV-): F (2; 18) = 4.8; p = 0.02; 
one-way ANOVA for F344/Crl(Ger/DPPIV-): F (2; 19) = 13.6; p = 0.0002]. However, neither 
significant differences for the factor “substrain” nor significant “substrain” × “treatment” 
interactions were found (Table 1). 
Anxiety 
Elevated plus maze 
Two-way ANOVA revealed no significant effect for the factor “substrain” on the ratio 
between open and total arm entries as an indicator of anxiety [F (2; 51) = 1.1; p = 0.3; Fig. 3], 
although this ratio increased dose-dependent significantly after i.c.v. treatment with NPY 
(factor “treatment”: F (2; 51) = 10.5; p < .0001). Additionally, NPY administration increased 
significantly the time spent on open arms [two-way ANOVA; factor “treatment”: F (2; 51) = 
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8.6; p = 0.0006; data not shown]. But since in both parameters no significant “substrain” × 
“treatment” interactions or significant substrain differences were found, these results indicate 
that the three substrains did not respond differentially to the anxiolytic-like effects of i.c.v. 
NPY as determined by the EPM. 
However, the motor activity (total arm entries) was significantly reduced in the mutant 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) animals [two-way ANOVA; factor 
“substrain”: F (2; 51) = 6.4; p = 0.003] compared to the wildtype-like rats after i.c.v. 
administration of 1 nmol NPY [one-way ANOVA for 1 nmol: F (2; 16) = 10.2; p = 0.001; 
Fig. 4A]. Overall, NPY treatment significantly decreased motor activity, especially in the 
DPPIV-deficient rats of both substrains [two-way ANOVA; factor “treatment”: F (2; 51) = 
4.9; p = 0.01].  In addition, the frequency of enclosed arm entries was significantly reduced 
after i.c.v. treatment with NPY [two-way ANOVA; factor “treatment”: F (2; 51) = 12.1; p < 
.0001; one-way ANOVA for F344/DuCrj(DPPIV-): F (2; 18) = 5.8; p = 0.01; one-way 
ANOVA for F344/Crl(Ger/DPPIV-): F (2; 19) = 4.7; p = 0.02; Table 2], although the 
differences between the substrains failed to be statistically significant [two-way ANOVA; 
factor “substrain”: F (2; 51) = 2.3; p = 0.11]. Furthermore, a significant “substrain” × 
“treatment” interaction regarding the time spent on open arms per entry was found [two-way 
ANOVA; “substrain” × “treatment”: F (2; 51) = 2.6; p < .05; Fig. 4B]. Although one-way 
ANOVA revealed no significant differences regarding the factor “substrain” within the 
differential NPY treatments, the animals, which lack DPPIV-like activity, were found to stay 
longer on the open arms per entry than the control F344/Crl(Por) rats (Fig. 4B). NPY 
treatment significantly increased the time spent on open arms per entry [two-way ANOVA; 
factor “treatment”: F (2; 51) = 7.7; p = 0.0012]. 
Social interaction 
Recording the time spent in active social interaction (SI) in pairs of rats of the same substrain 
and treatment as an indicator of anxiety revealed that the time spent in various behaviors was 
increased in F344/DuCrj(DPPIV-) rats (trend, not significant) as well as significantly 
increased in the F344/Crl(Ger/DPPIV-) animals of the 0.2 nmol NPY treatment group [two-
way ANOVA; factor “substrain”: F (2; 48) = 7.8; p = 0.001; one-way ANOVA for 0.2 nmol: 
F (2; 16) = 9.4; p = 0.002; Fig. 5A]. Furthermore, two-way ANOVA revealed a significant 
NPY-dependent increase in the social interaction time of all animals [factor “treatment”: F (2; 
48) = 11.3; p < .0001; Fig. 5A]. Additionally, we found a significant “substrain” × 
“treatment” interaction in the frequency of anal sniffing [two-way ANOVA; “substrain” × 
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“treatment” interaction: F (2; 48) = 3.0; p = 0.03], which was significantly increased in the 
F344/Crl(Ger/DPPIV-) rats after treatment with 0.2 nmol NPY [two-way ANOVA; factor 
“substrain”: F (2; 48) = 3.5; p = 0.04; one-way ANOVA for 0.2 nmol: F (2; 16) = 10.9; p = 
0.001; Fig. 5B]. The significantly decreased frequency of self-grooming in the DPPIV-
deficient substrains disappeared after i.c.v. treatment with 1 nmol NPY [two-way ANOVA; 
factor “substrain”: F (2; 48) = 7.6; p = 0.001; one-way ANOVA for vehicle: F (2; 18) = 4.2; p 
= 0.03; one-way ANOVA for 0.2 nmol: F (2; 16) = 4.2; p = 0.03; Fig. 5C]. Additionally, two-
way ANOVA revealed a significant reducing effect of NPY administration on the frequency 
of self-grooming [factor “treatment”: F (2; 48) = 3.8; p = 0.03]. Interestingly, the sum of 
frequencies of the various social behaviors (anal sniffing, following, allo grooming, walking 
over, crawling under, and nosing) exhibited no significant differences between the substrains 
[two-way ANOVA; factor “substrain”: F (2; 48) = 2.6; p = 0.09; Fig. 6], although the overall 
motor activity of the rats (measured by number of square entries) was significantly reduced by 
NPY [two-way ANOVA; factor “treatment”: F (2; 48) = 55.2; p < .0001]. 
 131 I.c.v. effect of NPY in DPPIV-deficient rats: Pharmacol Biochem Behav 75. 2003. 869-79. 
 
 
5.4 Discussion 
This study shows for the first time a differential response in rats that differ in their 
endogenous DPPIV-like enzymatic activity to i.c.v. administration of NPY. Namely, the 
different doses of NPY induced significantly more pronounced sedative-like effects on EPM 
behavior and anxiolytic-like effects on the rat social interaction test in the DPPIV-deficient 
F344 rats. The study provides further evidence for the orexigenic, potent sedative-, and 
anxiolytic-like effects of NPY and confirms previously described spontaneous mutation in the 
Dpp4 gene in the two F344 rat substrains, which leads to an extreme reduction of DPPIV-like 
activity in the F344/DuCrj(DPPIV-) and the F344/Crl(Ger/DPPIV-) animals (Karl et al., 
2003a; Tsuji et al., 1992). 
NPY, as a physiological appetite transducer (Kalra et al., 1999), is the only known peptide 
that can cause animals to eat until they are obese (Inui, 1999). Injections of NPY either in the 
third ventricle (Jolicoeur et al., 1991; Levine and Morley, 1984), the hypothalamus (Schwartz 
et al., 2000; Stanley et al., 1986), and especially into the paraventricular nucleus (PVN) (Brief 
et al., 1992; Merlo Pich et al., 1992) exert a powerful stimulatory effect on feeding and 
drinking behavior of rats. All animals of the different substrains exhibited a dose-dependent 
increase in food intake after i.c.v administration of NPY. In addition, for the first time this 
study proved a stimulating effect of i.c.v. administrated NPY on the latency to start eating, 
which could be discussed as an influence of NPY on the feeding motivation of rodents. 
However, in contrast to the proposed hypothesis, no pronounced differences in feeding 
behavior were found between the wildtype-like and mutant F344 substrains. This may be due 
to the fact that active DPPIV in the wildtype-like animals cleaves NPY to NPY3-36, which 
results in a loss of Y1 receptor subtype but not Y5 (and Y2) receptor subtype affinity. 
Importantly, the feeding behavior of rodents is very likely mediated via Y1 and Y5 receptors 
(Inui, 1999; Kalra et al., 1999; Turnbull et al., 2002) and possibly also via Y2 receptors 
(Sainsbury et al., 2002). Y5 agonists stimulate food intake (Bischoff and Michel, 1999) and 
inhibition of NPY-stimulated food intake has been observed upon central administration of 
antisense oligonucleotides directed against the Y5 receptor. Additionally, Y5 receptor mRNA 
was detected in abundance in the PVN and the lateral hypothalamus, areas that have been 
implicated in the control of feeding behavior (Gerald et al., 1996). Antisense oligonucleotides 
directed against the Y1 receptor were also reported to inhibit NPY-stimulated food intake 
(Bischoff and Michel, 1999), and treatment with Y1 receptor antagonists like BIBO3304 or 
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BIBP3226 blocked NPY-induced food intake (Bischoff and Michel, 1999; Inui, 1999). Also 
the Y2 receptor subtype seems to be involved in feeding and body weight regulation (Inui, 
2000). Y2 receptor knockout mice developed increased food intake and body weight 
(Naveilhan et al., 1999), which indicates an inhibitory role for this receptor subtype in the 
central regulation of these parameters. After all, the stimulating effect of NPY on feeding 
seems to be mediated via the Y1, Y5, and perhaps the Y2 receptor, although NPY, Y1, and Y5 
receptor knockout mice did not show expected impaired feeding and body weight loss 
(Erickson et al., 1996; Marsh et al., 1998; Pedrazzini et al., 1998). Therefore, it is not 
surprising that the food intake of all F344 substrains is similar because endogenous native 
NPY in the mutant substrains and cleaved NPY3-36 in the wildtype-like substrain are both 
potent mediators for feeding behavior.  
NPY is deeply involved in anxiety-like behaviors of rodents (Kask et al., 2002). I.c.v. 
administration of NPY and Y1 agonists decreased anxiety in the EPM (Broqua et al., 1995; 
Heilig et al., 1989) and the open field (von Horsten et al., 1998b). Furthermore, bilateral 
microinjections of NPY into the dorsocaudal septum increased the social interaction time in 
the social interaction test (Kask et al., 2001b). In addition, rats treated with antisense 
oligodeoxynucleotides blocking Y1 receptors displayed behavioral signs of anxiety 
(Wahlestedt et al., 1993) and the Y1 receptor antagonists BIBO3304 and BIBP3226 blocked 
anxiolytic-like effects of exogenously administered NPY (Kask et al., 2001b; Kask et al., 
1996; von Horsten et al., 1998b). These findings strongly suggest a role for the Y1 receptor in 
mediating the anxiolytic-like action of NPY (Heilig et al., 1989; Kask and Harro, 2000). But 
anxiolytic-like effects of NPY are not only mediated via NPY Y1 receptors in the amygdala 
(Sajdyk et al., 1999) and the dorsal periaqueductal gray matter (Kask et al., 1998a) but 
probably also via Y2 receptors in the locus coeruleus (Kask et al., 2001b; Kask et al., 1998b) 
and via Y5 receptors (Sajdyk et al., 2002). Importantly, also a dose-dependent sedative effect 
of NPY on locomotor activity in the plus maze has been reported (Broqua et al., 1995; Heilig 
et al., 1989). In addition, central NPY administration suppressed activity in the open field and 
in the homecage (Heilig and Murison, 1987), which was interpreted as sedation (Fuxe et al., 
1983). Also other studies proved a dose-dependent decrease in the motor activity of rats after 
i.c.v. administration of NPY (Jolicoeur et al., 1995) and NPY antibody treatment increased 
motor activity (Yamada et al., 1996). This suppression of activity is supposed to be mediated 
by Y1 receptors (Heilig et al., 1988; Kask et al., 1999; von Horsten et al., 1998b), which are 
also involved in the NPY-induced sensitization to sedation (Naveilhan et al., 2001). 
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In our study the NPY-treated mutant animals of F344/DuCrj(DPPIV-) and 
F344/Crl(Ger/DPPIV-) exhibited a dose-dependent reduction in motor activity in the EPM. 
The wildtype-like F344/Crl(Por) rats were unaffected by the sedative effect of NPY, probably 
because of differences in the NPY catabolism between the F344 substrains with a DPPIV-
dependent cleavage of NPY to the Y1 receptor unspecific NPY3-36 only in control rats. Also 
the dose-dependent increased time spent on open arms per entry in the mutant animals 
supports a probably Y1-mediated sedative-like effect of NPY. The differential response of the 
three F344 substrains to the different doses of NPY in regard to this parameter supports our 
hypothesis regarding the DPPIV-dependent differential NPY catabolism in wildtype-like and 
mutant animals. In addition, NPY had an anxiolytic-like effect in all substrains, which was 
detected by an increase in the ratio of open arm to total arm entries and in the total time spent 
on open arms. Notably, these possible anxiolytic-like effects of NPY on the total time spent 
on open arms could also be influenced by the sedative-like effect of NPY. At least in the F344 
genetic background, importantly, a very narrow pharmacological window between sedative-
like and anxiolytic-like effects of NPY especially in the EPM has to be considered in order to 
avoid false positive results. Therefore, not only the time spent on open arms should be 
recorded as a parameter for detecting anxiolytic-like behaviors in the EPM. Furthermore, 
various behavioral tests for anxiety have to be used for a complete screening of anxiety-like 
behaviors in rodents. Therefore, we also applied the social interaction test for recording 
anxiolytic-like effects of NPY. Interestingly, in this task, the DPPIV-deficient rats exhibited 
an increased anxiolytic-like response to the NPY administration compared to the wildtype-
like animals by an increased SI time. This is supported by the frequency of anal sniffing with 
a significant differential response of the substrains regarding the different NPY treatments. To 
check for possible sedative-like influences of NPY on the anxiety-like behaviors in this task, 
we analyzed the overall motor (number of square entries) and social-like (summed frequency 
of social behaviors) activity of our animals. Motor activity was dose-dependently reduced by 
NPY treatment, but despite the sedative effect on ambulatory activity, social-like behaviors 
remained unaffected by NPY. Thus, NPY exerts a clear effect on anxiety as exemplified by an 
increased SI time in the rat social interaction test in the mutant animals, which was further 
substantiated by a significantly reduced frequency of self-grooming (as a measurement for 
displacement activity) in the mutant substrains, which disappeared dose-dependently after 
NPY treatment. 
Overall, these data show the suggested differences between the wildtype-like and mutant 
F344 substrains regarding their NPY catabolism because of the more potent Y1 receptor-
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mediated anxiolytic-like and sedative-like effects of the neurotransmitter in the mutant, 
DPPIV-deficient animals. The differences within the two DPPIV-deficient substrains 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) in the social interaction test could be due to 
different compensatory mechanisms during ontogeny, but further studies are necessary 
focusing on this phenomenon.  
In conclusion, this study shows for the first time a differential potency and specificity of NPY 
between wildtype-like and DPPIV-deficient rat substrains and thereby supports the concept 
that these animals provide a useful model to study the various behavioral and physiological 
effects associated with DPPIV-enzymatic activity. Therefore, F344 rat substrains 
F344/Crl(Por), F344/DuCrj(DPPIV-), and F344/Crl(Ger/DPPIV-) indicate an excellent 
natural animal model to study the “DPPIV-NPY-axis”. In particular, the mutant animals 
exhibited an increased responsiveness to the sedative-like and anxiolytic-like effect of i.c.v.-
administered NPY, which is very likely mediated via a Y1 receptor-dependent mechanism. 
Since pharmacological inhibition of DPPIV-like activity has been demonstrated to potentiate 
the effects of NPY administration in vivo (Dimitrijevic et al., 2002), it seems possible that 
DPPIV inhibitors specifically targeting the CNS are useful modifiers of the centrally mediated 
effects of NPY.  
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5.7 Tables and figures 
 
Table 1:  
Latency to eat during the light phase [s] 
NPY F344/Crl(Por) F344/DuCrj(DPPIV-) F344/Crl(Ger/DPPIV-) 
             
Vehicle 
 
77.1 ± 20.4 
 
60.3 ± 21.2 
 
85.7 ± 18.2 
             
0.2 nmol  
 
    12.7 ±  2.3++ 
 
 12.7 ±  1.1+ 
 
      17.5 ±  3.3+++ 
             
1.0 nmol  
 
      10.6 ±  1.6+++ 
 
13.3 ±  4.3+ 
 
       8.0 ±  0.8+++ 
 
Latency to eat during the dark phase [s] 
NPY F344/Crl(Por) F344/DuCrj(DPPIV-) F344/Crl(Ger/DPPIV-) 
             
Vehicle 
 
51.6 ± 18.5 
 
80.6 ± 15.3 
 
54.3 ± 16.1 
             
0.2 nmol  
 
39.8 ± 14.8 
 
      17.5 ±  3.4+++ 
 
38.2 ± 14.0 
             
1.0 nmol  
 
10.3 ±  1.5 
 
      12.3 ±  1.3+++ 
 
14.2 ±  1.4 
Latency to start eating in F344 substrains; animals´ feeding behavior (food intake) was 
recorded [s] after receiving an i.c.v. injection of vehicle or NPY (0.2 nmol/1.0 nmol). Data 
represent means ± SEM. Significant post hoc effects for the factor “treatment” versus the 
vehicle-treated animals are indicated by crosses (+p < .05; ++p < .01; +++p < .001). 
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Table 2:  
NPY F344/Crl(Por) F344/DuCrj(DPPIV-) F344/Crl(Ger/DPPIV-) 
             
Vehicle 
 
4.3 ± 0.75 
 
3.9 ± 0.77 
 
3.8 ± 0.87 
             
0.2 nmol  
 
3.1 ± 0.51 
 
2.0 ± 0.85 
 
2.7 ± 0.68 
             
1.0 nmol  
 
2.4 ± 0.41 
 
    0.6 ± 0.31++ 
 
    1.0 ± 0.38++ 
Motor activity in the EPM [n]; the number of enclosed arm entries as an additional parameter 
for motor activity is presented [n]; animals were tested after receiving an i.c.v. injection of 
vehicle or NPY (0.2 nmol/1.0 nmol). Data represent means ± SEM. Significant post hoc 
effects for the factor “treatment” versus the vehicle-treated animals are indicated by crosses 
(++p < .01). 
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Fig. 1: Test setting; test biography of rats of the three different substrains F344/Crl(Por), 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-). The animals´ age in the various tests is 
shown. 
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Fig. 2: DPPIV-like activity; DPPIV-like activity [mU/ml] of all test animals was screened; 
blood from the tail vain was sampled and analyzed as described above. Data represent means 
+ SEM. Asterisks (***p < .001) reflect significant differences versus F344/Crl(Por) – 
detected in the Fisher-PLSD-test. 
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Fig. 3: Anxiolytic-like effects in the EPM; the number of arm entries of the test animal into 
open and enclosed arms were recorded for 5 min; the ratio of open arm entries to total arm 
entries serves as a measure for anxiety [%]; animals were tested after receiving an i.c.v. 
injection of vehicle or NPY (0.2 nmol/1.0 nmol). Data represent means + SEM.  
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Fig. 4A: Motor activity in the EPM; the total number of arm entries of the test animal was 
recorded for 5 min; the number of total arm entries serves as a measure for motor activity [n]; 
animals were tested after receiving an i.c.v. injection of vehicle or NPY (0.2 nmol/1.0 nmol). 
Data represent means + SEM. Asterisks (***p < .001; **p < .01) reflect significant 
differences versus F344/Crl(Por) – detected in the Fisher-PLSD-test.  
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Fig. 4B: Sedation in the EPM; the time spent on open arms per entry was recorded [s]; 
additionally, the overall time spent on open arms per entry in each substrain is presented; 
animals were tested after receiving an i.c.v. injection of vehicle or NPY (0.2 nmol/1.0 nmol). 
Data represent means + SEM. Asterisks (**p < .01) reflect significant differences versus 
F344/Crl(Por) – detected in the Fisher-PLSD-test. 
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Fig. 5A: Anxiolytic-like effects in the social interaction test; the time spent in active social 
interaction (SI) was recorded [s]; additionally, the overall effect of different doses of NPY on 
SI is presented; animals were tested after receiving an i.c.v. injection of vehicle or NPY (0.2 
nmol/1.0 nmol). Data represent means + SEM. Asterisks (***p < .001) reflect significant 
differences versus F344/Crl(Por), whereas double crosses (#p < .05) display significant 
differences between F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) – detected in the 
Fisher-PLSD-test. Significant post hoc effects for the factor “treatment” versus the vehicle-
treated animals are indicated by crosses (+p < .05; +++p < .001), whereas “x” (xp < .05) 
reflects significant differences between the two different NPY doses 0.2 nmol and 1.0 nmol - 
detected in the Fisher-PLSD-test. 
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Fig. 5B: Anal sniffing in the social interaction test; the frequency of anal sniffing was 
recorded during 10 min of observation [n]; rats of different substrains but of the same 
treatment group were compared; animals were tested after receiving an i.c.v. injection of 
vehicle or NPY (0.2 nmol/1.0 nmol). Data represent means + SEM. Asterisks (**p < .01) 
reflect significant differences versus F344/Crl(Por), whereas double crosses (###p < .001) 
display significant differences between F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) – 
detected in the Fisher-PLSD-test. 
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Fig. 5C: Self-grooming in the social interaction test; the frequency of self-grooming was 
recorded during 10 min of observation [n];  rats of different substrains but of the same 
treatment group were compared; animals were tested after receiving an i.c.v. injection of 
vehicle or NPY (0.2 nmol/1.0 nmol). Data represent means + SEM. Asterisks (*p < .05) 
reflect significant differences versus F344/Crl(Por) – detected in the Fisher-PLSD-test. 
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Fig. 6: Motor activity and social-like behaviors in the social interaction test; the summed 
frequency of social-like behaviors was recorded [n]; additionally, the overall effect of NPY on 
motor activity is presented by the total number of square entries after receiving an i.c.v. 
injection of vehicle or NPY (0.2 nmol/1.0 nmol). Data represent means + SEM. Significant 
post hoc effects for the factor “treatment” versus the vehicle-treated animals are indicated by 
crosses (+++p < .001), whereas “x” (xxxp < .001) reflects significant differences between the 
two different NPY doses 0.2 nmol and 1.0 nmol - detected in the Fisher-PLSD-test. 
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Abstract 
Dipeptidyl-peptidase IV (DPPIV; CD26) is involved in several physiological functions via 
cleavage of dipeptides with a Xaa-Pro or Xaa-Ala sequence of regulatory peptides such as 
neuropeptide Y (NPY). Cleavage of NPY by DPPIV results in NPY3-36, which lacks affinity 
for the Y1, but not for other NPY receptor subtypes. Among other effects, the NPY Y1 
receptor seems to be involved in analgetic-like effects of NPY. In this study we investigated 
whether intracerebroventricular (i.c.v.) administration of different doses of NPY (vehicle, 0.2, 
or 1.0 nmol) or of the DPPIV inhibitor isoleucyl-thiazolidide (Ile-Thia) (vehicle, 0.5, or 5.0 
nmol) modulates the behavioral response in the hot plate paradigm in wildtype-like and 
DPPIV-negative F344 substrains. Untreated non-habituated DPPIV-deficient animals, which 
display an anxiolytic-like phenotype, exhibited a reduced latency to respond to an aversive 
thermal stimulus in the hot plate, suggesting a process of reduced stress-induced analgesia. 
I.c.v. administration of NPY decreased the pain sensitivity of these animals but not of the 
wildtype-like F344 rats. DPPIV inhibition resulted in an increased nociception of the 
wildtype-like animals in the same paradigm. The differential response to i.c.v. administration 
of NPY confirms the recently described differential NPY catabolism within the different F344 
substrains. Furthermore, the study demonstrates for the first time that the modulation of 
nociception by NPY can be modified by DPPIV-like enzymatic activity. The differences in 
pain sensitivity are based on a more potent Y1 receptor-like tone in the DPPIV-deficient rats, 
which mediates the analgetic-like effect. 
 
 
 
Keywords: Dipeptidyl-peptidase IV – CD26 – Neuropeptide Y - Isoleucyl-thiazolidide – 
F344 rats –– Nociception – Stress-induced analgesia – Hot plate 
 156 I.c.v. effect of NPY on nociception in DPPIV-deficient rats: in preparation. 
 
 
 
6.1 Introduction 
The enzyme and binding protein dipeptidyl-peptidase IV (DPPIV) belongs to the class of 
membrane-associated peptidases (De Meester et al., 1999). The ectopeptidase is identical to 
the leukocyte differentiation marker CD26 and is involved in T-cell dependent immune 
responses (Kahne et al., 1999) and in cell adhesion (Mentlein, 1999; Shingu et al., 2003). Due 
to its unique ability to liberate Xaa-Pro and Xaa-Ala dipeptides from the N-terminus of 
regulatory peptides, important substrates include neuropeptides such as neuropeptide Y 
(NPY), peptide YY (PYY), and endomorphin (Hildebrandt et al., 2000; Mentlein, 1999). 
Further substrates are glucagon-like peptide 1 (GLP-1), GLP-2, enterostatin, substance P, and 
various chemokines (De Meester et al., 2000). Endomorphin-2, substance P, and especially 
NPY are discussed in regard to their analgetic-like effects in tests for nociception. 
We previously investigated the role of the DPPIV-like activity on behavioral and 
physiological processes in a mutant rat model for DPPIV deficiency. Spontaneous mutations 
in the Dpp4 gene of F344 substrains from breeding colonies of Charles River Laboratories 
(Crl) in Sulzfeld, Germany (Thompson et al., 1991), and Atsugi, Japan (Tiruppathi et al., 
1993; Watanabe et al., 1987), result in an almost complete lack of DPPIV-like activity in 
these animals. This DPPIV deficiency does not exist in wildtype-like F344 rats from Crl 
breeding colonies in Portage, USA (Karl et al., 2003a). In a systematical behavioral and 
physiological characterization of the different substrains, we observed differences in the 
mutant, DPPIV-deficient F344 rats showing reduced anxiety-like behaviors and increased 
nociception (Karl et al., 2003b). In another study (Karl et al., 2003c) we showed that the 
anxiolytic-like phenotype of the DPPIV-deficient substrains is based on a differential 
degradation of NPY, strongly suggesting that a more potent NPY Y1 receptor-like tone in the 
DPPIV-deficient F344 substrains causes these differences. 
Among several other physiological responses NPY especially affects anxiety and nociception 
(Kalra et al., 1999; Kask et al., 2002; Naveilhan et al., 2001; Wettstein et al., 1995) via the 
NPY Y1 receptor subtype, although the effect on pain sensitivity is discussed controversially. 
Some studies described an analgetic effect after NPY administration (Hua et al., 1991; Merlo 
Pich et al., 1990), some showed a hyperalgesic effect of the same neuropeptide (Broqua et al., 
1996; von Horsten et al., 1998b) and others did not find any influence of NPY on nociception 
processes (Heilig et al., 1993; Jolicoeur et al., 1991). We hypothesize that the hyperalgesic 
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phenotype of the two DPPIV-deficient F344 substrains from Japan [F344/DuCrj(DPPIV-)] 
and Germany [F344/Crl(Ger/DPPIV-)] (Karl et al., 2003b) compared to the wildtype-like rats 
could be due to a differential stress response along with a differential stress-induced 
analgesia. This could be based on the recently proven differential NPY metabolism within the 
different substrains (Karl et al., 2003c). Furthermore, we postulate an antinociceptive effect of 
NPY on pain sensitivity. Such processes could sufficiently explain the increased pain 
sensitivity in the mutant, DPPIV-deficient substrains. 
To test this hypothesis, we re-investigated the phenomenon of a differential stress-induced 
analgesia in different F344 substrains and tested whether NPY applied 
intracerebroventricularly (i.c.v.) produces differential effects in the different F344 substrains 
in regard to their pain sensitivity. Thus, we characterized the effect of i.c.v. administration of 
different doses of NPY in the F344/DuCrj(DPPIV-), F344/Crl(Ger/DPPIV-), and 
F344/Crl(Por) rats in the hot plate paradigm. To prove our hypothesis that the various 
behavioral and physiological differences between the different F344 substrains – especially 
the hyperalgesic phenotype of the mutant animals – is based on the DPPIV deficiency we also 
investigated pharmacologically the effect of i.c.v. DPPIV inhibition on the hot plate response 
of these animals.  
 
 158 I.c.v. effect of NPY on nociception in DPPIV-deficient rats: in preparation. 
 
 
 
6.2 Materials and methods 
Animals 
For clarity, animal groups were coded as previously described (Karl et al., 2003a): F344 rats 
derived in 1998 from breeding colonies of Crl in Atsugi (Japan) were called 
F344/DuCrj(DPPIV-), animals from breeding colonies in Sulzfeld (Germany) 
F344/Crl(Ger/DPPIV-), and wildtype-like rats obtained from colonies in Portage (USA) 
F344/Crl(Por). 
All F344 rats of the three different substrains were housed and bred at the Central Animal 
Facility of the Hannover Medical School as previously described (Karl et al., 2003a). Animals 
were maintained in a separated minimal barrier sustained facility and kept in Macrolon type 
III cages with a standard bedding (Altromin GmbH, Lage, Germany). Food (Altromin 
Standard Diät 1320: Altromin GmbH) and water were available ad libitum. Environmental 
temperature was automatically regulated at 21 ± 2 °C and relative humidity was 55 ± 5% with 
an air change rate of 15 times per hour. The animal rooms were operated with a positive 
pressure of 0.6 Pa. Rats were maintained under a 12:12 h light regime (light onset at 4am). 
They underwent routine animal care once a week. Routine microbiologic monitoring 
according to FELASA recommendations (Rehbinder et al., 2000) did not reveal any evidence 
of infection with common murine pathogens except for Pasteurella pneumotropica and 
Staphylococcus aureus. All research and animal care procedures were approved by the 
Review Board for the Care of Animal Subjects of the district government, Hannover, 
Germany, and performed according to international guidelines for the use of laboratory 
animals. 
Determination of DPPIV-like enzymatic activity 
All test animals were characterized in regard to their DPPIV-like enzymatic activity as 
previously described (Karl et al., 2003a). For determination of plasma activity of F344 rats a 
microplate based fluorescence assay was used. EDTA-plasma samples were kept at –80 °C 
until use. DPPIV enzyme activity of the different rat substrains was determined by monitoring 
the release of 4-Amino-7-Methylcoumarin (AMC) from the substrate Gly-Pro-AMC at 
360/480 nm (Ex/Em) and 30 °C using the Novostar fluorescence microplate reader (BMG, 
Offenburg, Germany). The assay consists of 20 µl plasma sample, 100 µl H2O and 100 µl 
HEPES buffer pH 7.6 and 50 µl Gly-Pro-AMC. Activity was calculated from the linear slope 
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using a factor of 3.116*10-4 µmol/l calculated from an AMC standard curve and the sample 
dilution. One unit is defined as the enzyme activity, which cleaves 1 µmol Gly-Pro-AMC per 
minute. The assay is selective for DPPIV-like activities. It has been proven that the substrate 
is cleaved by DPPIV, by DP II, and by attractin. Probably, they are also substrates for DP8 
and DP9. Importantly, the chromophores are not released by other proline-specific peptidases, 
such as prolidase, prolyl endopeptidase or aminopeptidase P. 
Surgery of i.c.v. cannulation 
For surgery, animals were anesthetized with intramuscular (i.m.) ketamine hydrochloride (0.1 
ml/100 g body weight; Albrecht, Aulendorf, Germany) and dormitor (0.01 ml/100 g body 
weight; Pfizer GmbH, Karlsruhe, Germany). The i.c.v. cannulation technique was identical to 
that outlined in a previous report (von Horsten et al., 1998a). After placement of the rat in a 
stereotactic apparatus (model 900: David Kopf Instruments, Tujunga, USA), the incisor bar 
was adjusted on position zero and the ear bars were adjusted to equal positions so that the 
rat´s head was fixed in the apparatus. The eyes were protected against drying with eye-
ointment (Bepanthen Augen- und Nasensalbe: Hoffmann-La Roche AG, Grenzach-Wyhlen, 
Germany). The skull was exposed by a midline incision, the periost was removed, the bone 
surface was dried, and the position of the bregma was identified. Three stainless steel anchor 
screws (Breitfeld & Schliekert, Karben, Germany) were secured to the skull and a stainless 
steel guide cannula (Plastics one, Roanoke, USA) was implanted in the right lateral ventricle 
and cemented in place with dental cement (Durelon Maxicap: Espe Dental AG, Seefeld, 
Germany). The coordinates for the lateral ventricle were 0.7 mm caudal and 1.6 mm lateral to 
the bregma, with the guide cannula (Plastics one) extending 3.4 mm ventral to the skull 
surface. Flow of small amounts of 0.9% saline (Braun Melsungen AG, Melsungen, Germany) 
through the protracted injection (internal) cannula (Plastics one) was used to verify that the 
guide cannula was positioned just above the ventricular system. The guide cannula was then 
fitted with a dummy cannula (Plastics one) of the same length to prevent leakage of 
cerebrospinal fluid. Animals were housed individually after surgery. The anatomical position 
of the cannula was verified by post mortem i.c.v. dye application (Berlin blue) and inspection 
of the stained third ventricle in randomly chosen rats. The animals of the three F344 
substrains F344/DuCrj(DPPIV-), F344/Crl(Ger/DPPIV-), and F344/Crl(Por) were operated at 
an age of 95 (±5) days. The observation of the animals’ behavior in the hot plate test 
commenced after a recovery phase of at least 10 days. 
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Drugs, i.c.v. injections, and dosages 
A stock solution of human/rat NPY (2 mol; Polypeptide GmbH, Wolfenbüttel, Germany) was 
adjusted under sterile conditions to final concentrations (0.2 nmol/5 µl and 1.0 nmol/5 µl) 
using 0.9% saline. A stock solution of the DPPIV inhibitor isoleucyl-thiazolidide (Ile-Thia) 
(Probiodrug AG, Halle, Germany) was adjusted under sterile conditions to final 
concentrations (0.5 nmol/5 µl and 5.0 nmol/5 µl) using 0.9% saline. The final concentrations 
of NPY and Ile-Thia were made 24 h before the different experiments.  
For the i.c.v. administration animals were taken out of the home cage and the dummy cannula 
was replaced by the internal cannula. Peptide, inhibitor or 0.9% saline was injected i.c.v. in a 
volume of 5 µl over 20 s through the internal cannula extending 4.4 mm ventral to the skull 
surface. The internal cannula was attached to a microsyringe (Hamilton Bonaduz AG, 
Bonaduz, Switzerland) with approximately 30 cm of polyethylene tubing (Plastics one), 
which allowed the animal to move freely during the i.c.v. injection. Then the internal cannula 
was replaced by the dummy cannula again and the rat was returned into the home cage. All 
experiments started 15 min after the administration procedure. For the procedure of i.c.v.-
injection, animals were habituated to experimental handling daily over 7 days prior to the start 
of the first experiment. During the habituation phase the handling procedure was exactly the 
same except for the application of the compound. 
Two different doses of NPY/Ile-Thia were used for this study and a 3 (substrain) × 3 
(treatment) experimental design was set up. Thus, F344 rats of each substrain were divided 
into three treatment groups each (n = 7), which were treated with 0.9% saline (vehicle: 0.0 
nmol/5 µl), or two different doses of NPY (0.2 nmol/5 µl, or 1.0 nmol/5 µl) or of Ile-Thia (0.5 
nmol/5 µl, or 5.0 nmol/5 µl). 
Nociception 
A 30x30 cm hot plate analgesia meter (Columbus Instruments, Columbus, USA) was used for 
this experiment, which was carried out during the light phase. The experiments were 
performed as previously described (Karl et al., 2003b; Stephan et al., 2002). The rat was 
placed on the surface of the apparatus, which was maintained at 52.5 °C. The latency to 
respond (lick or raise a hindpaw) was recorded. To prevent any tissue damage, the rat was 
removed from the hot plate if the animal did not respond within 20 s (Naveilhan et al., 2001; 
von Horsten et al., 1998b). Non-habituated animals were tested twice in the hot plate 
paradigm. In the first test (Hot plate I) rats (age: 111 ± 3 days) received an i.c.v injection of 
NPY (vehicle, 0.2, or 1.0 nmol/5 µl). Fifteen days later (Hot plate II) animals were tested 
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once more in this paradigm but this time rats were treated with the DPPIV inhibitor Ile-Thia 
(vehicle, 0.5, or 5.0 nmol/5 µl).  
 
Statistical analysis 
The analysis of the various behavioral data was assessed using a two-way analysis of variance 
(ANOVA; factor: “substrain” × “treatment”) and by one-way ANOVA (factor: “substrain” or 
“treatment” - split by the corresponding factors) followed by the Fisher-PLSD-test for post 
hoc comparison, if appropriate. Differences were regarded as statistically significant if p < 
.05. In the results section the degrees of freedom, F-values, and p-values of two- and one-way 
ANOVAs are given, while in the figures the p-values of the corresponding post hoc tests 
(Fisher-PLSD-test) are provided. In most cases the number of animals per substrain and 
treatment group was n  = 7. Presenting the degrees of freedom indicates exceptions from this. 
Significant post hoc effects for the factor “substrain” versus the control animals of the 
F344/Crl(Por) substrain are indicated by asterisks (*p < .05; **p < .01; ***p < .001), whereas 
significant differences between the two DPPIV-deficient rat substrains F344/DuCrj(DPPIV-) 
and F344/Crl(Ger/DPPIV-) are shown by rhombs (#p < .05; ##p < .01; ###p < .001). All data 
are displayed as means ± standard error of the mean (SEM). 
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6.3 Results 
DPPIV-like activity 
One-way ANOVA of the DPPIV-like activity of all animals exhibited significant differences 
between substrains (Fig. 1). An almost complete lack of enzymatic-like activity was found in 
the two mutant substrains F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) and a wildtype-
like pattern of DPPIV-like activity was found in the rats from the F344/Crl(Por) substrain [F 
(2; 61) = 400.4; p < .0001]. 
Nociception 
In the first hot plate experiment (Hot plate I) two-way ANOVA revealed a significantly 
reduced latency in the mutant F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) substrains to 
lick or raise a hindpaw [factor “substrain”: F (2; 55) = 10.1; p = 0.0002] after treatment with 
vehicle. This significant hyperalgesic effect of DPPIV deficiency in the mutant substrains 
[one-way ANOVA; factor “substrain” - vehicle-treated: F (2; 19) = 6.9; p = 0.006; Fig. 2A] 
disappeared after i.c.v. administration of NPY. In the second experiment (Hot plate II) using 
the DPPIV-inhibitor Ile-Thia, again, vehicle-treated DPPIV-deficient animals of 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) exhibited a significantly shortened latency 
to respond to the thermal stimulus of the hot plate [two-way ANOVA; factor “substrain”: F 
(2; 44) = 4.9; p = 0.01; one-way ANOVA; factor “substrain” – vehicle-treated: F (2; 18) = 
3.6; p = 0.049]. Injections of 0.5 nmol or 5.0 nmol Ile-Thia attenuated the differences in 
nociception between the different substrains. DPPIV-inhibition increased the pain sensitivity 
in control animals of the F344/Crl(Por) substrain (Fig. 2B). 
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6.4 Discussion 
The DPPIV-deficient animals of the F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) 
substrains exhibited hyperalgesia compared to control animals of the F344/Crl(Por) substrain. 
I.c.v. treatment with NPY had a dose-dependent hypoalgesic effect only in the mutant rats, 
whereas i.c.v. administration of the DPPIV inhibitor Ile-Thia had a hyperalgesic effect only in 
the wildtype-like animals.  
The effect of NPY on nociception is discussed controversially, although the presence of NPY-
immunoreactivity in some areas involved in pain modulation, such as the periaqueductal gray 
(PAG), locus coeruleus, amygdala, thalamus, or the dorsal horn of the spinal cord, suggests a 
role for NPY as a putative regulator of pain transmission and perception (Broqua et al., 1996; 
Jolicoeur et al., 1991). In the hot plate test i.c.v. administration of NPY to spontaneously 
hypertensive rats induced an elevation in the nociceptive threshold in the hot plate paradigm 
(Merlo Pich et al., 1990) and intrathecal administration of NPY produced a dose-dependent 
elevation in the nociceptive threshold (Hua et al., 1991). In other studies i.c.v. administration 
of very low doses of NPY induced hyperalgesia (Broqua et al., 1996; von Horsten et al., 
1998b), while some studies did not find any effect of NPY on nociception (Heilig et al., 1993; 
Heilig et al., 1992; Heilig et al., 1989; Jolicoeur et al., 1991). In our study an analgetic effect 
of i.c.v. administered NPY in the DPPIV-deficient F344 substrains in the hot plate test is 
obvious. Y1 receptor knockout mice develop hyperalgesia to acute thermal, cutaneous, and 
visceral chemical pain (Naveilhan et al., 2001). Therefore, it is concluded that the Y1 receptor 
is required for central physiological and pharmacological NPY-induced analgesia (Broqua et 
al., 1996; Wang et al., 2000), although another study described a Y2 receptor-mediated effect 
of NPY on thermal hyperalgesia (Tracey et al., 1995). Wildtype-like F344/Crl(Por) rats with a 
normal DPPIV-like activity lose the Y1 receptor subtype-specific affinity of endogenously 
released NPY more rapidly by DPPIV-dependent cleavage processes. This is based on the 
cleavage of NPY to the C-terminal fragment NPY3-36, which has a high affinity for the NPY 
Y2 and Y5 receptor subtypes but only a low affinity for the Y1 receptor subtype. This 
differential NPY catabolism could increase the pain sensitivity in these animals. Surprisingly, 
and in contrast to this hypothesis, hyperalgesia was detected in the vehicle-treated DPPIV-
deficient F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) animals. This phenotype could be 
based on recently reported reduced anxiety levels in the mutant animals (Karl et al., 2003b; 
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Karl et al., 2003c). Simililar to our wildtype-like animals, NPY-deficient mice appear to be 
hypoalgesic in the hot plate paradigm (Bannon et al., 2000) and exhibit an anxiogenic-like 
phenotype. This phenotype seems to be based on an extremely reduced Y1 receptor-like tone 
in the DPPIV-deficient rats and NPY-deficient mice. The increased anxiety of both mice and 
rats could increase the pain threshold in these animals by stress-induced analgesia, which is 
associated with or even triggered by a release of analgesia-inducing endogenous opioid 
peptides from central and peripheral sites (Kelley, 1986). In addition, stress based on anxiety 
increases the endogenous NPY-release so that the endogenous NPY level in our less anxious 
DPPIV-deficient rats could be reduced compared to the wildtype-like substrain. Therefore, a 
potent stress-induced NPY release in the wildtype-like animals paired with stress-induced 
analgesia could lead to the observed hypoalgesic phenotype. After i.c.v. administration of 
NPY the pain sensitivity in the mutant rats decreased dose-dependently, which is a strong 
indication of the antinociceptive effect of NPY. The effect is only present in DPPIV-deficient 
rats, which manifests the recently observed differences in the NPY catabolism between the 
mutant and wildtype-like substrains (Karl et al., 2003c). In the control animals NPY had no 
further analgetic effect, probably because of anxiogenic-induced already high endogenous 
levels of NPY in F344/Crl(Por). Furthermore, substance P, another substrate of the DPPIV, is 
involved in nociception. Similar to NPY, it could be cleaved differentially in the DPPIV-
deficient and the wildtype-like F344 substrains. This difference in substance P metabolism 
could influence the pain sensitivity of these animals as already shown for the DPPIV substrate 
NPY in our study. It has to be mentioned that another substrate of the DPPIV, endomorphin-
2, also seems to be involved in nociception processes. 
In addition, we investigated the effect of i.c.v. DPPIV inhibitor treatment in the F344 
substrains. As expected, no effects were observed in the DPPIV-deficient animals, but in the 
control animals DPPIV inhibition led to hyperalgesia. This could be based on DPPIV 
inhibition-caused reduced anxiety levels of the wildtype-like animals, which could be linked 
to a decreased endogenous NPY-release and a reduced stress-induced analgesia.  
Overall, these data confirm the suggested differences between the wildtype-like and mutant 
F344 substrains regarding their NPY catabolism because of the more potent Y1 receptor-
mediated analgetic-like effects of the neurotransmitter in the DPPIV-deficient animals. 
Furthermore, the various behavioral and physiological differences between the wildtype-like 
and DPPIV-deficient F344 substrains are exclusively based on the DPPIV deficiency because 
pharmacological inhibition of DPPIV in the control substrain results in a phenotype similar to 
the DPPIV-deficient animals. Most likely, the “DPPIV-NPY” axis represents an interesting 
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system for specific pharmacotherapy including but not limited to pain syndromes. Thus, this 
bidirectional up- and down-regulation of the latency to respond in the hot plate test by either 
NPY or DPPIV inhibitor in either the DPPIV-deficient or the wildtype-like animals strongly 
suggests a specific role of the “DPPIV-NPY” axis in the central pain perception and 
processing systems. 
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6.6 Figures 
 
Fig. 1: DPPIV-like activity; DPPIV-like activity [mU/ml] of all test animals was screened; 
blood from the tail vain was sampled and analyzed as described above. Data represent means 
± SEM. Asterisks (***p < .001) reflect significant differences versus F344/Crl(Por) – 
detected in the Fisher-PLSD-test. 
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Fig. 2A: Nociception; pain sensitivity [s] was analyzed in the hot plate test; animals were 
tested after receiving an i.c.v. injection of vehicle or NPY (0.2 nmol or 1.0 nmol); the latency 
to respond (lick or raise a hindpaw) was recorded (Hot plate I). Data represent means ± SEM. 
Asterisks (*p < .05; **p < .01) reflect significant differences versus F344/Crl(Por) – detected 
in the Fisher-PLSD-test. 
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Fig. 2B: Nociception; pain sensitivity [s] was analyzed in the hot plate test; the rat was tested 
after receiving an i.c.v. injection of vehicle or Ile-Thia (0.5 nmol or 5.0 nmol); the latency to 
respond (lick or raise a hindpaw) was recorded (Hot plate II). Data represent means ± SEM. 
Asterisks (*p < .05) reflect significant differences versus F344/Crl(Por) – detected in the 
Fisher-PLSD-test. 
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7. Discussion 
In a first step of our study, we screened different F344 rat substrains obtained from breeding 
colonies of Charles River Breeding Laboratories in Portage and in Raleigh (USA), in Atsugi 
(Japan), and in Sulzfeld (Germany) for their DPPIV-like activity (Karl et al., 2003b). These 
substrains were purchased at different time points in the years 1998 and 2001. We observed 
that F344/DuCrj(DPPIV-) rat substrains from Atsugi (Japan) constantly exhibit an almost 
complete lack of DPPIV-like enzymatic activity, while rats of the F344/Crl(Ger) substrain 
from the breeding colony in Sulzfeld (Germany) only occasionally showed a lack of DPPIV-
like enzymatic activity [only in animals, which were obtained in 1998 from Crl: 
F344/Crl(Ger/98/DPPIV-)]. Recently, a genome wide screening of both DPPIV-deficient 
substrains (which were obtained in 1998) with anonymous microsatellite markers revealed 
that the genetic background between F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) is not 
identical (cooperation with Dr. D. Wedekind: Institute for Laboratory Animal Science and 
Central Animal Facility, Hannover Medical School, Germany - unpublished results). This 
finding suggests that segregation processes occurred in the F344/Crl(Ger/DPPIV-) colony, 
which were confirmed by the differences in the DPPIV-like activity between animals obtained 
from the German breeding colony of Crl (Sulzfeld) in 1998 and in 2001. Rats obtained from 
the Crl colony in Portage (USA) in 1998 [F344/Crl(Por/98)] and Raleigh (USA) in 2001 
[F344/Crl(Ral/01)] show the expected wildtype-like DPPIV activity. Surprisingly, animals of 
the Portage colony obtained in 2001 show gender-dependent differences in DPPIV-like 
enzymatic activity. The differences in the DPPIV-like activity among the F344 rat substrains 
from the different breeding colonies of a world-wide operating vendor at different intervals 
and the results of the microsatellite analyses of F344/DuCrj(98/DPPIV-) and 
F344/Crl(Ger/98/DPPIV-) clearly indicates a persisting segregation for the Dpp4 gene in 
some of these colonies (Portage, USA and Sulzfeld, Germany). Furthermore, the laboratory 
code of the substrains from the different breeding colonies in the USA and Germany does not 
differentiate between the various breeding locations. 
These findings on variation in DPPIV-like enzymatic activity in the different F344 substrains 
indicate that scientists, who obtain F344 rats from this vendor (which have originated from 
above described colonies) or who work on DPPIV-dependent physiological processes in these 
rats should screen their animals in regard to their DPPIV-like activity and should be aware of 
the origin of their F344 rat substrain. 
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Furthermore, the extreme differences in the DPPIV-like activity found between several other 
rat strains (such as LEW/Ztm, DA/Ztm, BN/Ztm) suggest that a screening of DPPIV-like 
activity is an important experimental step in case of research in regard to DPPIV-dependent 
physiological processes (the differential DPPIV-like activity among various rat strains could 
be attributed to differences among coding regions of the Dpp4 genes or to modifier genes of 
the respective genetic backgrounds). 
For all our experiments we used animals received from the breeding colonies in Portage 
[F344/Crl(Por)], Atsugi [F344/DuCrj(DPPIV-)], and Sulzfeld [F344/Crl(Ger/DPPIV-)] in 
1998 and screened every single test animal in regard to its DPPIV-like activity. Only the 
animals of the postulated DPPIV-deficient substrains exhibited the expected extreme 
reduction in the DPPIV-like activity (to nearly 0%). We assume that the deficiency in DPPIV-
like activity in F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) could be attributed to a 
spontaneous mutation previously described in F344/DuCrj(DPPIV-) (Tsuji et al., 1992) 
resulting in a null allele. Very recently, we were able to confirm this point mutation identified 
by Tsuji and coworkers (1992) also in F344/Crl(Ger/DPPIV-) and additionally found three 
other point mutations in the Dpp4 gene (in regard to the catalytic center of DPPIV) of both 
mutant substrains (cooperation with Dr. T. Hoffmann: Probiodrug AG, Halle, Germany - 
unpublished results).  
Using an SSLP marker located within the sequence of rat Dpp4 we were able to confirm the 
position of the Dpp4 gene on rat chromosome 3 (RNO3). Furthermore, we demonstrated that 
the Dpp4 gene is inherited in a semi-dominant fashion in the F344/DuCrj(DPPIV-) substrain. 
In these animals the DPPIV-like activity remains on an intermediate level in F344 rats 
heterozygous for the Dpp4 gene. Thus, out- and intercrosses between homozygous DPPIV-
deficient F344/DuCrj(DPPIV-) and homozygous wildtype-like F344/Ztm, F344/Crl(Por/98), 
or F344/Crl(Ral/01) animals could be a valuable tool to examine the impact of DPPIV-like 
activity on DPPIV-dependent physiological parameters. 
We analysed the glucose tolerance in the F344 substrains obtained in 1998 to proof the 
physiological relevance of this enzymatic system. DPPIV is reported to play an essential role 
in the physiological control of blood glucose. This is reflected by an improved glucose 
tolerance in the DPPIV-deficient F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) rats. 
DPPIV-inhibition improves the glucose tolerance (Ahren et al., 2000; Pederson et al., 1998) 
and also enhances the insulin secretion (Pauly et al., 1999). Furthermore, it is effective to 
suppress the degradation of incretins like GLP-1 (Deacon et al., 1998; Holst and Deacon, 
1998), which stimulates insulin gene expression, increases glucose-stimulated insulin 
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secretion (Ahren et al., 2000; Balkan et al., 1999), and inhibits glucagon secretion, all of 
which contribute to normalize elevated blood glucose levels (Holst and Deacon, 1998). Thus, 
active GLP-1 has a powerful influence on glucose tolerance. Inhibition of DPPIV results in 
increased levels of active GLP-1 and GIP (Kieffer et al., 1995) and an improved glucose 
tolerance. Therefore, the lack of DPPIV-like activity in the two DPPIV-deficient substrains 
seems to be responsible for the improved glucose tolerance by an incretin-mediated 
mechanism (Ahren et al., 2000). 
Furthermore, we demonstrated that an extreme reduction in DPPIV-like activity is associated 
with a decreased NK cell mediated lysis of tumor cells. This finding on blunted NK cell 
mediated cytotoxicity against syngenic tumor cell targets suggests that DPPIV is involved in 
mediating specific aspects of NK cell function. It seems to be involved in the regulation of 
NK cell proliferation, whereas natural cytotoxicity seems to be regulated independently 
(Buhling et al., 1994; Shingu et al., 2003). 
In conclusion, we present a gene linked SSLP marker, which allowed us to map Dpp4 to rat 
chromosome 3 (RNO3). We found considerable differences in the DPPIV-like enzymatic 
activity between various rat strains and within different F344 substrains. The DPPIV 
deficiency of two F344 substrains [F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-)] was 
found to be associated with an improved glucose tolerance and decreased NK cell function. 
Overall, the variations in DPPIV-like enzymatic activity reported here could act as 
confounding factors in biomedical research. The manipulation of plasma incretin 
concentrations by acute inhibition of DPPIV could be a therapeutic approach for improving 
the glucose tolerance and could prevent the transition to type 2 diabetes. Thus, our different 
F344 substrains may represent a useful tool for research focusing on glucose homeostasis (e.g. 
by developing a congene rat model with a Leprfa mutation on a DPPIV-deficient F344 
background). 
Differences in the DPPIV-like activity probably affects not only the NK cell function and the 
glucose tolerance but also the degradation and half-life of regulatory peptides such as 
enterostatin, GLP-1, substance P and especially NPY, which are substrates for the DPPIV (see 
1.2: Table 1). Therefore, in the second step of this study, the influence of DPPIV deficiency 
on behavioral and additional physiological topics (see 1.4: Table 2) was analyzed (Karl et al., 
2003c). The systematic phenotyping of F344 substrains with or without endogenous DPPIV-
like enzymatic activity demonstrated an important involvement of the ectopeptidase DPPIV in 
several behavioral and physiological processes, which are dependent on these regulatory 
peptides. The two DPPIV-deficient F344 substrains [F344/DuCrj(DPPIV-) and 
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F344/Crl(Ger/DPPIV-)] exhibited a significantly reduced body weight and water intake, a 
significant hyperalgesia in the non-habituated hot plate test, and a significant differential 
response to the habituation for this experiment. In the open field we observed significantly 
increased exploratory-like behavior in these rats, while the anxiety was significantly reduced 
in the F344/Crl(Ger/DPPIV-) rats in the social interaction test and in F344/DuCrj(DPPIV-) 
rats in the passive avoidance task. Interestingly, a reduced susceptibility to the sedative effect 
of ethanol was evident in the mutant F344 substrains. 
The observed differential body weight in the different F344 substrains could be based on 
elevated endogenous levels of the DPPIV substrate enterostatin in young DPPIV-deficient rats 
(Erlanson-Albertsson and York, 1997). Enterostatin, which is stabilized by DPPIV inhibition 
with val-pro-asp-pro-arg (VPDPR) (Mentlein, 1999), produces a chronic decrease in body 
weight and body fat levels (Erlanson-Albertsson and York, 1997). The decreased water intake 
of DPPIV-deficient animals could be mediated via enhanced levels of active GLP-1, which 
functions as a potent inhibitor of basal and angiotensin II-induced water intake (Drucker, 
1998). Studies with DPPIV knockout mice (Marguet et al., 2000) and F344/DuCrj(DPPIV-) 
rats (Kieffer et al., 1995; Nagakura et al., 2001) described already the inactivating effect of 
DPPIV on active GLP-1 levels in vivo. 
The hyperalgesic phenotype of F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) rats in the 
hot plate test could be related to the involvement of DPPIV substrates such as substance P and 
NPY in pain sensitivity (Bannon et al., 2000; Hua et al., 1991; Luttinger et al., 1984; Post and 
Paulsson, 1985). The neurotransmitter NPY is known to increase the pain threshold in rats 
especially in the hot plate paradigm (Broqua et al., 1996; Merlo Pich et al., 1993) and overall 
thermal hyperalgesia (Tracey et al., 1995). Since a powerful stress response increases NPY 
release in the CNS (Colmers and Wahlestedt, 1993; Pralong et al., 1993), the endogenous 
NPY level of the wildtype-like substrain with its higher stress-associated behavioral response 
in tests of anxiety could be elevated compared to mutant animals. Thus, increased levels of 
NPY could be responsible for a decrease in pain sensitivity in the wildtype-like animals. In 
addition, the anxiogenic-like phenotype of these rats could increase the pain threshold by 
stress-induced hypoalgesia (Kelley, 1986; Millan, 1999). 
The pattern of the findings in the anxiety-related paradigms strongly supports the concept of a 
reduced behavioral stress response in the mutant F344 substrains, which was associated with 
several indicators of reduced anxiety such as a high ambulation in the open field, an increased 
SI time, and an increased light-dark transversion time. These differences in the level of 
arousal and/or anxiety between the different F344 substrains could be based on a differential 
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degradation of NPY (De Meester et al., 2000). NPY administration decreases anxiety (Broqua 
et al., 1996; Kask et al., 2001b; Sajdyk et al., 1999; Thorsell et al., 2000) and has been 
reported to reduce stress responsiveness in transgenic NPY overexpressing rats (Thorsell et 
al., 2000). This anxiolytic-like effect of NPY is primarily mediated via the Y1 receptor 
subtype (Heilig, 1995; Wahlestedt et al., 1993). The non-degraded NPY in the DPPIV-
deficient rats is a more potent activator of the Y1 receptor subtype than the degraded NPY3-36 
in the wildtype-like animals (see 1.5.2: Fig. 1). Thus, differences in the NPY catabolism 
between the different F344 substrains, which are probably linked to DPPIV, seem to be 
responsible for the reduced anxiety of the DPPIV-deficient F344/DuCrj(DPPIV-) and 
F344/Crl(Ger/DPPIV-) substrains. The anxiolysis is probably due to elevated levels of non-
cleaved native NPY in these substrains.  
The DPPIV-deficient substrains exhibited a reduced susceptibility to the sedative effect of 
ethanol. But in regard to a possible involvement of the NPY system in this phenomenon, 
further investigations have to be conducted.  
In conclusion, in this second experimental step, the DPPIV-deficient F344/DuCrj(DPPIV-) 
and F344/Crl(Ger/DPPIV-) rats exhibited a reduced behavioral stress response in tests like the 
hot plate, social interaction, and passive avoidance. These findings suggest an involvement of 
DPPIV-like activity in the regulation of anxiety-like behaviors, and these effects are possibly 
mediated by a differential degradation of NPY and/or alternative DPPIV substrates. Overall, 
this part of the study was based on a systematic behavioral and physiological phenotyping 
(Karl et al., 2003a). This includes a broad range of different behavioral tests, which are 
necessary for an extensive characterization and for detecting specific behavioral differences. 
This strategy for analyzing mutant rodents is becoming an increasingly important and useful 
tool in biomedical research. 
To prove our hypothesis that the observed differences in behavior and physiology between the 
wildtype-like and mutant F344 rats could be based especially on differences in the 
metabolism of NPY, in the third experimental step of this study, we analyzed the effect of 
i.c.v. administration of different doses of NPY (0.0/0.2/1.0 nmol) in the wildtype-like 
[F344/Crl(Por)] and mutant [F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-)] rats on 
behavioral tasks like feeding (food intake), anxiety, and nociception (Karl et al., 2003d; Karl 
et al., 2003e). Furthermore, we administered singularly different doses of the DPPIV-inhibitor 
Ile-Thia (0.0/0.5/5.0 nmol) to confirm that the observed differences in the behavioral and 
physiological phenotype of our different substrains are based on the DPPIV deficiency of 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) and not on other genetic or physiological 
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differences between the DPPIV-deficient and wildtype-like substrains (Karl et al., 2003e). 
The study shows for the first time a differential response to i.c.v. administration of NPY in 
rats that differ in their endogenous DPPIV-like enzymatic activity. Namely, the different 
doses of NPY induced a significant stimulatory effect on the feeding behavior, a significantly 
more pronounced sedative-like effect on elevated plus maze behavior, a significantly more 
potent anxiolytic-like effect on the rat social interaction test, and a significant more potent 
analgetic-like effect in the hot plate test in the DPPIV-deficient F344 rats. Furthermore, 
treatment with Ile-Thia resulted in a hyperalgesic phenotype in the wildtype-like 
F344/Crl(Por) substrain. 
The stimulatory effect of NPY on the feeding behavior has already been described in 
literature (Brief et al., 1992; Jolicoeur et al., 1991; Levine and Morley, 1984; Merlo Pich et 
al., 1992; Schwartz et al., 2000; Stanley et al., 1986) and NPY, as a physiological appetite 
transducer (Kalra et al., 1999), is the only known peptide that can cause animals to eat until 
they are obese (Inui, 1999). The similarity in the feeding response to NPY administration 
between the different substrains is likely due to the affinity of cleaved NPY3-36 to Y5 and Y2 
receptor subtypes, which are, like the Y1 receptor subtype, involved in the feeding behavior of 
rodents (Bischoff and Michel, 1999; Inui, 1999; Inui, 2000; Kalra et al., 1999; Naveilhan et 
al., 1999; Sainsbury et al., 2002; Turnbull et al., 2002). Native NPY in the DPPIV-deficient 
and NPY3-36 in the wildtype-like rat substrains could both mediate potent orexigenic effects of 
similar power. 
A dose-dependent sedative effect of NPY on locomotor activity, which is interpreted as 
sedation (Fuxe et al., 1983), has been reported by several studies (Broqua et al., 1995; Heilig 
and Murison, 1987; Heilig et al., 1989; Jolicoeur et al., 1995). This suppression of activity is 
supposed to be mediated by Y1 receptors (Heilig et al., 1988; Kask et al., 1999; von Horsten et 
al., 1998a), which are also involved in the NPY-induced sensitization to sedation (Heilig et 
al., 1988; Kask et al., 1999; Naveilhan et al., 2001b; von Horsten et al., 1998a). In our study 
the NPY-treated mutant animals of F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) 
exhibited a dose-dependent reduction in motor activity. This effect in the DPPIV-deficient 
animals is based on the differences in the NPY catabolism between the F344 substrains with a 
DPPIV-dependent cleavage of NPY to the Y1 receptor unspecific NPY3-36 only in control rats. 
The dose-dependent differential response of the three F344 substrains with respect to this 
parameter supports our hypothesis regarding the DPPIV-dependent differential NPY 
catabolism in wildtype-like and mutant animals. 
 178  
 
 
I.c.v. administration of NPY is also deeply involved in anxiety-like behaviors of rodents 
(Broqua et al., 1995; Heilig et al., 1989; Kask et al., 2002; von Horsten et al., 1998a). The 
results of several studies suggest a role for the Y1 receptor in mediating the anxiolytic-like 
action of NPY (Heilig et al., 1989; Kask and Harro, 2000; Kask et al., 2001a; Kask et al., 
1996; Wahlestedt et al., 1993), although also the Y2 (Kask et al., 2001a; Kask et al., 1998) and 
Y5 (Sajdyk et al., 2002) receptor subtype could be involved. 
NPY administration had an anxiolytic-like effect in all substrains in the elevated plus maze, 
which could be influenced also by the sedative-like effect of NPY. At least, a very narrow 
pharmacological window in the F344 genetic background between sedative-like and 
anxiolytic-like effects of NPY especially in the elevated plus maze has to be considered in 
order to avoid false positive results. Therefore, we also applied the social interaction test for 
recording the anxiolytic-like potency of NPY, in which the DPPIV-deficient rats exhibited an 
increased anxiolytic-like response (independent from the sedative-like effect) to the NPY 
administration compared to the wildtype-like animals. Motor activity was dose-dependently 
reduced by NPY treatment, but despite this sedative effect on ambulatory activity, social-like 
behaviors remained unaffected by NPY. Overall, these data show the suggested differences 
between the wildtype-like and mutant F344 substrains regarding their NPY catabolism 
because of the more potent Y1 receptor-mediated anxiolytic-like and sedative-like effects of 
the neurotransmitter in the mutant, DPPIV-deficient animals. The differences in anxiety levels 
in the social interaction test between the two DPPIV-deficient substrains F344/DuCrj(DPPIV-
) and F344/Crl(Ger/DPPIV-) are probably dependent on segregation-based differences in the 
genetic background between these substrains.  
Centrally injected NPY exerted a dose-dependent hypoalgesic effect only in the mutant rats, 
whereas i.c.v. administration of the DPPIV inhibitor Ile-Thia had a hyperalgesic effect in the 
wildtype-like animals. The effect of NPY on nociception is discussed controversially, 
although there is evidence for the presence of NPY-immunoreactivity in some areas of the 
CNS, which are involved in pain modulation (Broqua et al., 1996; Jolicoeur et al., 1991). 
I.c.v. or intrathecal administration of NPY in the hot plate paradigm produced a dose-
dependent elevation in the nociceptive threshold (Hua et al., 1991; Merlo Pich et al., 1990). In 
other studies NPY induced hyperalgesia (Broqua et al., 1996; von Horsten et al., 1998b) or 
did not have any effect on nociception (Heilig et al., 1993; Heilig et al., 1992; Heilig et al., 
1989; Jolicoeur et al., 1991). However, Y1 receptor knockout mice develop hyperalgesia to 
acute thermal pain (Naveilhan et al., 2001a). Therefore, it is concluded that the Y1 receptor is 
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required for central physiological and pharmacological NPY-induced analgesia (Broqua et al., 
1996; Wang et al., 2000). 
The results of our study could point towards a Y1 receptor-mediated analgetic-like effect of 
NPY. Wildtype-like F344/Crl(Por) rats with a normal DPPIV-like activity lost more rapidly 
the Y1 receptor subtype-specific affinity of exogenously administered NPY by DPPIV-
dependent cleavage processes than the DPPIV-deficient animals. In the mutant rats the 
exogenously administered native and non-cleaved NPY decreased their pain sensitivity, which 
is a strong hint for the antinociceptive effect of i.c.v. applied NPY. The hyperalgesic 
phenotype of the vehicle-treated DPPIV-deficient F344/DuCrj(DPPIV-) and 
F344/Crl(Ger/DPPIV-) animals was already discussed as an effect of the reduced anxiety 
levels and concomitant reduced stress-induced analgesia of these animals (Karl et al., 2003c). 
NPY-deficient mice appear to be hypoalgesic in the hot plate paradigm (Bannon et al., 2000). 
Also these mice exhibit an anxiogenic-like phenotype (such as F344/Crl(Por) rats). Their 
increased anxiety seems to increase their pain threshold probably by stress-induced analgesia, 
which is associated with or even triggered by a release of analgesia-inducing endogenous 
opioid peptides from central and peripheral sites (Kelley, 1986). This process could also occur 
in our wildtype-like rats. Furthermore, a potent stress-induced NPY release in the wildtype-
like animals paired with the described stress-induced analgesia could manifest in the observed 
hypoalgesic phenotype. In addition, substance P and endomorphin-2, two other substrates of 
the DPPIV are involved in nociception and could be differentially degraded in the different 
substrains. 
I.c.v. treatment with the DPPIV-inhibitor Ile-Thia exhibited no effects in the DPPIV-deficient 
animals but rather exerted an hyperalgesic effect in the control animals. This could be based 
on DPPIV inhibition-caused reduced anxiety levels in the wildtype-like animals, which could 
be linked to a decrease in endogenous NPY-release and a reduction in stress-induced 
analgesia.  
In conclusion, this third experimental step demonstrates for the first time a differential 
potency and specificity of exogenously administered NPY between wildtype-like and DPPIV-
deficient rat substrains (based on differential cleavage processes of NPY). Thereby, the study 
supports the concept that these animals provide a useful model to study the various behavioral 
and physiological effects associated with DPPIV-enzymatic activity. Furthermore, we could 
confirm the stimulatory effect of NPY on feeding behavior (food intake) and its sedative-like, 
anxiolytic-like, and probably also analgetic-like effect in rats. 
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In the present series of studies we found an overall wide range of differences between the 
wildtype-like and DPPIV-deficient F344 substrains. These differences seem to be based on a 
differential DPPIV-dependent cleavage of regulatory peptides such as enterostatin, GLP-1, 
and especially NPY. The results of the i.c.v. administration of NPY show that the mutant 
animals exhibited an increased responsiveness to the sedative-like, anxiolytic-like effect, and 
probably analgetic-like effect of i.c.v.-administered NPY, which is most likely mediated via 
increased and prolonged activation of NPY Y1 receptor-dependent pathways and mechanisms. 
Thus, a differential cleavage of NPY in our different substrains is strongly suggested and can 
be considered at least as one of the main reasons for the observed differences in behavior and 
physiology between wildtype-like and DPPIV-deficient rats. Our F344 substrains 
F344/Crl(Por), F344/DuCrj(DPPIV-), and F344/Crl(Ger/DPPIV-) represent an excellent and 
valid animal model to study the “DPPIV-NPY-axis” and other DPPIV-dependent behavioral 
and physiological processes. Furthermore, these animals could serve as a physiological and 
molecular model for behavioral modulations. Since pharmacological inhibition of DPPIV-like 
activity has been demonstrated to potentiate the effects of NPY administration in vivo 
(Dimitrijevic et al., 2002), it seems possible that DPPIV inhibitors specifically targeting the 
CNS are useful modifiers of centrally mediated effects of NPY. 
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